1 (131)  Clinical Study Protocol  
 Drug Substance Anifrolumab (MEDI-546) 
 Study Code D3461C00008 
 Version 1.0 
 Date 20 Sep 2016 
   
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 
Study Characterizing the Pharmacokineti cs, Pharmacodynamics, and Safety 
of Anifrolumab following subcutaneous administration in Adult Systemic Lupus Erythematosus Subjects with Type I Interferon test high result and 
active skin manifestations 
Sponsor:  AstraZeneca AB, 151 85 Södertälje, Sweden 
3 (131) This submission document contains confidential commercial information, disclosure of which 
is prohibited without provid ing advance notice to AstraZeneca and opportunity to object. 
This Clinical Study Protocol has been subject to a peer revi ew according to AstraZeneca 
Standard procedures.  The clinical study protocol  is publicly registered and the results are 
disclosed and/or published according to the Ast raZeneca Global Policy on Bioethics and in 
compliance with prevailing laws and regulations. 
4 (131) PROTOCOL SYNOPSIS 
 
A Multicenter, Randomized, Double-b lind, Placebo-controlled, Phase 2 
Study Characterizing the Pharmacokinetics, Pharmacodynamics, and 
Safety of Anifrolumab following subcutaneous administration in Adult Systemic Lupus Erythematosus Subjects with Interferon type I test high result and active skin manifestations 
 
 
Study site(s) and number of subjects planned 
Approximately 32 subjects are planned to be randomized from approximately 15 sites in 4-5 
countries.  
Study period  Phase of development 
Estimated date of first subject enrolled Q4 2016 Phase 2  
Estimated date of last subject completed Q4 2018 Phase 2  
Study design 
This is a Phase 2, multicentre, double- blind, randomized, placebo-controlled study 
characterizing the pharmacokinetics, pharmacodyn amics, and safety of  two fixed doses of 
anifrolumab administered as Subcutaneous (SC) injections in adult type I Interferon (IFN) test 
-high Systemic Lupus Erythematosus (SLE) subjects with active skin manifestations while receiving Standard of Care (SOC) treatment.  The study will be double-blind until primary analysis performed after all subjects have completed Week 12.  Thereafter, the sponsor will be unblinded while investigators and subjects wi ll remain blinded throughout the remainder of 
the study. 
Approximately 32 subjects will be randomized to one of the four treatment groups in a 3:1:3:1 
ratio receiving:  
x anifrolumab at a fixed dose of 150mg as added to SOC, given Q2W as one SC injection in a volume of 1mL (12 subjects);  
x placebo as added to  SOC, given Q2W as one SC injection in a volume of 1mL  (4 subjects);  
x anifrolumab at a fixed dose of 300mg as added to SOC, given Q2W as two SC injections in a volume of 1mL each (12 subjects) or  
Clinical Study Protocol Synopsis 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
5 (131) x placebo as added to SOC, given Q2W as two SC injections in a volume 
of 1mL each (4 subjects). 
The study is blinded with respect to anifrolumab or placebo but not for dose since treatments 
will be given as one or two SC injections depending on dose level. 
Objectives 
Primary Objective: Outcome Measures: 
To characterize the PK and PD of 150 mg 
and 300 mg anifrolumab administered as SC injections Q2W as measured by anifrolumab 
concentrations, PK parameters, 
21-gene type I IFN PD signature and 
neutralisation ratio at Week 12 Anifrolumab concentrations and PK parameters including maximum concentration (C
max) after first 
dose and trough concentration (C trough) after subsequent 
dosing 
21-gene type 1 IFN PD signature and neutralization 
ratio (relative to baseline) 
 
Secondary Objectives: Outcome Measure : 
To characterize the safety and tolerability of anifrolumab when SC administered for a 52 Week treatment period Adverse events (AE); serious adverse events (SAEs); adverse events of special interest (AESIs) including herpes zoster, influenza, opportunistic infections, 
non-opportunistic serious infections, tuberculosis 
(TB), malignancies, non-SLE related vasculitis, 
anaphylaxis, and major adverse cardiovascular events 
(MACE); laboratory variables; physical examinations; vital signs; and ECG 
To characterize the immunogenicity of anifrolumab when administered SC for a 52 Week treatment period Anti-drug antibodies (ADA) 
 
Exploratory Objectives: Outcome Measure: 
To characterize the efficacy of SC administered anifrolumab on SLE skin manifestations as measured by the change in Cutaneous Lupus erythematosus disease Area and Severity Index (CLASI) activity score from baseline Proportion of subjects achieving 50% improvement 
in CLASI activity score from baseline to Week 12 and week 52 
To explore the effects of SC administered anifrolumab on type I IFN and other pathway-related gene expression in skin tissue 
(optional part of study)  21-gene type I IFN and other pathway-related gene 
expression in skin tissue at baseline and at Week 12 
 
Clinical Study Protocol Synopsis 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
7 (131) Two data base locks and analyses are planned for the study, i.e., the ma in analysis after all 
randomized subjects complete Week  12 or discontinue the st udy prior to Week 12, and the 
“end of extension”-analysis that  take place once all subjects  have completed Week 60 or 
discontinued the study prior to Week 60. 
The full analysis set will be used as the primary population for reporting PD, efficacy and 
safety data.  This comprises of all subjects rand omized into the study who receive at least 1 
dose of IP and did not disconti nue IP, and will be analyzed ac cording to randomized treatment 
(modified Intention-To-Treat).  All subjects w ho received anifrolumab and who had at least 1 
quantifiable serum PK observation post first dose,  will be included in the PK analysis dataset. 
All PK summaries will be based on this analysis set.  Descriptive statistics (number, mean, standard  deviation [SD], median, minimum, maximum, 
and coefficient of variance [%CV]) will be provided by dose level for continuous variables, 
and counts and percentages will be pr esented for categorical variables. 
The primary characterization of the effect of anifrolumab on the 21-gene type I IFN PD signature will be carried out th rough the individual and median 21-gene type 1 IFN signature 
scores and neutralization ratios at Week 12.  The PD ge ne signature will also be explored over 
time.  The primary characterization of anifrolumab PK will be done by  descriptive statistics of 
the derived PK parameters. 
  CCI
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
8 (131) TABLE OF CONTENTS PAGE 
 
TITLE PAGE ................. ................................................................................ .......... 1
VERSION HISTORY ......... ................ ................ ............................................. ........ 2
PROTOCOL SYNOPSIS ......... ................ ................ .............. ............. ............. ........ 4
TABLE OF CONTENTS ....... .................. ................ .............. ............. ............. ........ 8
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS .......................... 15
1. INTRODUCTION .............. ................ ................ ............................. .............. ........ 18
1.1 Background ................................. ........................................................................... 18
1.2 Rationale for study population, study  design, and dosing ..................................... 19
1.2.1 Rationale for study population and study design ................................................... 19
1.2.2 Rationale for primary endpoint selection ......... ................ ................ .............. ........ 20
1.
2.3 Rationale for dosing and study duration ............. ................... .................. .............. 20
1.2.4 IFN test background ......... ................ ................ ................................ .............. ........ 21
1.3 Benefit/risk and ethical assessment ....................................................................... 22
1.4 Study Design ............ ................ ................ .............. .................. .............. ................ 27
2. STUDY OB
JECTIVES ....... ................ ................ ............................. .............. ........ 30
2.1 Primary objective ........ ................ ................ ................................................ ........... 30
2.2 Secondary objectives ............................................................................................. 30
2.3 Safety objectives .................................................................................................... 30
2.4 Exploratory objectives ........................................................................................... 31
3. SUBJECT SELECTION, ENROLMENT, RANDOMIZATION, 
RESTRI
CTIONS, DISCONTINUATION AND WI THDRAWAL ........ .............. 31
3.1 Inclusion criteria .................................................................................................... 31
3.2 Exclusion criteria ................................................................................................... 34
3.2.1 General exclusion criteria ........ ................ .............. .................. .............. ................ 35
3.2.2 Exclusion criteria related to concomitant me dicati ons  ....... ........................... ........ 36
3.2.3 Exclusion criteria related to syst emic lupus erythematosus and other 
diseases ............ ................................................................................ .............. ........ 37
3.2.4 Exclusion criteria related to infection and ma lignancy risk fac tors ............... ........ 38
3.3 Subject enrolment and randomization  ................ ................ ............. .............. ........ 39
3.
4 Procedures for handling incorrectly enrolled or randomized subjects  ........... ........ 39
3.5 Methods for assigning treatment groups ................................................................ 40
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
9 (131) 3.6 Methods for ensuring blinding .... ................ ................ ................................ ........... 40
3.7 Methods for unblinding ............... ................ ................ ................................ ........... 41
3.8 Restrictions ......... ................ ................ ................................ ........................... ........ 41
3.8.1 Fasting lipid profile ................................................................................................ 41
3.8.2 Perioperative management of investigational pr oduct ........... .................. .............. 41
3.9 Discontinuation of investigational product ...... ................ ................ .............. ........ 42
3.
9.1 Discontinuation of investigational product due  t o worsening of SL E ........... ........ 43
3.9.2 Procedures for discontinuation of a subject fr om investigational product ............. 43
3.10 Criteria for withdrawal ............. ................ .............. .................. .............. ................ 43
3.10.1 Screen failures ............. ................ ................ ................................................ ........... 43
3.10.2 Withdrawal of the informed consent .............. ................ ................ ................ ........ 44
3.10.3 Lost to follow-up ......... ................ ................ ................................................ ........... 44
3.11 Discontinuation of the study ....... ................ ................ ................................ ........... 44
4. STUDY PLAN AND TIMING OF PROCEDURES ..... ................ ................ ........ 44
4.
1 Enrolment/screening period ........ ................ ................ ................................ ........... 52
4.1.1 Re-testing and re-screening .... .................. .............. .................. .............. ................ 52
4.1.2 Other considerations for screening ................ ................ ................ ................ ........ 52
4.1.2.1 Medical history ...................................................................................................... 52
4.1.2.2 SLE medication history .......... .................. .............. .................. .............. ................ 52
4.1.2.3 Oral examination ......... ................ ................ ................................................ ........... 53
4.1.2.4 Mammography ............................ ........................................................................... 53
4.2 Treatment period .................................................................................................... 53
4.2.1 Patient survey at week 12 ...................................................................................... 53
4.2.2 Follow-up visits after premature discontinuation of investigational product ........ 54
4.3 Follow-up period ......... ................ ................ ................................................ ........... 54
4.4 Unscheduled visits ................. .................. .............. .................. .............. ................ 54
5. STUDY ASSESSMENTS .......... ................ ................ ................................ ........... 55
5.1 Efficacy assessments .............................................................................................. 55
5.1.1 Training and certification for Systemic Lupus Erythematosus assessments ......... 55
5.1.2 Cutaneous Lupus Erythematosus Disease Area and Severity Index .............. ........ 56
5.1.3 Systemic Lupus Erythematosus Disease Activ ity In dex 2000............ ............. ...... 56
5.1.4 Physician Global Assessment ........ ................ ................ ................................ ........ 56
5.1.5 Oral corticosteroid tapering ........ ................ ................ ................................ ........... 57
5.2 Safety assessments ................. .................. .............. .................. .............. ................ 57
5.2.1 Clinical Laboratory assessments ................. ................ ................ ................ ........... 57
5.2.1.1 Haematology, clinical chemistry, and urinalys is test i ng........ .................. .............. 59
5.2.1.2 Coagulation Testing ............ ................ ................ ............................. .............. ........ 59
5.2.1.3 Infectious Disease Panel .......... ................... ................ ................................ ........... 59
5.2.1.4 Fasting lipid profile ................................................................................................ 59
5.2.1.5 Tuberculosis Testing .............. .................. .............. .................. .............. ................ 59
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
10 (131) 5.2.1.6 Pregnancy Testing ....... ................ ................ ................................................ ........... 59
5.2.2 Physical examination ....... ................... ................... .................. ................... ........... 60
5.
2.3 ECG ............. ................ ................ ................................................................ ........... 60
5.2.4 Vital signs ........... ................ ................ ................................ ........................... ........ 60
5.2.5 Assessment of Injection Sites ................................................................................ 60
5.2.6 Other safety assessments ........ .................. .............. .................. .............. ................ 60
5.2.6.1 Chest x-ray ............. .................. ................ .............. .................. .............. ................ 60
5.2.6.2 Tuberculosis screening and monitoring ................................................................. 61
5.2.6.3 Cervical cancer screening ........ ................ .............. .................. .............. ................ 63
5.2.6.4 Colombia-Suicide Severity Rating Scale (C-SSR S) .............. .................. .............. 64
5.3 Pharmacokinetics ................................................................................................... 64
5.3.1 Collection of samples ............................................................................................. 64
5.3.2 Determination of drug concentration  .................. ................ ............. .............. ........ 64
5.
3.3 Storage and destruction of pharmacokinetic sa mp les ............ .................. .............. 65
5.4 Immunogenicity ..................................................................................................... 65
5.4.1 Anti-drug antibodies ................ ................... ................ ................................ ........... 65
5.4.2 Neutralising antibodies ............ ................... ................ ................................ ........... 65
5.5 Pharmacodynamics .......... ................ ................ ................................ .............. ........ 65
5.5.1 21-gene type I IFN PD signature in whole blood (PD marker) ....... .............. ........ 65
5.5.2 4-gene type I IFN test ............ .................. .............. .................. .............. ................ 65
5.5.3 Exploratory Transcriptome Analysis (optional) .................................................... 66
5.6 Pharmacogenetics (Not Applicable)  ................... ................... .................. .............. 66
5.7 Biomarker analysis (Not Applicable) ............ ................................ ................ ........ 66
5.8 Storage, re-use and destruction of biological sa mp les ........... .................. .............. 66
5.9 Labelling and shipment of biol ogical  sam ples ....... .................. .............. ................ 66
5.10 Chain of custody of biological samples ......... ................ ................ ................ ........ 67
5.11 Withdrawal of Informed Consent for donated  biological sam ples .. .............. ........ 67
6. SAFETY REPORTING AND MEDICAL MANAGEME NT ................ .............. 68
6.
1 Definition of adverse events .................................................................................. 68
6.2 Definitions of serious adverse event .............. ................ ................ ................ ........ 68
6.3 Recording of adverse events .. .................. .............. .................. .............. ................ 68
6.3.1 Time period for collection of adverse events ... ................ ................ .............. ........ 68
6.
3.2 Follow-up of unresolved adverse events ........ ................ ................ ................ ........ 69
6.3.3 Variables ............. ................ ................ ................................ ........................... ........ 69
6.3.4 Causality collection ................................................................................................ 70
6.3.5 Adverse events based on signs and symptoms ................ ................ .............. ........ 70
6.
3.6 Adverse events based on examinations and tests ................................................... 70
6.3.7 Hy’s Law ............. ................ ................ ............................................. .............. ........ 71
6.3.8 Disease progression/worsening of SLE ........... ................ ................ .............. ........ 71
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
11 (131) 6.4 Reporting of serious adverse ev en ts............... ................................................ ........ 71
6.5 Overdose ................ .................. ................ .............. .................. .............. ................ 72
6.6 Pregnancy ............ ................ ................ ............................................. .............. ........ 72
6.6.1 Maternal exposure .................................................................................................. 72
6.6.2 Paternal exposure ................................................................................................... 73
6.7 Adverse Events of Special Interest ........................................................................ 73
6.7.1 Non-opportunistic serious infecti on ............ ................ ................ ................ ........... 73
6.7.2 Opportunistic serious infection ... ................ ................ ................................ ........... 73
6.7.3 Anaphylaxis ................ ................ ................ ................................................ ........... 74
6.7.4 Malignancy ............ .................. ................ .............. .................. .............. ................ 74
6.7.5 Herpes zoster ............ ................ ................ .............. .................. .............. ................ 74
6.
7.6 Tuberculosis ........................................................................................................... 74
6.7.7 Influenza ............. ................ ................ ................................ ........................... ........ 75
6.7.8 Vasculitis (non-Systemic Lupus Erythematosus)  .................. .................. .............. 76
6.7.9 Major acute cardiovascular events ................... ................ ................ .............. ........ 76
6.
8 Reporting of adverse events of special interest ................... ............. .............. ........ 76
6.9 Management of IP related toxicities ...................................................................... 77
6.9.1 Anaphylaxis, hypersensitivity, and injection-related reactions ............................. 77
6.9.2 Infections ................................................................................................................ 77
6.10 Study governance and oversight .... ................ ................ ................................ ........ 78
7. INVESTIGATIONAL PRODUCT AND OTHER TR EATM ENTS ...... .............. 78
7.1 Identity of investigational product(s) ..................................................................... 78
7.2 Dose and treatment regimens ................... ................... ................ ................ ........... 78
7.2.1 Investigational product administration procedures  ................ .................. .............. 79
7.2.2 Monitoring of investigational product administra ti on ............. ................... ........... 79
7.3 Labelling ................ .................. ................ .............. .................. .............. ................ 79
7.4 Storage ................ ................ ................ ................................ ........................... ........ 79
7.5 Compliance ............................................................................................................ 80
7.6 Accountability ............. ................ ................ ................................................ ........... 80
7.7 Concomitant treatment ........................................................................................... 80
7.7.1 Standard of Care treatment for SLE ................. ................ ................ .............. ........ 80
7.
7.2 Corticosteroid treatment ......................................................................................... 81
7.7.2.1 Protocol-specified corticosteroid tapering ..... ................ ................ ................ ........ 81
7.7.2.2 Corticosteroid bursts .............................................................................................. 82
7.7.2.3 Increase in oral corticosteroids for inte rcurrent disease or to prevent 
adrenal insufficiency .............................................................................................. 83
7.7.2.4 Topical therapy ...................................................................................................... 83
7.7.3 Anti-hypertensive agents and statins ............. ................ ................ ................ ........ 83
7.7.4 NSAIDs ............ ................ ................ .............................................................. ........ 84
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
12 (131) 7.7.5 Acetaminophen or equivale nt ................................ ................................................ 84
7.
7.6 Low-dose aspirin ......... ................ ................ ................................................ ........... 84
7.7.7 Narcotic analgesics ..... ................ ................ ................................................ ........... 84
7.7.8 Other concomitant treatment ....... ................ ................ ................................ ........... 84
7.8 Prohibited medications ........................................................................................... 84
7.9 Post Study Access to Study Treatment ............ ................ ................ .............. ........ 86
8. STATIST
ICAL ANALYSES BY ASTRAZENECA . ................ ................ ........... 86
8.
1 Statistical considerations ........................................................................................ 86
8.2 Sample size estimate ........ ................ ................ ................................ .............. ........ 87
8.3 Definitions of analysis sets .................................................................................... 87
8.3.1 All subjects analysis set ...... ................ ................ ................ ........................... ........ 87
8.3.2 Full analysis set ........... ................ ................ ................................................ ........... 87
8.3.3 PK analysis set ............ ................ ................ ................................................ ........... 87
8.4 Outcome measures for analyses .................. ................ ................ ................ ........... 87
8.4.1 Primary outcome measures ......... ................ ................ ................................ ........... 88
8.4.1.1 Pharmacodynamics (PD) ............ ................ ................ ................................ ........... 88
8.4.1.2 Pharmacokinetics (PK) .......................................................................................... 88
8.4.2 Secondary outcome measures ..... ................ ................ ................................ ........... 88
8.4.2.1 Immunogenicity ..................................................................................................... 88
8.4.2.2 Safety ............... ................ ................ ................................................ .............. ........ 88
8.4.3 Exploratory outcome measures ... ................ ................ ................................ ........... 89
8.4.3.1 Efficacy ............... ................ ................ ................................ ........................... ........ 89
8.4.3.2 Oral corticosteroid management . ................ ................ ................................ ........... 89
8.4.3.3 Skin tape test (optional) ......... .................. .............. .................. .............. ................ 89
8.5 Methods for statistical analyses ............................................................................. 89
8.5.1 Analysis of the primary variable (s) ............ ................ ................ ................ ........... 90
8.5.2 Analysis of the secondary variab les ............... ................ ................................ ........ 90
8.5.2.1 Safety ............... ................ ................ ................................................ .............. ........ 90
8.5.2.2 Immunogenicity ..................................................................................................... 91
8.5.3 Interim analysis ........... ................ ................ ................................................ ........... 91
8.5.4 Sensitivity analysis .............. ................ ................ ................ ........................... ........ 91
8.5.5 Analysis methods for exploratory outcome meas ures  ........... .................. .............. 91
8.5.5.1 Efficacy ............... ................ ................ ................................ ........................... ........ 91
8.5.5.2 Oral corticosteroid management . ................ ................ ................................ ........... 92
8.5.5.3 Skin tape test ....... ................ ................ ................................ ........................... ........ 92
9. STUDY AND DATA MANAGEMENT BY ASTR AZENE C A .......... .......... ...... 92
9.1 Training of study site personnel ............................................................................. 92
9.2 Monitoring of the study ........... ................ .............. .................. .............. ................ 93
9.2.1 Source data ............... ................ ................ .............. .................. .............. ................ 93
9.
2.2 Study agreements ........... .................. ................ ................ ................ .............. ........ 93
9.2.3 Archiving of study documents . ................ .............. .................. .............. ................ 94
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
13 (131) 9.3 Study timetable and end of study ........................................................................... 94
9.4 Data management by AstraZeneca or delegate ...................................................... 94
10. ETHICAL AND REGULATORY REQUIREMENTS .. ............... ................ ........ 95
10.1 Ethical conduct of the study ................................................................................... 95
10.2 Subject data protection ........................................................................................... 95
10.3 Ethics and regulatory review ................................................................................. 95
10.4 Informed consent ........ ................ ................ ................................................ ........... 96
10.5 Changes to the protocol and informed consent form ............. .................. .............. 96
10.6 Audits and inspections ........... .................. .............. .................. .............. ................ 97
11. LIST OF REFERENCES ....................................................................................... 97
 
LIST OF TABLES 
Table 1 Highly effective intrauterine  device and hormonal methods and 
effective barrier methods of birth control (2 method s are required, 
one being a barrier method and one being a intrauterine 
device/hormonal method) ......... .................. .............. .................. .............. 33
Table 2 Study plan detailing the procedures at screening ............... .............. ........ 45
Table 3
Study plan detailing the procedur es during the Treatm ent Period ........... 47
Table 4 Study plan detailing the procedures dur ing F o llow-up ...... .............. ........ 51
Table 5 Clinical Laboratory Variables ............ ................ ................ .............. ........ 57
 
LIST OF FIGURES 
Figure 1  Mean serum concentrations of anifrolumab following single SC 
(300 and 600 mg) and IV (300 mg) dosing in healthy volunteers ............ 20
Figure 2 Distribution of IFN transcript scores ................................ ................ ........ 22
Figure 3 Study flow chart ......... ................ .............. .................. .............. ................ 29
 
LIST OF APPENDICES 
Appendix A Additional Safety Information .......... ............................................. ......... 100
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
14 (131) Appendix B International Airline Transportation Association (IATA) 6.2 
Guidance Document ......... .................. ................ .............. ............. ......... 102
Appendix C Actions Required in Cases of Increases in Liver Biochemistry and 
Ev
aluation of Hy’s Law .... .................. ...................................... .............. 104
Appendix D American College of Rheumatology Criteria for Systemic Lupus 
Eryt
hematosus Classification ................... .................. ................ ............ 108
Appendix E Systemic Lupus Erythematosus Disease Activity Index 2000 ............... 110
Appendix F Cutaneous Lupus Erythematosu s Disease Area and Severity Index ...... 112
Appendix G Physician global assessment .......... ................ ................ ................ ......... 113
Appendix H Oral Corticosteroid Guidance ........ ................................ ................ ......... 114
Appendix I General guidance for Determinati on of Maj o r Surgery.... ............. ......... 115
Appendix J Guidance for abnormal Pap-smear re sults ............. ................... .............. 116
App
endix K Anaphylaxis ........... ................... .................. ................ ................ ............ 117
App
endix L Classification criteria for catas t rophic anti-phospholipid syndrome ...... 121
Appendix M Columbia Suicide Severity Rating Scale (C-SSRS) ......... ............. ......... 122
App
endix N Vasculitic syndromes excluded from the study ...................................... 128
Appendix O Patient Survey at Week 12............................................................. ......... 129
 
 
  
  
 
 
 
  
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
15 (131) LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
The following abbreviations and special terms are used in this study Clinical Study Protocol. 
Abbreviation or special term Explanation 
ACR American College of Rheumatology  
ADA Anti-Drug Antibodies  
AE Adverse Event 
AESI Adverse Events of Special Interest  
AIS Adenocarcinoma In Situ  
ALP Alkaline Phosphatise  
ALT Alanine Aminotransferase  
ANA Antinuclear Antibody  
anti-dsDNA Anti-Double Stranded Deoxyribonucleic Acid  
AST Aspartate Aminotransferase  
AUC Area Under the Curve 
BCG Bacillus Calmette-Guerin  
BICLA British Isles Combined Lupus Assessment 
BP Blood Pressure 
C3 Third Component of Complement 
C4 Fourth Component of Complement 
CDC Centers for Disease Control and Prevention 
CH50 Total Haemolytic Complement 
CHMP Committee for Medicinal Products for Human Use  
CIS Carcinoma In Situ  
CK Creatine Kinase  
CLASI Cutaneous Lupus Erythematosus Disease Area and Severity Index  
Cmax Maximum plasma (peak) drug concentration after single dose administration 
C
trough Trough concentration 
CNS Central Nervous System 
CRF Case Report Form 
CSA Clinical Study Agreement  
CSR Clinical Study Report 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
16 (131) Abbreviation or special term Explanation 
C-SSRS Colombia Suicidality Severity Rating Scale  
CV-EAC Cardiovascular Event Adjudication Committee  
EC Ethics Committee 
ECG Electrocardiogram 
EOT End of Treatment  
EULAR European League Against Rheumatism  
FSH Follicle-Stimulating Hormone  
GCP Good Clinical Practice  
GMP Good Manufacturing Practice  
HBcAb Hepatitis B Core Antibody  
HBsAg Hepatitis B Surface Antigen  
HBV Hepatitis B Virus  
HDL High Density Lipoprotein  
HIPAA Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
ICF Informed Consent Form  
ICH International Conference on Harmonisation 
IFA Immunofluorescent Assay  
IFIGx Interferon-Inducible Gene Expression  
IFN Interferon  
IFNAR1 Type I Interferon Receptor 
Ig Immunoglobulin IP Investigational Product  
IRB Institutional Review Board  
IV Intravenous  
IVIG Intravenous Immunoglobulins  
IXRS Interactive Voice/Web Response System  
LDL Low Density Lipoprotein  
LLOQ Lower Limit of Quantitation 
mAb Monoclonal Antibody  
MCV Mean Corpuscular Volume 
MedDRA Medical Dictionary for Regulatory Activities  
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
17 (131) Abbreviation or special term Explanation 
mRNA Messenger Ribonucleic Acid  
NSAID Nonsteroidal anti-Inflammatory Drugs 
OCS Oral Corticosteroids  
PA Posterior-Anterior 
PCR Polymerase Chain Reaction 
PD Pharmacodynamic 
PK Pharmacokinetics 
PGA Physician Global Assessment 
PI Principal Investigator  
PP Per-Protocol  
PT Prothrombin Time  
PTT Partial Thromboplastin Time  
Q2W Every 2 Weeks 
Q4W Every 4 Weeks 
QFT-G QuantiFERON-TB Gold 
RT-PCR Reverse Transcriptase Polymerase Chain Reaction  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SC Subcutaneous 
SLE Systemic Lupus Erythematosus 
SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000 
SOC Standard of Care  
SRI[4] Systemic Lupus Erythematosus Responder Index of 4  
SSc Systemic Sclerosis  
TB Tuberculosis  
ULN Upper Limit of Normal  
WBDC Web Based Data Capture  
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
18 (131) 1. INTRODUCTION
1.1 Background
Systemic Lupus Erythematosus (SLE) is a ch ronic, multisystemic, disabling autoimmune 
rheumatic disease of unknown aetiology.  The disease predom inantly affects women of 
childbearing years (Cooper et al, 1998; Lahita, 1999) with a female-t o-male ratio in the 
childbearing years of about 12:1 (Ramsey-Goldm an and Manzi, 2000).  There is substantial 
unmet medical need in the treatment of SLE, particularly in subjects with moderate or severe 
disease.  SLE has a broad range of clinical ma nifestations including constitutional symptoms, 
alopecia, skin rashes, serositis, arthritis, nephritis, vasculitis, lymphadenopathy, splenomegaly, 
haemolytic anaemia, cognitive dysfunction and other nervous system involvement.  Skin is the 
second most commonly involved organ and even  though the reported prevalence varies among 
different studies more than 80% of SLE patients have skin symptoms at some stage of their 
disease (Rothfield N et al, 2006, Kapadia N et al, 1996, Wysenbeek AJ et  al, 1992, Grönhagen 
CM et al, 2010).  Both  the disease manifestations as well as the currently used SOC treatment, 
commonly oral corticosteroids (OCS) and other immunosuppressive agents, cause a 
significant disease burden (Doria and Briani, 20 08; Petri, 2001; Zonana-Nanach et al, 2000).  
All currently used SLE therapies have well known adverse effects and there is a medical need to identify new targeted therapies, particularly agents that may reduce the requirement for 
corticosteroids and cytotoxic agents. 
There is growing evidence that type I IFNs play an important role in autoimmune diseases 
including SLE.  Subjects with high anti-double stranded deoxyribonucleic acid (anti-dsDNA) 
antibody titers, progressive skin rashes, and lupu s nephritis (LN), have high serum levels of 
type I IFN (Bengtsson et al, 2000).  Overexpres sion of type I IFN activated genes, the so 
called “interferon signature”, has been shown in  blood and skin biopsies from SLE subjects 
with acute skin involvement (Dall’era et al, 20 05, Blomberg S et al, 2001, Farkas et al, 2001, 
Yao et al, 2009). 
Anifrolumab is a human immunoglobulin G1 kappa (IgG1 ț) monoclonal antibody (mAb) 
directed against subunit 1 of the type I IFN r eceptor (IFNAR1).  Anifrolumab inhibits binding 
of type I IFN to IFNAR and inhibits the biologic activity of all type I IFNs.  The growing 
evidence that type I IFNs play an important role in SLE, suggests that inhibition of the 
biological activity of type I IFNs with anifrolumab may be a novel therapy for the treatment of 
SLE patients with significant unmet medical need. 
Anifrolumab as administered as intravenous (IV) infusions is currently being investigated by 
the Sponsor for treatment of moderate to seve re active SLE in the following ongoing studies; 
one global open-label extension phase 2 study, one phase 2 study in adult Japanese subjects, 
two global phase 3 studies and a long-term exte nsion study of these, and in proliferative LN 
(one global phase 2 study).  
Development of a SC route of administration for anifrolumab is expected to offer increased 
flexibility in meetin g patients’ dosing ne eds and to improve treatment accessibility and 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
19 (131) compliance.  The PK/PD, bioavailability and safety of SC administered anifrolumab in 
healthy volunteers is being evaluated in a phase 1 study (D3461C00006). 
The purpose of this study is to better understand the PK and PD of SC administered 
anifrolumab in SLE with the goal to identify do se and dosing regimen to be further evaluated 
in future development of the SC route of administration. 
1.2 Rationale for study population, study design, and dosing 
1.2.1 Rationale for study population and study design 
The overall aim of this Phase 2, multicentre, double-blind, randomized, placebo-controlled 
study is to provide PK/PD, safety and efficacy data to facilitate identification of dose and dosing regimen for future development of the SC route of administration of anifrolumab in 
SLE.  To allow optimal evaluation of the PD marker, i.e., changes of the 21-gene type 1 IFN 
PD signature, only subjects with type I IFN test-hi gh results will be eligible for the study.  In 
addition to evaluate the effects on the 21-gene type I IFN PD signature, anifrolumab efficacy 
on active skin manifestations will be characterized by recruitment of subjects with CLASI 
activity score 10.  
Data from phase 2b study (CD- IA-MEDI-546-1013) show s that ani frolumab administered IV 
Q4W, demonstrated a clinically relevant benefit in patients with moderate  to severe SLE when 
added to SOC.  The proportion of patients achieving a SLE responder index (SRI) 4 response 
with a sustained reduction in corticosteroids at Day 169, was greater in both the 300 mg 
(34.3%) and 1000 mg (28.8%) anifrolumab groups than in the placebo group (17.6%).  
Similar response rates were seen in the type I IFN test-high subpopulation (approximately 
75% of the overall population): 13.2% in the placebo group, 36.0% in the 300 mg anifrolumab 
group, and 28.2% in the 1000 mg anifrolumab group. 
Anifrolumab showed efficacy across multiple efficacy measures including improvement of 
skin symptoms.  The proportion of subjects with a CLASI activity score  10 at baseline who 
achieved at least a 50% decrease from baseline was numerically higher for anifrolumab than 
placebo group and the difference was observed fr om Day 29 and was sustained during the 52 
week treatment period.  Furthermore, data showed that the majority of subjects with active skin manifestations exhibited high IFN test scores. 
To ensure adequate treatment, subjects will remain on stable doses of SOC treatment with at 
least one of the following; oral corticosteroids, antimalarials, or immunosuppressants.  This is 
consistent with both the European League Against Rheumatism (EULAR) (Bertsias et al, 
2008) and American College of Rheumatology (ACR) (ACR ad hoc committee, September 1999) management guidelines of moderate to severe SLE, including treatment of skin 
manifestations. 
The study will be randomized, placebo-controlle d, and double-blind until primary analysis 
after all subjects have completed Week 12 to ensure a robust design and minimise bias.  The 
study is blinded with respect to anifrolumab and placebo, but not blinded at dose level.  This is 
the preferred design as outlined in the June 2010 FDA Guidance for Industry Systemic Lupus 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
20 (131) Erythematosus-Developing Medical Products  for Treatment and in the Committee for 
Medicinal Products fo r Human Use (CHMP) Guid eline on clinical investigation of medicinal 
products for the treatment of SLE and LN (CHMP, February 2015).  After Week 12, and 
unblinding of the sponsor, treatment will continue with investigators and subjects kept blinded 
throughout the remainder of the study.  A treatment period of 52 weeks will allow further 
characterization of PK/PD, safety, and efficacy of SC administered anifrolumab. 
1.2.2 Rationale for primary endpoint selection 
The 21-gene type I IFN PD signature was chosen as a PD biomarke r as an increase in type I 
IFN inducible mRNAs is a direct molecular conse quence of increased e xpression of type I 
IFN proteins.  Furthermore, measurement of  mRNA via reverse transcription-polymerase 
chain reaction (RT-PCR) is a comprehensive a nd reliable technique.  A robust panel of 21 
type I IFN-inducible genes were  selected based on th e magnitude of their overexpression in 
whole blood of patients with SLE, providing a sensitive and specific PD marker where mRNA 
expression can be meas ured quantitatively. 
CCI
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
21 (131) 1.2.4 IFN test background 
Type I IFN has long been considered to be  important in the pathogenesis of SLE and 
inhibition of this pathway is an attractive goal, targeted by anifrolumab.  To understand the 
relationship between type I IFN expression and response to anti-IFN therapy, it is necessary to 
know if a specific patient’s disease is driven by ty pe I IFN activation.  Direct measurement of 
the IFN is challenging, so a transcript-based  marker, measuring the effect of IFN, was 
developed to evaluate the effect of over-expression of the targ et protein on a specific set of 
messenger ribonucleic acid (mRNA) markers.  The expression of these markers is easily 
detected in whole blood and demonstrates a corre lation with expression in diseased tissue, 
such as skin, in SLE.  The bimodal distribution of the tran script scores for SLE patients, as 
shown in the Figure 2 below,  supports defining an IFN test-high and IFN test-low 
subpopulation. CCI
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
22 (131) Figure 2 Distribution of IFN transcript scores 
 
1.3 Benefit/risk and ethical assessment 
A detailed assessment of the overall benefit/risk of anifrolumab is discussed in the 
Investigator’s Brochure. 
There is significant unmet medical need for the treatment of patients with moderate to severe 
SLE.  Since type I IFNs seem very likely to have  a role in SLE, a therap y such as anifrolumab, 
that targets type I IFN receptors, may be beneficial. 
Anifrolumab has been, or is being, investigated in the following MedImmune/AstraZeneca-
sponsored clinical studies in adult subjec ts with systemic sclerosis (SSc) or SLE: 
x Study MI-CP180 was a Phase 1, open-label, dose escalation study of 
single and multiple IV doses of anifrolumab in adult subjects with SSc 
(completed study). 
x Study CD-IA-MEDI-546-1013 was a Phase 2b, randomized, double-
blind, placebo-controlled study of anifrolumab (300 mg and 1000 mg IV 
Q4W) in adult subjects with moderately to severely active SLE 
(completed study). 

Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
23 (131) x Study CD-IA-MEDI-546-1145 is the open-label extension for subjects 
completing Study CD-IA-MEDI-546-1013 (ongoing at the time of 
writing this protocol). 
x Study D3461C00002 is an open-label study in Japanese adult subjects 
with moderately to severely active SLE (ongoing at the time of writing 
this protocol). 
x Study D3461C00004 and study D346 1C00005 are phase 3 randomized, 
double-blind, placebo-controlled studies evaluating safety and efficacy in 
adult subjects with moderately to severely active SLE (ongoing at the 
time of writing this protocol). 
x Study D3461C0007 is a Phase 2 ra ndomized, double-blind, placebo-
controlled study characterizing the safety and efficacy of anifrolumab in adult subjects with LN (ongoing at the time of writing this protocol). 
x Study D3461C009 is randomized, doub le-blind, placebo-c ontrolled phase 
3 extension study characterizing the long-term safety and tolerability of anifrolumab in adult subj ects with moderately to severely active SLE 
enrolling subjects who have completed studies D3461C00004 and 
D3461C00005 (ongoing at the time of writing this protocol). 
x Study D3461C00006 is a Phase 1 study evaluating two dose levels (300 
and 600 mg) of SC administered and one dose level (300 mg) of IV administered anifrolumab in healthy volunteers. 
Study CD-IA-MEDI-546-1013 
This was a Phase 2b, randomized, double-blind, placebo-controlled, parallel group study to 
characterize the efficacy and safety of anifrolumab in adult subjects with moderately to 
severely active SLE with an inadequate respons e to SOC treatment.  In total 305 subjects were 
randomized and received placebo (n=102), anifro lumab 300 mg (n=99), or anifrolumab 1000 
mg (n=104) IV Q4W while continuing SOC treatment.  The study has been completed.  
Efficacy findings 
Anifrolumab demonstrated a clinically relevant  benefit with the proportion of patients 
achieving the primary endpoint, an SRI (4 ) response with a sustained reduction in 
corticosteroids at Day 169, being greater in both the 300 mg (34.3%) and 1000 mg (28.8%) 
anifrolumab groups than in the placebo group (17.6%).  The response rates in the IFN test- 
high population (appro ximately 75% of the overall population) were 13.2% in the placebo 
group, 36.0% in the 300 mg anifrolumab group, and 28.2% in the 1000 mg anifrolumab group.  Compared with the placebo group, a numerically higher proportion of patients in the anifrolumab groups achieved SRI (4) response with sustained reduction of OCS at Day 365 
(placebo, 25.5%; 300 mg, 51.5%; and 1000 mg, 38.5%).  The 300mg anifrolumab group saw a numerically higher proportion of patients have a reduction of background OCS dose to 7.5 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
25 (131) Expression of type I IFN-inducible genes in whole blood using the 21-gene type I IFN PD 
signature decreased following anifrolumab admini stration for all dose groups in subjects with 
a baseline IFN test-high result in whole blood.  For both the 300 mg and 1000 mg anifrolumab 
groups, > 85% median neutralization of the 21 -gene type I IFN PD si gnature was observed 
through Day 365, with numerically greater neutr alization observed in the 1000 mg group.  In 
the placebo group (N = 70 at baseline), no neutralization of the 21-gene type I IFN PD 
signature was observed at any time point.  Beca use subjects who were PD signature negative 
do not have significant type I IFN signature ex pression at baseline, the level of signature 
neutralization could not be robustly determined in this population. 
Safety findings  
The 300 and 1000 mg doses of anifrolumab were  generally safe and well tolerated compared 
to placebo.  After the review of all adverse events (AEs) as well as pre-specified safety topics 
of interest, the review revealed  a favourable safety profile fo r anifrolumab.  The overall 
number of patients with treatment-emergent adverse events (TEAEs), treatment-emergent 
serious adverse events (TESAEs), and AESIs; new or reactivated tuberculosis; malignancy; 
and infusion, hypersensitivity, or anaphylactic reactions, and non SLE related vasculitis) were 
similar between the placebo and anifrolumab groups.  TESAEs classified by the investigator 
as related to the study drug were observed in  5.9% of the patients in the placebo group, 3.0% 
in the 300 mg anifrolumab group, and 1.0% in  the 1000 mg anifrolumab group.  AEs leading 
to discontinuation of the study drug were observ ed in 7.9% in the placebo group, 3.0% in the 
300 mg anifrolumab group, and 9.5% in the 1000 mg anifrolumab group.  There was 1 death 
in the 1000 mg anifrolumab group  and none in the other 2 treatment groups. 
There was a higher frequency of patients with infection-related AEs in both the 300 mg 
(63.6%) and 1000 mg (61.9%) anifrolumab groups compared with  the placebo group (51.5%).  
An event of special interest, herpes zoster , was reported more frequently in the anifrolumab-
treated patients (300 mg anifrolumab group [5.1%]; 1000-mg anifrolumab group [9.5%]) 
compared with placebo-treated patients (2.0%).  Importantly, patients with herpes zoster 
infection responded well to standard antiviral treatment.  One TESAE of transverse myelitis with a positive varicella zoster  virus polymerase chain reaction in cerebrospinal fluid was 
reported.  The patient fully recovered following treatment with pulsed steroid and standard antiviral medication. 
Herpes zoster  reactivation, including cutaneous events , has been confirmed as an identified 
risk associated with administration of anifrolumab. There was a higher number of patients with infe ctions reported as influenza in the anifrolumab 
groups (300 mg [6.1%]; 1000 mg [7.6%]) co mpared with placebo (2.0%); however, the 
protocol did not require objective evidence confirming the aetiology of these infections. 
Infusion-related reactions were observed in 5.9% of placebo-treated patients, 2.0% in the 300 
mg anifrolumab group, and 3.8% in the 1000 mg anifrolumab group.  The characteristics and 
severity of these reactions were similar in all 3 treatment groups. 

Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
26 (131) No clinically important difference was observed in haematology, chemistry, urinalysis, vital 
signs, lipid parameters, or electrocardiograms (ECGs) in any of the treatment groups. 
Overall benefit/risk assessment 
Anifrolumab demonstrated a clinically relevant benefit in subjects with moderate to severe 
SLE receiving SOC treatment.  The efficacy was supported by a broad range of clinical 
measures of global (various levels of SRI responses, BICLA) and organ-specific disease 
activity (CLASI, joint count).  A clinically re levant increase in the proportion of subjects 
achieving pre-specified corticosteroid reducti on in the 300 mg group was observed compared 
with placebo.  No apparent difference was observed when comparing the 1000 mg and 
placebo group.  Anifrolumab was generally well tolerated.  A dose ordered increase in the proportion of subjects with uncomplicated herpes zoster  infections was observed in subjects 
receiving anifrolumab compared with placebo.  Herpes zoster  has been determined to be an 
identified risk associated with anifrolumab treatment in SLE patients. 
To date, in clinical studies of anifrolumab, hypersensitivity events or 
anaphylaxis/anaphylactoid events have not occu rred more frequently in subjects who were 
treated with anifrolumab IV as compared to  placebo, although careful monitoring for such 
events will continue.  The administration of any foreign protein may be associated with acute allergic reactions that may be severe, and may result in death.  Reports of infusion-related reactions from clinical studies conducted to date suggest that the frequency, severity and 
characteristics of these reactions are similar across all treatment groups after IV 
administration. In the Phase 1 SC study (Study D3461C00006), anifrolumab 300 mg or 
placebo were administered SC to healthy volun teers.  Both anifrolumab and placebo were 
administered as 2 injections into the SC tissu e of the anterior thigh or abdomen.  Subjects 
experienced minimal to mild and very transien t pain immediately after the injections with no 
difference between the placebo and anifrolumab group.  Similarily, injection-site pruritus was 
minimal and transient and showed no difference between anifrolumab and placebo groups.  
Even though anifrolumab is a human monoclonal antibody, subjects can develop ADA that 
may neutralise the activity of the drug or may be associated with acute or delayed 
hypersensitivity reactions, including anaphylax is.  Subjects will be monitored for clinical 
manifestations that may be associated with the formation of specific antibodies to anifrolumab 
generated during the study, as well as for the presence of such antibodies. 
In order to minimise the risk associated with anifrolumab treatment, subjects with risk factors 
for serious infections, recurrent herpes zoster , malignancy, or immune deficiency disorders 
are specifically excluded from participation.  Serious infections including non-opportunistic 
serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster , TB 
(including latent TB), influenza, and vasculitis (non-SLE) are designated as AESIs in this 
study.  An external independent adjudication committee will assess all deaths and 
cardiovascular SAEs to determine if they meet  criteria for MACE (stroke, acute coronary 
syndrome, myocardial infarction, or cardiovascula r death).  Specific detai ls will be addressed 
in a cardiovascular event adjudication charter.  There have been no imbalances in reported rates of MACE or other non-MACE cardiovascular  events observed either with anifrolumab 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
27 (131) or other agents sharing a similar mechanism of action compared to controls/placebo to date. 
However, since accelerated coronary artery disease and cerebrovascular accidents are 
recognised complications of SLE, the adjudication pr ocess is put in place to support rigorous 
case identification and categorisation for si gnal detection activity across treatment arms. 
Compared to the general population, patients w ith lupus have a higher rate of depression and 
suicide.  Therefore, subjects will be screened for suicidality and those who are at high risk as 
assessed at screening and baseline will be excluded from participation in the study.  
In conclusion, AstraZeneca believes that the available non-clinical and clinical data indicate 
an acceptable safety profile for anifrolumab when administered via the IV route.  A similar 
safety and tolerability profile has been seen in a Phase 1 SC study in healthy volunteers.  The 
proposed dosing regimens for this study are ad equately justified and the management plan for 
potential risks associated with anifrolumab is ap propriate.  The emerging safety profile has not 
identified any risks that would preclude continue d investigation of anifrolumab.  AstraZeneca 
believes that anifrolumab continues to demonstr ate an overall positive benefit/risk balance to 
support its clinical evaluation in subjects with mode rate to severe SLE and development of a 
SC administration route. 
1.4 Study Design
This is a Phase 2, multicentre, double- blind, randomized, placebo-controlled study 
characterizing the PK/PD, and safety of two fixe d doses of anifrolumab administered as SC 
injections in adult SLE subjects with type I IFN test-high result and active sk in manifestations 
while on stable SOC treatment.  The study will  be double-blind until database lock for the 
primary analysis performed after all subjects co mpleted Week 12.  Thereafter, the sponsor will 
be unblinded while the investigators and subjects will remain blinded throughout the 
remainder of the study. 
Approximately 32 subjects will be randomized to one of the four treatment groups in a 3:1:3:1 
ratio receiving:  
x anifrolumab at a fixed dose of 150mg as added to SOC, given Q2W as one SC injection in a volume of 1mL (12 subjects);  
x placebo as added to  SOC, given Q2W as one SC injection in a volume of 1mL  (4 subjects);  
x anifrolumab at a fixed dose of 300mg as added to SOC, given Q2W as two SC injections in a volume of 1mL each (12 subjects) or  
x placebo as added to SOC, given Q2W as  two SC injections in a volume 
of 1mL each (4 subjects). 
Subjects must be taking either 1 or any combination of the followings: OCS, antimalarial, or 
immunosuppressants at stable doses.  Specif ic medication restriction are contained in the 
eligibility criteria as described in Sections 3.1 and 3.2.2.  OCS doses should remain stable 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
28 (131) through Week 12, unless there is a clinical, safety or ethical reason for not to taper in which 
case reduction of OCS dose may be permitted from Week 4.  Starting at Week 12 a mandatory 
steroid tapering attempt will be required for all subjects with an OCS dose 10.0 mg per day 
of prednisone or equivalent at randomizatio n as described in Section 7.7.2.1.  
See Figure 3 for outline of the study design.  
This study includes:  
A screening period  of up to 30 days; 
A treatment period  of 52 weeks;  
A follow-up period  of 8 weeks. 
IP will be administered at study visits for a to tal of 26 doses (Week 0 to Week 50) during the 
treatment period and the last follow-up visit w ill be 10 weeks after the last IP dose.  
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
29 (131) Figure 3 Study flow chart 
 
Abbrev: Q2W= once every second week; SOC= standard of care; OCS=oral corticosteroids 

Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
30 (131) 2. STUDY OBJECTIVES 
2.1 Primary objective 
Primary Objective: Outcome Measures: 
To characterize the PK and PD of 150 mg 
and 300 mg anifrolumab administered as SC 
injections Q2W as measured by anifrolumab 
concentrations, PK parameters, 21-gene type 
I IFN PD signature score and neutralisation ratio at Week 12. Anifrolumab concentrations and PK parameters 
including maximum concentration (C
max) after first 
dose and trough concentration (C trough) after subsequent 
dosing 
21-gene type 1 IFN PD signature  and neutralization 
ratio (relative to baseline) 
 
2.2 Secondary objectives 
Secondary Objective: Outcome Measure : 
To characterize the safety and tolerability of 
anifrolumab when SC administered for a 52 Week treatment period  Adverse events (AE); serious adverse events (SAEs); Adverse events of special interest (AESIs) including herpes zoster, influenza, opportunistic infections, 
non-opportunistic serious infections, tuberculosis 
(TB), malignancies, non-SLE related vasculitis, 
anaphylaxis, and major adverse cardiovascular events (MACE); laboratory variables; physical examinations; vital signs; and ECG 
To characterize the immunogenicity of 
anifrolumab when administered SC for a 52 
Week treatment period  Anti-drug antibodies (ADA) 
 
 
2.3 Safety objectives 
Safety Objective: Outcome Measure : 
See above.  
 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
31 (131) 2.4 Exploratory objectives 
Exploratory Objective: Outcome Measure : 
To characterize the efficacy of SC administered anifrolumab on SLE skin manifestations as measured by the change in 
Cutaneous Lupus erythematosus disease Area 
and Severity Index (CLASI) score from 
baseline Proportion of subjects achieving 50% improvement 
in CLASI activity score from baseline to Week 12 
and Week 52 
 
To explore the effects of SC administered 
anifrolumab on type I IFN and other pathway-
related gene expression in skin tissue (optional 
part of study) 21-gene type 1 IFN and other pathway-related gene 
expression in skin tissue at baseline and at Week 12 
3. SUBJECT SELECTION, ENROLMENT, RANDOMIZATION, 
RESTRICTIONS, DISCONTINUATION AND WITHDRAWAL  
Each subject should meet all of the inclusion criteria and none  of the exclusion criteria for this 
study.  Under no circumstances can th ere be exceptions to this rule. 
3.1 Inclusion criteria 
1. In the opinion of the investigator, the su bject must be able to understand the 
informed consent form (ICF), and all protocol-related assessments 
2. Written informed consent and any locally required authorisation (e.g., Health 
Insurance Portability and Accountability  Act [HIPAA] in the US, Data Privacy 
Directive in the European Union [EU]) obtained from the subject prior to 
performing any protocol-related proced ures, including screening evaluations 
3. Completion of all screening procedures within 30 days of signing the ICF 
4. Aged 18 through 70 years at the time of screening 
5. Diagnosis of paediatric or adult SLE for  24 weeks prior to signing the ICF and 
fulfilling at least 4 of the 11 ACR classification criteria for SLE with at least one of 
which  being:  
x Positive antinuclear antibody (ANA) test at screening by 
immunofluorescent assay (IFA) at the central laboratory with titer 1:40; 
or 
x anti-dsDNA antibodies at screening elevated to above normal (i.e., 
indeterminate or positive results) as per central laboratory or  
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
32 (131) x anti-Smith (anti-Sm) antibodies at screening elevated to above normal 
(i.e., positive or equivocal results), as per central laboratory 
Clinical criteria may have been present by history if documented in the medical record. 
Historical laboratory values can be counted for SL E criteria but at leas t one of the values 
specified above must  be met during screening for eligibility. 
6. Weight 40.0 kg at screening 
7. Type I IFN test-high result 
8. Having a CLASI activity score   10 at screening 
9. Currently receiving at least 1 of the following for treatment of SLE*: 
x A dose of oral prednisone or equivalent of 40 mg/day for a minimum of 
2 weeks prior to signing the ICF.  The dose of oral prednisone or 
equivalent must be stable for a minimum of 2 weeks prior to randomization at Day 1 
x Any of the following medications administered for a minimum of 12 weeks prior to signing the ICF, and at a stable dose for a minimum of 8 
weeks prior to randomization at Day 1: 
(i) Azathioprine 200 mg/day 
(ii) Antimalarials (eg, chloroquine, hydroxychloroquine, quinacrine) 
(iii) Mycophenolate mofetil 2 g/day or mycophenolic acid 1.44 g/day 
(iv) Oral, subcutaneous (SC), or intramuscular methotrexate 25 mg/week 
(v) Mizoribine 150 mg/day 
* If receiving oral prednisone (or equivalent) co mbined with another agent listed above, the 
dose duration for both must be met. If subject´s immunosuppressive treatment consists of oral 
prednisone or other oral corticosteroid alone the minimal dose must be 7.5 mg/day or 
equivalent. 
10. Negative serum ȕ-human chorionic gonadotropin ( ȕ-hCG) test at screening (females 
of childbearing potential only) 
11. Females of childbearing potential must us e effective methods (Table 1) of avoiding 
pregnancy, only one of which is a barrier method and the other is a highly effective 
intrauterine device or hormonal method desc ribed in Table 1 below, from Screening 
until 12 weeks after the final dose of IP unless the subject is surgically sterile (i.e., 
bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy), has a 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
33 (131) sterile male partner, is 1 year post-menop ausal, or practices su stained abstinence. 
Cessation of birth control after the specified period for IP should be discussed with 
a responsible physician. 
x Sustained abstinence is an acceptable practice; however, periodic 
abstinence, the rhythm method, and the withdrawal method are not 
acceptable methods of contraception. 
x Post-menopausal is defined as at least 1 year since last menses and the subject having an elevated follicle-stimulating hormone (FSH) level 
greater than the central laboratory value of post-menopausal at screening 
if  <55 years of age at the time of signing the ICF. 
Effective methods of birth control include those listed in Table 1. 
Table 1 Highly effective intrauterine device and hormonal methods and 
effective barrier methods of birth control (2 methods are required, one 
being a barrier method and one being a intrauterine device/hormonal 
method) 
Contraceptive methods 
Barrier Methods 
(choose only one) Intrauterine Device/Hormonal Methods (choose only one) 
 Intrauterine Device 
Methods   Hormonal Methods  
Male condom 
(with spermicide*) Progesterone T  Contraceptive implants 
Cap (with spermicide cream or 
jelly*) Copper T Hormone shot or injection 
Diaphragm (with spermicide 
cream or jelly*)  Combined pill (progesterone and 
estrogen) 
  Minipill (progesterone only) 
  Contraceptive patch 
*where commercially available 
 
12. All males (sterilised or non-sterilised) who are sexually active must use condom 
(with spermicide where commercially available for contraception if sexually active 
with a woman of child bearing potential) from Day 1 until at least 12 weeks after receipt of the final dose of IP.  It is strongly recommended that  female partners of child bearing potential of  male subjec ts also use a highly effective method of 
contraception from Table 1 (other than a barrier method) throughout this period. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
34 (131) 13. Male subjects must not donate sperm during the course of the study and for 12 
weeks after the last dose of the IP. 
14. Females with an intact cervix must have documentation of a normal Pap smear with 
no documented malignancy (e.g., cervical in traepithelial neoplasia grade III [CIN 
III], carcinoma in situ [CIS], or adenocarci noma in situ [AIS]) within 2 years prior 
to randomization. (See Appendix J for guidance on abnormal Pap smear results). 
Any abnormal Pap smear result documented within 2 years prior to randomization 
must be repeated to confirm patient eligibility .  
15. Meets all the following TB criteria: 
(a) No history of latent or active TB prior to  screening, with the exception of latent TB with 
documented completion of appropriate treatmen t or currently receiving prophylactic treatment 
for latent TB and the subject commits to completing the full duration of prophylaxis (b) No signs or symptoms suggestive of active TB from medical history or physical 
examination 
(c) No recent close contact with  a person with active TB or if  there has been such contact, 
referral to a physician specialising in TB to undergo additional evaluation prior to 
randomization (documented appropriately in source ), and, if warranted, receipt of appropriate 
treatment for latent TB at or before the first administration of IP 
(d) Meet one of the following criteria: 
xNegative QuantiFERON-TB Gold [QFT-G] test result for TB obtained from 
central laboratory within 30 days prior to randomization or 
xPositive QFT-G test result for TB obtained during the screening period from 
central laboratory for which active TB has been ruled out and appropriate 
treatment for latent TB has been initiated prior to the first IP administration and the subject commits to completing the fu ll duration of prophylaxis, which may 
mean completing prophylax is during the study  or 
xIndeterminate (confirmed as indeterminate on retest during screening) QFT-G test for TB obtained during the screening period from central laboratory with ongoing QFT-G testing for TB to the Study Plan (Table 2) 
xA chest radiograph with no evidence of current active TB or other infection, or old active TB, malignancy, or clinically significant abnormalities (unless due to SLE) obtained during the screening period or anytime within 12 weeks prior to 
signing of the ICF 
3.2 Exclusion criteria 
Subjects should not enter the study if any of the following exclusion criteria are fulfilled. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
35 (131) 3.2.1 General exclusion criteria 
1. Any condition that, in the opinion of the Investigator, would interfere with 
evaluation of the IP or interpretation of subject safety or study results. 
2. Concurrent enrolment in another clinical study with an IP. 
3. Individuals involved with the conduct of the study, their employees, or immediate 
family members of such individuals. 
4. Lactating or pregnant females or females who intend to become pregnant anytime 
from initiation of Screening until the 12-week safety follow-up period following 
last dose of IP.  If serum or urine ȕ-hCG is positive at randomization the subject 
must be excluded. 
5. Current alcohol, drug or chemical abuse, or a history of such abuse within 1 year 
prior to randomization. 
6. Major surgery within 8 weeks prior to signing the ICF or elective major surgery 
planned during the study period. 
7. Spontaneous or induced abortion, still or live birth, or pregnancy 4 weeks prior to 
signing the ICF. 
8. At Screening (within 4 weeks before Week 0 [Day 1]), any of the following: 
xAspartate aminotransferase (AST) >2.0 × upper limit of normal (ULN) 
xAlanine aminotransferase (ALT) >2.0 × ULN 
xTotal bilirubin >ULN (unless due to Gilbert's syndrome) 
xSerum creatinine >2.0 mg/dL (or >181 ȝmol/L) 
xUrine protein/creatinine ratio >2.0 mg/mg (or >226.30 mg/mmol) 
xNeutrophil count <1000/ ȝL (or <1.0 × 109/L) 
xPlatelet count <25000/ ȝL (or <25 × 109/L) 
xHaemoglobin <8 g/dL (or <80 g/L), or <7 g/dL (or <70 g/L) if related to subject's SLE such as in active haemolytic anaemia 
xGlycosylated haemoglobin (HbA1c) >8% (or >0.08) at screening 
(diabetes subjects only) 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
36 (131) Note: Abnormal screening laboratory tests may be repeated once on a separate sample before 
subject is declared a screen failure. 
3.2.2 Exclusion criteria related to concomitant medications 
9. Receipt of any IP (small molecule or biologi c agent) within 4 weeks or 5 half-lives 
prior to signing of the ICF, whichever is greater. 
10. Prior receipt of anifrolumab 
11. Receipt of any commercially available biologic agent (as indicated in Section 7.8) 
within 5 half-lives prior to randomization 
12. Receipt of B cell-depleting therapy (including but not limited to ocrelizumab, 
ofatumumab, obinutuzumab, or rituximab) 26 weeks prior to signing the ICF.  If 
B-cell depleting therapy was administered >26 weeks ago an absolute B cell count 
(CD19+ cells determined duri ng screening by the central laboratory) less than the 
lower limit of normal or baseline value prior to receipt of B cell-depleting therapy 
(whichever is lower) will be exclusionary prior to signing the ICF. 
13. Receipt of epratuzumab, belimumab, or tabalumab 12 weeks prior to signing the 
ICF or atacicept 40 weeks prior to signing the ICF 
14. A known history of allergy or reaction to any component of the IP formulation or 
history of anaphylaxis to any human gamma globulin therapy 
15. Receipt of any of the following: 
xIntra-articular, intramuscular or IV glucocorticosteroids within 2 weeks 
prior to signing the ICF. 
xAny live or attenuated vaccine within 8 weeks prior to signing the ICF 
(administration of killed vaccines is acceptable, the Sponsor recommends Investigators ensure all subjects are up to date on required vaccinations, 
including influenza [inactivated/recombinant] vaccine prior to study 
entry); 
xBacillus Calmette-Guerin (BCG) vaccine within 1 year of signing the 
ICF; 
xAny prohibited medication listed in Section 7.8, if the washout period is 
not met; 
xBlood transfusion within 4 weeks prior to signing the ICF 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
37 (131) 3.2.3 Exclusion criteria related to systemic  lupus erythematosus and other diseases  
16. History of, or current diagnosis of, a clinically significant non SLE-related vasculitis 
syndrome.  Vasculitis due to SLE is allowed in the study; 
17. History or evidence of suicidal ideation (severity of 4 [active: method and intent, but 
no plan] or 5 [active: method, intent, and plan]) within the past 6 months; or any suicidal behaviour within the past 12 months based on an assessment with the C-SSRS at screening or at baseline;  
18. Active severe or unstable neuropsyc hiatric SLE including, but not limited to: 
aseptic meningitis; cerebral vasculitis; myelopathy; demyelination syndromes 
(ascending, transverse, acute inflammato ry demyelinating polyradiculopathy); 
acute confusional state; impa ired level of consciousness; psychosis; acute stroke or 
stroke syndrome; cranial neuropathy; status epilepticus; cerebellar ataxia; and 
mononeuritis multiplex:  
xThat would make the subject unable to fully understand the ICF OR  
xWhere, in the opinion of the Pr incipal Investigator (PI), protocol specified  
SOC is insufficient and utilisation of a more aggressive therapeutic 
approach, such as adding IV cyclophosphamide and/or high dose IV 
pulse corticosteroid therapy or other treatments not permitted in the 
protocol, is indicated; 
19. Active severe SLE-driven renal disease where, in the opinion of the investigator, 
protocol specified SOC is insufficient and utilisation of a more aggressive 
therapeutic approach, such as adding IV cyclophosphamide and/or high dose IV pulse corticosteroid therapy or other treatments not permitted in the protocol, is indicated 
20. History of or current diagnosis of catastr ophic or severe anti- phospholipid syndrome 
within 1 year prior to signing the ICF. Antiphospholipid syndrome adequately controlled by anticoagulant therapy for at least 3 months is acceptable 
21. History of, or current, inflammatory joint or skin disease other than SLE that, in the 
opinion of the Investigator, could interfere with the inflammatory arthritis or skin 
assessments and confound the disease activity assessment 
22. History of any non-SLE disease that has re quired treatment with oral or parenteral 
corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to 
signing the ICF 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
38 (131) 3.2.4 Exclusion criteria related to in fection and malignancy risk factors  
23. Known history of a primary immunodeficiency (e.g., common variable 
immunodeficiency syndrome), splenectomy, or any underlying condition that 
predisposes the subject to infection 
24. Opportunistic infection requiring ho spitalisation or parenteral antimicrobial 
treatment within 3 years of randomization 
25. Any of the following: 
- Clinically significant chronic infection (i.e., osteomyelitis, bronchiectasis, etc.) within 8 weeks prior to randomization (chronic nail infections  not causing open skin lesions are allowed) 
- Any infection requiring hospitalisation or treatment with IV anti-
infectives not completed at least 4 weeks prior to randomization  
- Any infection requiring IV or oral anti-infectives (including antivirals) 
within 2 weeks prior to randomization 
26. Confirmed positive HIV test at screening 
27. Confirmed positive test for hepatitis B serology for 
- Hepatitis B surface antigen, or 
- Hepatitis B core antibody (HBcAb) and hepatitis B virus (HBV) DNA 
with a quantifiable level detected by reflex testing by the central 
laboratory at screening. 
Note: Subjects with HBcAb positivity at screening will be tested every 3 months for HBV 
DNA. To remain eligible in the study, subject HBV DNA levels must remain below the lower 
level of quantitation (LLOQ) as per the central laboratory. 
28. Positive test for hepatitis C antibody as confirmed by central laboratory 
29. Any severe herpes zoster  infection at any time prior to randomization, including, 
but not limited to, disseminated herpes (ever), herpes encephalitis (ever), recurrent 
herpes zoster (defined as 2 episodes within 2 years) or ophthalmic herpes (ever) 
30. Any herpes zoster  infection that has not completely resolved within 12 weeks prior 
to signing the ICF; 
31. History of cancer, apart from:  
- Squamous or basal cell carcinoma of the skin treated with documented 
success of curative therapy 3 months prior to randomization 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
39 (131) - Cervical cancer in situ treated w ith apparent success with curative 
therapy 1 year prior to randomization 
Procedures for withdrawal of incorrectly enrolled subjects see Section 3.4. 
3.3 Subject enrolment and randomization 
If a subject does not meet eligibility criteria on the basis of a laboratory value at screening, 
then the laboratory parameter may be repeated on ce within the screening period; this will be 
considered as re-testing and re-screening is not required.  Please refer Section 4.1.1 for details 
on re-screening and re-testing. 
Investigator(s) should keep a record, the subjec t screening log, of subjects who entered pre-
study screening. 
The Investigator(s) will: 
1. Obtain signed informed consent from th e potential subject before any study specific 
procedures are performed.  The subject is considered enrolled when the ICF is 
signed and the enrolment call is done in the interactive voice/web response system 
(IXRS). 
2. Assign potential subject a unique enrolment number, beginning with . 
3. Determine subject eligibility.  See Section 3. 
4. At randomization the IXRS will assign eligible subjects to one of the four treatment 
groups, and assign eligible subjects a unique randomization code and blinded IP kit 
number(s) to the subject.  
If a subject withdraws from participation in th e study, then his/her en rolment/randomization 
code cannot be reused. 
Randomization codes will be assigned strictly sequentially as subjects become elig ible for 
randomization. 
IP (anifrolumab or placebo) should, if possible, be administered the same day the IP kit 
number is assigned.  
3.4 Procedures for handling incorrectly enrolled or randomized 
subjects 
Subjects who fail to meet the eligibility criteria, other than laboratory parameter as described 
in section 3.2, should not, under any circumstances, be enrolled or receive IP.  There can be 
no exceptions to this rule.  Subjects who are enrolled, but subsequently found not to meet all 
the eligibility criteria must not be randomized or initiated on treatment, and must be 
withdrawn from the study.

Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
40 (131) Where a subject does not meet all the eligibility criteria but is randomized in error, or 
incorrectly started on treatment, the Investigator should inform the AstraZeneca study 
physician immediately, and a discussion s hould occur between the AstraZeneca study 
physician and the investigator re garding whether to continue or  discontinue the patient from 
treatment.  The AstraZeneca study physician must ensure all decisions are appropriately documented. 
3.5 Methods for assigning treatment groups 
Block randomization using an IXRS will be used to randomize subjects and the AstraZeneca 
Biometrics and Information Sciences group is responsible for generating the randomization 
scheme for this study using the AZRand. 
All 32 subjects will be randomized to one of the four treatment groups in a 3:1:3:1 ratio 
receiving:  
x anifrolumab at a fixed dose of 150mg as added to SOC, given Q2W as 
one SC injection in a volume of 1mL (12 subjects);  
x placebo as added to  SOC, given Q2W as one SC injection in a volume of 
1mL  (4 subjects);  
x anifrolumab at a fixed dose of 300mg as added to SOC, given Q2W as 
two SC injections in a volume of 1mL each (12 subjects) or  
x placebo as added to SOC, given Q2W as  two SC injections in a volume 
of 1mL each (4 subjects). 
3.6 Methods for ensuring blinding 
This is a double-blind study in which anifrolumab and placebo are distinguishable during 
preparation of the suspension for injection by syringe.  Given that the treatments will be given 
as one or two SC injections depending on dose level, the study is double-blinded with respect 
to anifrolumab or placebo, but not to dose le vel.  The double-blind period will last up until 
analyses of primary endpoints at Week 12.  Th ereafter investigators and subjects will remain 
blinded throughout the remainder of the study.  All packaging and labelling of IP is done in 
such way as to ensure blinding for all Sponsor and investigational site staff other than the unblinded person responsible for final preparation steps and for injections of IP and placebo. 
The kits on the shelf look identical.  Preparation of IP and placebo and injections must be 
done by an unblinded, qualif ied person (e.g., pharmacist or nurse) who is otherwise not 
involved in the study. 
Neither the subject nor any of the Investigator or Sponsor staff/designee who are involved in 
the treatment or clinical evaluation and monitoring of the subjects will be aware of if the subjects has received ani frolumab or placebo.  In the event that the treatment allocation for a 
subject becomes known to the Investigator or other study staff involved in the management of 
study subjects, the Sponsor, or designee must be notified immediately by the Investigator. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
41 (131) 3.7 Methods for unblinding  
Individual treatment codes, indicating the treatment randomization for each randomized 
subject, will be available to the Investigator(s) or pharmacists from the IXRS.  Routines for 
this will be described in the IXRS user manual that will be provided to each centre. 
The treatment code should not be broken except in medical emergencies when the appropriate 
management of the subject requires knowledge of the randomized treatment allocation.  The 
Investigator documents and reports the action to AstraZeneca, without revealing the treatment 
given to subject to the AstraZeneca staff.  
AstraZeneca retains the right to break the co de for SAEs that are unexpected and are 
suspected to be causally related to an IP and that potentially require expedited reporting to 
regulatory authorities.  Treatment codes will not  be broken for the planned analyses of data 
until all decisions on the evaluability of the da ta from each individual subject have been made 
and documented. 
3.8 Restrictions 
3.8.1 Fasting lipid profile 
Subjects will be required to fast for at least 8 hours prior to assessment of lipid profile at the 
visits described in Study Plan (Table 2 and Table 3).  If the subject has not fasted, he/she should fast before the next visit, and the test can be done at that visit. 
3.8.2 Perioperative management of investigational product 
Planned surgeries should be avoided during the study if clinically feasible. 
Pre-operative management of investigational product:   
If a non-urgent major surgery becomes necessar y during the study, it should be scheduled at 
least 4 weeks after the last administration of investigational product, if clinically feasible.  The 
determination of whether or not a surgery is “urgent” will be at the discretion of the investigator, preferably in consultation with the AstraZeneca study physician.  The decision to withhold investigational product administration is at the Investigator’s discretion.  
Post-operative management of investigational product:
Investigational product administration can be re sumed at the Investigator’s discretion after all 
of the following criteria are met:
x External wound healing is complete and 
x Any post-operative antibiotic course is completed and 
x All acute surgical complications have resolved 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
42 (131) Blood donation 
Subjects must not donate blood from date of randomization until 12 weeks after the last dose 
of IP. 
3.9 Discontinuation of investigational product 
At any time, subjects are free to discontinue IP or withdraw from the study without prejudice 
to further treatment.  A subject that decides to discontinue IP will always be asked about the 
reason(s) and the presence of any adverse even ts.  Discontinuation of IP does not mean 
withdrawal from study participation.  
Subjects may be discontinued from IP in the following situations; 
1. Subject decision.  The primary reason should be documented as one of the 
following: 
xSubject is unable to comply with protocol-specified visits and/or 
procedures due to conflicts not related to clinical trial 
xAn AE or laboratory abnormality is of concern to the subject, but not 
clinically significant to physician 
xThe subject perceives the IP to be ineffective 
xSubject wishes to participate in another clinical trial 
xSubject is interested in taking a treatment that is not allowed in this study 
xSubject perceives logistics at the clinical site to be unacceptable 
xOther reason 
2. Adverse event that, in the opinion of the Investigator or AstraZeneca Study 
physician contradicts further dosing with IP. 
3. Severe non-compliance with the study protocol. 
4. The Investigator or AstraZeneca Study Phys ician deems withdrawal as being in the 
subject's best interest. 
5. Pregnancy, positive pregnancy test, or subj ect expresses an interest to become 
pregnant. 
6. Isolated HBc positivity with HBV DNA above LLQ confirmed by the central 
laboratory. 
7. Receipt of any medications identified in Section 7.8. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
43 (131) 8. The use of SOC medications listed in Section 7.7.1 in doses exceeding the maximal 
allowed doses, if the AstraZeneca study physician, determines the subject must be 
discontinued. 
9. A diagnosis of active TB, premature discontinuation of treatment for latent TB, or 
noncompliance with latent TB therapy.  Note: Duration of treatment for latent TB 
should follow the local practice.  If local pr actice is not defined,  then CDC guidance 
for immunocompromised patients should be used. 
10. Subjects who develop worsening of SLE as described in Section 3.9.1.  
11. IP is unblinded by the Investigator. 
If a subject is withdrawn from study, see Section 3.10 for details. 
3.9.1 Discontinuation of investigational product due to worsening of SLE 
IP will be discontinued at any time during the study in subjects who develop active severe 
SLE disease manifestations that in the opini on of the Investigator, require treatment with 
cyclophosphamide, high dose corticosteroids, plasmapheresis, or intravenous 
immunoglobulins (IVIG) or other treatments not permitted in the protocol. 
3.9.2 Procedures for discontinuation of a subject from investigational product  
In order to support safety analysis (see Section 8) for anifrolumab subjects who are 
discontinued from the IP should continue to undergo study visits 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 28 (as applicable).  All visit-rela ted procedures except t hose associated with IP 
administration should be completed, (Table 3).  Protocol-specified OCS tapering will not be 
required for these subjects.  All subjects should complete an observation period of at least 10 
weeks after the last IP received.  In case this does not occur within the time frame of the visits 
specified above, a follow-up vi sit might be required.  The ap proach taken and reason for 
premature discontinuation of IP should be registered in the CRF.  If the subject permanently 
discontinues IP prior to their completion of the study and wishes to continue with only selected study assessments; prioritised assessments are listed in Section 3.9.  For subjects who 
wish to withdraw from the study comp letely refer to Section 3.10.2.  
3.10 Criteria for withdrawal  
3.10.1 Screen failures  
Screening failures are subjects who have provided informed consent but who do not fulfil the 
eligibility criteria for the study, and therefore mu st not be randomized.  These subjects should 
have the reason for study withdrawal recorded as  “Screen Failure” (i.e., subject does not meet 
the required eligibility criteria).  This reason for study withdrawal is only valid for screen 
failures (not randomized subjects).  For eligibility for re-screening of a subject refer to Section 
4.1.1.  Rescreening of a subject will be permitted once. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
44 (131) 3.10.2 Withdrawal of the informed consent 
Patients are free to withdraw from the study at any time (IP and assessments), without 
prejudice to further treatment.  A patient who withdraws consent will always be asked about the reason(s) and the presence of any adverse events (AE).  The Investigator will follow up AEs outside of the clinical study.  If a subject withdraws from participation in the study, then his/her enrolment/randomization code cannot be reused.  
3.10.3 Lost to follow-up 
Subjects will be considered lost to follow-up only if no contact has been established, despite 
several attempts, by the time of study completion.” Lost to follow-up” as a reason for study withdrawal must be documented by time and date of last contact and time. 
3.11 Discontinuation of the study 
The study may be terminated at individual centers if the study procedures are not being 
performed according to Good Clinical Practice (G CP), or if recruitment is slow.  AstraZeneca 
may also terminate the entire study prematurely if concerns for safety arise within this study or in any other study with anifrolumab.  The study may be stopped if, in the judgement of the 
Sponsor, study subjects are placed at undue risk  because of clinically significant findings that: 
x Meet individual stopping criteria (see Section 3.9 for reasons for 
discontinuation of investigational product) or are otherwise considered 
significant 
x Are assessed as causally related to investigational product 
x Are not considered to be consistent with continuation of the study 
Regardless of the reason for termination, all data available for the subject at the time of 
discontinuation of follow-up must be recorded in the CRF.  All reasons for discontinuation of 
treatment must be documented. 
In terminating the study, the Sponsor will ensure that adequate consideration is given to the 
protection of the subjects’ interests. 
4. STUDY PLAN AND TIMING OF PROCEDURES  
Table 2, Table 3 and Table 4 below show the procedures for the Screening, Treatment, and 
Follow-up visits, respectively.  
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
46 (131) Visit 
 V1  
Screening
Study Day  Day -30 to Day -1 
Week / Procedure -4 to 0 
TB questionnaire X 
Colombia Suicidality Severity Rating Scale (C-SSRS) X 
Assessment of AEs/SAEs/AESIs X 
Verify eligibility criteria X 
aStandard 12-lead ECG 
bPA and lateral chest x-ray will be performed at screening, if not performed within the previous 12 weeks 
cThese assessment must all be completed at same visit (CLASI, SLEDAI-2K, PGA),  if applicable. 
dFemale subjects, unless surgically sterile or 1 year postmenopausal 
eFemales < 55 years of age suspected to be post menopausal. 
fOnly in females with an intact cervix who have not had a Pap smear the last 2 years prior to screening that 
metinclusion criteria 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
50 (131) gSubjects who are HBcAb positive at screening will be tested every 3 months for HBV DNA. To remain eligible for the study, the s ubject’s HBV DNA 
levelsmust remain below the LLOQ as per the central laboratory 
hQuantiFERON-TB Gold test will be followed for those subjects with indeterminate levels at screening.
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
52 (131) dQuantiFERON-TB Gold test will be followed for those subjects with indeterminate levels at screening. 
 
4.1 Enrolment/screening period 
At screening, consenting subjects are assessed to ensure that they meet eligibility criteria. 
Once the subject signs the informed consent, they are considered enrolled in the study.  
Subjects who do not meet eligibility criteria must not be randomized in the study. 
Screening assessments will be performed acco rdingly to the Screening Visit Procedures 
(Table 2), from Day -30 to Day -1.  Screening pr ocedures may take place during more than 1 
visit. Once screening assessments are complete and all necessary laboratory results are obtained, a 
subject may be randomized.  The randomization at Week 0 (Day 1) may occur at any time 
point within 30 days after screening visit provided that all required assessment results are 
available. 
Chest x-rays and Pap smears may be completed anytime during the screening period as long 
as all results have been reviewed by the Investigator prior to randomization.  4.1.1 Re-testing and re-screening 
Re-testing 
If a subject does not meet the eligibility criteria on the basis of a laboratory value for liver 
enzymes, haematological, or disease activity  related tests the laboratory parameter may be 
repeated once  within the screening period.  This re-testing is allowed without requirement for 
re-screening.  
Re-screening 
Subjects who fail to meet the inclusion/exclusion criteria (i.e., screening failures) may be 
eligible to be re-screened once and AstraZeneca Study Physician can be contacted for 
discussion and decision regarding re-screening.  Subjects who are re-screened will be required 
to re-consent and complete/ repeat all applicable study procedures.   
4.1.2 Other considerations for screening  
4.1.2.1 Medical history 
A complete medical history by body system will be completed during screening.  This will 
also include history of allergies and anaphylaxi s, concomitant diseases, viral reactivation 
events, and previous manifestations of SLE.  On Day 1, the medical history will be reviewed 
and any changes since screening will be documented, if applicable. 
4.1.2.2 SLE medication history 
All prescription medications the subject has ever taken for SLE should be documented in the 
subject's file (except for only minor dose adjustments if these were done ޓ3 months prior to 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
53 (131) the ICF signature date), including prior use of cyclophosphamide, mycophenolate mofetil, 
mycophenolic acid, oral and parenteral corticosteroids; if these were discontinued, then 
reasons for discontinuation must be included.  Any medications ongoing at the time of 
informed consent or received following signing the ICF are considered concomitant 
medications.  Any non-prescription medications , e.g., naturopathic or ayurvedic remedies, 
ever used for SLE or for any other purpose shoul d be documented, as well as continuing use 
of any non-prescription remedies not excluded from use during the study period. 
4.1.2.3 Oral examination 
In several biological programs there have been  serious infections and/or death related to 
Ludwig’s angina.  Although this has not been seen in the anifrolumab program, Investigators 
should check a subject’s oral cavity and review their dental health carefully during the screening process.  While a dental examination is not required prior to enrolment in this study, Investigators are cautioned to consider carefully whether subjects have active caries or a 
dental infection that might impact on subj ect safety prior to enrolment.  
4.1.2.4 Mammography 
As subjects with SLE have impaired immune response, are treated with immunosuppressants, 
and are at potential risk for malignancy, it is recommended that patients enrolled into the 
study are compliant and up to date with local recommendations for mammography or other 
screening procedures for breast cancer.  
4.2 Treatment period 
Assessments during the Treatment Period will be performed according to the Schedule of Treatment Visit procedures (Table 3), from Week 0 (Day 1) to Week 52.   
On Day 1, upon confirmation that the subject cont inues to meet eligibilit y criteria, the subject 
will be randomized in to the study via the IXRS system. 
Subjects will have scheduled visits at 2-week intervals to complete protocol-specified 
assessments and IP administration according to the Schedule of Treatment Visit Procedures (Table 3). 
The last dose of IP will be administered on Week 50. At Week 52, subjects will have End of 
Treatment (EOT) visit.  For subjects who prematurely discontinue IP and are not willing to 
continue to participate in the study refer to Section 3.9. 
4.2.1 Patient survey at week 12 
After subjects complete all the assessments/procedures required at week 12, subjects will be 
asked to complete patient survey for trial experi ence.  See Appendix O.  For subjects who are 
premature discontinued, the patient survey will be completed at the early discontinuation visit.  
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
54 (131) 4.2.2 Follow-up visits after premature discontinuation of investigational product 
Subjects who discontinue IP should continue to undergo study visits 4, 6, 8, 10, 12, 14, 16, 18, 
20, 22, 24, 26, and 28 (as applicable).  If the subject is unwilling to complete all regularly 
scheduled clinic visits, the subject should complete the Early Discontinuation Visit (Week 52 procedures) within 2 weeks of the last dose of  IP, as well as Follow-up Visits (Week 56 and 
Week 60 procedures) unless consent is withdrawn.  If the subject is unwilling to continue with 
any study visits, including EOT, at the minimum, the following assessment should be 
completed:  
x PK/PD blood sample 
x CLASI 
x SLEDAI-2K 
x PGA 
In addition the following safety assessments must be performed: 
x C-SSRS 
x Assessment of AEs/SAEs (including AESIs) 
x Concomitant medications 
x Targeted physical exam 
x Vital Signs (BP, HR, RR and body temperature) 
x Weight  
x Safety lab tests 
x ADA test 
x TB questionnaire 
4.3 Follow-up period 
All subjects will be followed for 10 weeks after the last IP dose.  Table 4 shows all procedures 
to be conducted during the follow-up period.  
4.4 Unscheduled visits 
If a subject needs an unscheduled visit the Investigator should decide the assessments needed to be completed based on the reason for the visit and for subject´s safety.  Concomitant 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
55 (131) medications and AEs should be collected at all unscheduled visits.  Efficacy assessments 
should not be completed at unscheduled visit. 
5. STUDY ASSESSMENTS 
The Rave Web Based Data Capture (WBDC) system will be used for data collection and 
query handling.  The investigator will ensure that data are recorded on the electronic Case 
Report Forms as specified in the study protocol and in accordance w ith the instructions 
provided. 
The investigator ensures the accuracy, completeness, and time liness of the data recorded and 
of the provision of answers to data queries according to the Clinical Study Agreement.  The 
investigator will sign the completed electronic Case Report Forms.  A copy of the completed 
electronic Case Report Forms will be archived at the study site. 
5.1 Efficacy assessments 
Efficacy measurements will be made at the times indicated in the Study Plan (Table 2, Table 3 
and Table 4).  
5.1.1 Training and certification for Systemic Lupus Erythematosus assessments 
In order to maintain consistent evaluation of SLE disease activity across study sites, training 
and certification of Investigator and designated site physicians who will be completing the 
disease evaluation listed below will be conducted.  
x CLASI 
x SLEDAI-2K 
x PGA  
The CLASI, SLEDAI-2K, PGA must be administered by the Investigator or another qualified 
physician, unless prior sponsor approval has been  obtained for any other c linically trained site 
personnel with documentation of adequate assess ment experience and training.  Training will 
include printed training materials, digital video disks (DVDs) and formal presentations, web-based training modules, as well as training sessions during investigator’s meeting if 
applicable.   
After attending study presentations (i.e., Invest igator Meeting) or after completion of online 
training module, all Investigators and designed site physicians must pass an online 
examination in order to obtain certification for all disease evaluation assessments.  
Investigators and designated site personnel must  be trained and certified prior to subjects 
entering screening at their respective sites.  If there is a change in site personnel over the 
course of the study, new Investigators or physic ians must be certified prior to perform the 
CLASI, SLEDAI-2K and PGA assessments.  
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
56 (131) Documentation of all training will be maintained in the site’s study file.  
Over the course of the study, Investigator assessments for a given subject should be completed 
by the same trained and/or certified Investig ator, designated physician, or qualified site 
personnel (as described above) whenever possible.  
5.1.2 Cutaneous Lupus Erythematosus Disease Area and Severity Index  
The CLASI is a validated index used for assessing the cutaneous lesions of SLE and consists 
of 2 separate scores: the first summarises the inflammatory activity of the disease; the second 
is a measure of the damage done by the disease (see Appendix F).  The activity score takes 
into account erythema, scale/hypertrophy, mucous membrane lesions, recent hair loss and 
non-scarring alopecia.  The damage  score represents dyspigmentation, 
scarring/atrophy/panniculitis, and scarring of the scalp.  Subjects are asked if their 
dyspigmentation lasted 12 months or longer, in which case the dyspigmentation score is 
doubled.  Each of the above parameters is m easured in 13 different anatomical locations, 
included specifically because they are most often  involved in cutaneou s lupus erythematosus 
(CLE).  The most severe lesion  is each area is measured.  
5.1.3 Systemic Lupus Erythematosus Disease Activity Index 2000 
The SLEDAI-2K disease activity index (See A ppendix E) consists of a list of organ 
manifestations, each with a definition.  A certified Investigator or designated physician will 
complete the SLEDAI-2K assessments and decide whether each manifestation is “present” or 
“absent” in the last 2 weeks.  The assessment also include the collection of blood and urine for 
assessment of the laboratory categories of the SLEDAI-2K.  
The SLEDAI-2K assessment consists of 24 lupus-r elated items.  It is a weighted instrument, 
in which descriptors are multiplied by a particular organ’s “weight”.  For example, renal 
descriptor are multiplied by 4 and central nervous descriptor by 8 and these weighted organ 
manifestations are totalled into the final score.  The SLEDAI-2K score range is 0 to 105 points 
with 0 indicating inactive disease.  The SLEDAI-2K score are valid, reliable and sensitive 
clinical assessments of lupus disease activity.  
5.1.4 Physician Global Assessment 
A trained and certified Investigator will complete the PGA (see Appendix G).  The PGA 
represents the physician’s overall assessment of  average SLE disease severity on a VAS scale 
with 0 (no disease) to 3 (severe) disease activity.  The PGA for a given subject should be 
completed by the same physician whenever possible.  
The PGA is a modification of the classic analogue scale in that it is anchored with numbers 
from 0 to 3 demarcating no, mild, moderate and severe disease.  The number 3 indicates 
severe disease and is at the end of the scale.  This  refers to the most se vere possible disease, 
and does not reflect the most severe seen in a particular subject, but the most severe disease 
ever seen in all SLE subjects.  Therefore, the line made by the physician along this scale should virtually never get to this edge.  Any di sease rated greater than 2.5 is very severe.  The 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
57 (131) range of moderate disease covers approximately 1.5 to 2.4. Mild disease falls below 1.5.  The 
instrument is similar to a logarithmic scale, wi th greater distances or demarcations possible 
among more mild-moderate symptoms.  
When scoring the PGA, the score from the previ ous visit should be reviewed and the mark 
should be moved relative to the score from the previous visit.  This is global assessment, 
factoring in all aspects of subject’s lupus dis ease activity.  It should not reflect non-lupus 
medical conditions.  
5.1.5 Oral corticosteroid tapering 
Please refer to Section 7.7.2 for all information regarding steroid tapering.  
5.2 Safety assessments 
5.2.1 Clinical Laboratory assessments All clinical laboratory tests will be performed in a central clinical laboratory at the times 
indicated in the Study Plan (Table 2, Table 3 and Table 4).  
A serum pregnancy test (or serum FSH in postmenopausal females of age < 55 years with 
menses absent for  1 year) will be performed at scre ening at the central laboratory.  Urine 
pregnancy tests will be performed at the site using a dipstick.  
Additional safety samples may be collected if cl inically indicated at the discretion of the 
Investigator.   
Every attempt should be made to redraw any missing safety laboratory tests, even if the 
subject has received the investigational product.  
The following laboratory variables will be measured: 
Table 5 Clinical Laboratory Variables 
Haematology (whole blood) Clinical Chemistry (serum) 
B-Haemoglobin (Hb) Calcium 
B-Leukocyte count Chloride 
B-Leukocyte differential count (absolute count) Potassium 
B-Platelet count Sodium 
B-Haematocrit AST* 
B-MCV, MCH, MCHC ALT* 
B cell count (only if prior B cell-depleting 
treatment) ALP* 
Urinalysis  GGT 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
58 (131) Colour BUN 
Appearance Creatinine 
Specific gravity Total bilirubin* (reflexively fractionated if elevated) 
pH Glucose 
Protein dipstick Albumin 
Glucose CK 
Ketones Fasting lipid profile : 
Blood Total Cholesterol 
Bilirubin High density lipoprotein (HDL) 
Microscopy including WBC/HPF, RBC/HPF, casts Low density lipoprotein (LDL)
Urine creatinine and protein, Urine protein/creatinine ratio Triglycerides 
Inflammatory marker panel  Infection related test  
ESR, IgM, IgG, IgA Human immunodeficiency virus (HIV)  
 Hepatitis B surface antigen (HbsAg) 
SLEDAI-2K lab tests  Hepatitis B core antibody (HbcAb) (reflex DNA testing if isolated HBc positive) 
C3, C4, CH50, anti-dsDNA, Urine 
protein/creatinine ratio, Hepatitis C antibody 
Autoantibody Panel Coagulation test 
ANA, anti-dsDNA, anti-Smith, anti-ribonuclear 
protein  Prothrombin time (PT) 
 Partial Thromboplastin time (PTT) 
Pregnancy  Other 
Serum ȕ-HCG pregnancy test Type I IFN 4-gee test  
Serum FSH Hemoglobin A1c (only diabetics) 
Urine pregnancy test QuantiFERON-TB Gold test 
*Note for serum chemistry: Tests for AST, ALT, ALP, and total bilirubin must be conducted 
concurrently and assessed concurrently. 
The Investigator should make an assessment of the available results with regard to clinically 
relevant abnormalities.  The laboratory results should be signed and dated and retained at centre as source data for laboratory variables.  For information on how AEs based on 
laboratory tests should be recorded and reported, see Section 6.3. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
59 (131) NB. In case a subject shows an AST or ALT 3xULN or total bilirubin  2xULN please refer 
to Appendix C ‘Actions required in cases of co mbined increase of Aminotransferase and Total 
Bilirubin – Hy’s Law’, for further instructions. 
5.2.1.1 Haematology, clinical chemistry, and urinalysis testing 
Haematology, chemistry, and urinalysis, will be taken throughout the study as described in 
Sections 4.1, 4.2 and 4.3.  Table 5 provides a complete list of the tests included in the Safety 
Laboratory Variables.  
5.2.1.2 Coagulation Testing 
Prothrombin time (PT) and partial thromboplastin time (PTT) will be performed as part of the 
screening tests. 
5.2.1.3 Infectious Disease Panel 
All subjects will be required to undergo infectious di sease testing as part of the screening 
assessments.  The Infectious Disease panel includes testing for human immunodeficiency 
virus, Hepatitis B and C virus. 
Subjects with a confirmed positive HIV test, Hepatitis B surface antigen, or Hepatitis C 
antibody will not be eligible to participate.  
Subjects with an isolated positive test for Hepatitis B core antibody at enrolment/screening, 
will be tested for Hepatitis B DNA at the central laboratory.  Subjects with HBV DNA test 
above LLQ the will not be eligible to participate and subjects with undetectable HBV DNA, 
defined as below the LLQ, will be eligible to participate and must be tested every 3 months 
for HBV DNA.  If, at any time during the Active Treatment period, HBV DNA is detected, the subject must be discontinued according to Section 3.9.2. 
5.2.1.4 Fasting lipid profile 
Subjects will have a fasting lipid profile (total cholesterol, high density lipoprotein 
cholesterol, low density lipoprotein cholesterol, and triglycerides) completed at times 
indicated in Table 2 and Table 3.  Subjects will be  required to fast for at least 8 hours prior to 
this assessment (see Section 3.8.1). 
5.2.1.5 Tuberculosis Testing 
Subjects will be tested for TB at screening an d at various additional time points throughout the 
study, if required.  Please refer to Section 5.2.6.2 for details of TB screening and monitoring. 
5.2.1.6 Pregnancy Testing 
Females of child-bearing potential will be required to have a negative serum ȕ-hCG test 
during the enrolment/screening period; please re fer to Section 4.1  A negative urine dipstick 
pregnancy testing is required prior to administration of IP and pregnancy testing is also 
required at follow-up visits; please refer to Sections 4.2 and 4.3. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
60 (131) Follicle-stimulating hormone (FSH) testing is re quired at screening for all post-menopausal 
female subjects of an age of < 55 years, defined as at least 12 months since last menses.  FSH 
level must be greater than the central laboratory value of post-menopausal.  If the FSH level is 
not above the central laboratory value of post-menopausal, two effective methods of 
contraception (see Table 1) must be used. 
5.2.2 Physical examination 
Complete physical examination 
A complete physical examination will be performed at the visits specified in Table 2, Table 3, 
and Table 4.  The examination includes assessments of;  general appearance, respiratory, cardiovascular, abdomen, skin, head and neck  (including ears, eyes, nose and throat), lymph 
nodes, thyroid, abdomen, musculo-skeletal (inc luding spine and extremities) and neurological 
systems. 
Targeted physical examination 
A targeted physical examination will include an assessment of the organ systems required to 
complete protocol-specified assessment tools (SLEDAI-2K and CLASI).  Additional assessment should be done as clinically indicated.  Abnormal findings will be recorded as part of AE, SAE, AESI, or SLE activity, as appropriate.  
5.2.3 ECG 
Standard 12-lead ECGs will be performed on all patients at specific time points as described 
in the Study Plan (Table 2, Table 3, and Table 4), as to local routines.  A single ECG will be taken after the patient has been resting for 5 minutes in the supine position.  Clinically significant abnormalities according to the Investigators´ discretion registered after screening visit should be reported as AEs.  
5.2.4 Vital signs 
Vital signs (body temperature, blood pressure [B P], pulse rate and respiratory rate) will be 
obtained at each visit and before and after IP administration as described in Section 7.2.2. 
7.2.2 
5.2.5 Assessment of Injection Sites 
Injection sites will be visually inspected before (except at Day 1) and after IP administration at 
every visit from Week 0 through Week 50.  
5.2.6 Other safety assessments 
5.2.6.1 Chest x-ray 
A posterioranterior (or anteriorposterior) and lateral view chest x-ray will be obtained during 
the screening period or can be substituted with documentation of a previous chest x-ray 
performed anytime within 12 weeks of the expected date of randomization. A chest x-ray that 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
61 (131) has no evidence of current active infection (e.g., TB) or old active TB, malignancy, or 
clinically significant abnormalities (unless due to SLE) is required to meet inclusion criteria. 
A formal radiologic report of the chest x-ray should be available at the site.  The report should 
allow the assessment of the following: 
x No evidence of any active infection including TB 
x No evidence of old active TB 
x No evidence of malignancy 
x No evidence of other clinically significant abnormalities unless felt 
secondary to SLE (these should be specified [e.g., pleural effusion]) 
5.2.6.2 Tuberculosis screening and monitoring 
Screening evaluation 
A blood test for TB will be done at screening using QFT-G.  This is an IFN gamma release 
assay (IGRAs) test.  Evaluation of all subjects by QFT-G test will be performed by the central clinical laboratory, and chest x-rays within 12 weeks prior to Week 0 (Day 1) will be 
completed.  Compared to culture confirmed TB, overall, 87.6% of patients have a positive 
QFT-G result (Cellestis, 2005).  The false negative rate in this setting appears to be over 12%. 
Further, the performance of the test in the setting of immunosuppressant drugs has not been 
evaluated.  Nor has it been evaluated in individuals with medical conditions other than, or in 
addition to, latent TB or TB disease.  The guide also states that “Medical treatments or 
conditions that impair immune functions can potentially reduce IFN-Ȗ  responses and prevent 
detection of a specific response to the (secretory proteins) ESAT-6 and CFP-10 (the test 
stimulators)”.  Given the population to be enrolled in this study, false negative tests are 
possible, so a chest x-ray, both PA and lateral views, is a relevant and warranted technique 
(unless limited by local practice) for detecting active pulmonary disease and minimising potential risk to study subjects. 
Tuberculosis results from screening evaluations 
x If the screening QFT-G test is negative and there is no known history of 
recent exposure to individuals with active TB, and chest radiograph shows no evidence of active TB, the subject may be randomized without 
prophylaxis. 
x If the screening QFT-G test is newly positive (can be preceded by an indeterminate or negative result) a nd chest x-ray shows no evidence of 
active TB, and the subject has no symptoms or medical history consistent 
with active TB, treatment for latent TB must be initiated prior to the first 
investigational product administration and the subject must commit to 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
62 (131) completing the full duration of prophylaxis, which may mean completing 
prophylaxis during the study. 
x If the screening QFT-G test is positive at screening but the subject is not 
newly positive, the subject may be randomized if: 
- Previous or current active TB infection was ruled out and 
- The subject was previously diagnosed with latent TB and has documentation confirming completion of appropriate latent TB treatment 
or 
- The subject was previously diagnosed with latent TB and is currently 
receiving prophylactic treatment for latent TB and commits to completing 
the full duration of prophylaxis. 
x If the screening QFT-G test is indeterm inate, the test must be repeated at 
least once by the central laboratory as soon as possible.  The subject may be randomized if: 
- The QFT-G test result remains indeterminate or becomes negative and 
- There are no signs or symptoms of active TB and 
- There is no known recent close contact with anyone with active TB and - There is no history of latent TB (unless diagnosed with documentation 
of completion of appropriate treatment or active TB. 
Additionally, an expert specialising in TB may be consulted prior to randomization, if deemed 
necessary in the opinion of the Investigator, after discussion with AstraZeneca study 
physician.  If the subject is randomized, additional QFT-G testing will be performed according 
to Table 3 and Table 4. 
Tuberculosis monitoring during the study 
If, during the trial a subject who had an indeterminate TB result at screening is determined to 
have a: 
x Positive QFT-G test result, the subject should be referred to a TB specialist.  If a TB specialist is not available, the local country guidelines 
should be followed for further diagnostic work up and anti-TB treatment regimens.  If no local guidelines exist for immunocompromised individuals, then CDC guidelines may be  followed.  This should also be 
reported as an AESI. Once a latent TB is confirmed, treatment must be 
instituted immediately and no investigational product may be 
administered until treatment of latent TB has begun. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
63 (131) x Negative QFT-G test result, then the subject does not need to continue 
TB testing outlined for subjects with indeterminate results at screening. 
x Indeterminate QFT-G test result, the subject will continue in the study 
and TB testing will be performed as outlined for subjects with 
indeterminate results at screening. 
For subjects with negative QFT-G at baseline and no symptoms of active TB: 
x Week 52 QFT-G negative: no further testing 
x Week 52 QFT-G indeterminate: repeat at Week 56. If negative no further testing, however if indeterminate repeat again at Week 60. 
x QFT-G positive at Week 52 or later. Confirm positive QFT-G on another 
blood sample.  If confirmed follow recommendations for positive QFT-G 
results during study.  If repeat test is indeterminate or negative follow 
recommendation for indeterminate results above.  Consider referral to TB 
specialist. 
Tuberculosis questionnaire 
To aid in the early detection of new or reactivated TB, a TB questionnaire will be used to 
evaluate subjects for signs and symptoms of TB prior to receiving investig ational product.  If 
the evaluation raises suspicion that a subject may have new or reactivated TB, an immediate 
and thorough investigation should be undertaken including, where possible, consultation with 
experts specialising in TB. 
Investigators should be aware that TB in immunocompromised patients may present as 
disseminated disease or with extrapulmonary features and should be referred for appropriate 
treatment. 
5.2.6.3 Cervical cancer screening 
Most cases of cervical cancer appear to be related to infection with human papilloma virus 
(HPV), usually HPV types 16 and 18.  Because of the potential for viral reactivation due to 
blockade of the IFN pathway, cervical dysplasia is being assessed in this study, although to 
date there has been no signal in the anifrolumab studies.  A Pap smear is required at screening in women who have not had their cervix surgically removed.  If a Pap smear was preformed 
within 2 years prior to screening with no documented malignancy (e.g., CIN III, CIS, or AIS), 
it does not need to be rep eated.  Subjects with abnormal Pap smear results of atypical 
squamous cells of undetermined significance (ASC-US), atypical squamous cells where high-
grade squamous intraepithelial lesion cannot be ruled out (ASC-H), atypical glandular cells 
(AGC), or CIN grades I and II (CIN I and II) will be allowed to enter the study (please see 
Appendix J for guidance).  The Pap smear will be repeated during the last 4 weeks of the 
study to ensure that there is no evidence of new cervical dysplasia.  Since the access to a Pap 
smear may vary by country, AstraZeneca recomm ends that local guidelin es for obtaining Pap 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
64 (131) smears in subjects who have received immunomodulators or immunosuppressive treatment be 
followed. 
If the Pap smear performed at Week 52 is not no rmal but shows no evidence of malignancy 
(e.g., CIN III, CIS, or AIS), it should be repeated as per the subject´s gynecologist´s 
recommendations.  If the subject´s gynaecologist  has recommended a specified interval, the 
Pap smear should be obtained as recommended and the report provided in the source 
document.  
5.2.6.4 Colombia-Suicide Severity Rating Scale (C-SSRS) 
The C-SSRS is a unique, simple, and short method  of assessing both behaviour and ideation 
that tracks all suicidal events, and provides a summary of suicidality (Posner et al, 2007).  It 
assesses the lethality of attempts and other features of ideation (frequency, duration, 
controllability, reasons for ideation, and deterrents), all of which are significantly predictive of 
completed suicide.  The C-SSRS will be administered at study visits by a trained assessor and 
the procedure is described in the Study Refe rence Manual.  The assessor will record the 
clinical observation on the scale, which will be us ed as the source document.  If possible, the 
same individual should perform the assessment at each visit to reduce scoring variability.  In the event the primary assessor is not available, a designated back-up assessor who meets the same qualifications may perform the C-SSRS.  If  a subject indicates having a rating of type 4 
or 5 suicidal ideation on the C-SSRS suicidal ideation scale at any time since the previous 
visit when the C-SSRS was administered or indi cates having had any suicidal behaviour since 
the previous visit, the subject should be referre d to a mental health professional immediately.  
If the C-SSRS is administered by an assessor other than the Investigator, it is recommended that the Investigator confirms suicidal ideation before making a refe rral to mental health 
services; however this should not delay the referral. 
5.3 Pharmacokinetics 
5.3.1 Collection of samples 
Blood samples for the determination of anifrolumab in serum will be taken at the times 
presented in the study plan (Table 3, Table 4).  A post-dose sample after should be collected 4 
days (Day 5 or  Day 6, 7, 8) after the first dose of investigational product administration to 
access anifrolumab concentration after dosing.  For all pharmacokinetic samples, it is very 
important that the date, time of anifrolumab administration, and the sample collection are recorded.  
Samples will be collected, labelled stored and shipped as detailed in the Laboratory Manual.  
5.3.2 Determination of drug concentration 
Samples for determination of anifrolumab conc entration will be analysed using a validated 
bioanalytical method.  Placebo samples will be anal ysed.  Full details of the analytical method 
used will be described in the methods sectio n of the pharmacokinetic subreport or study 
report. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
65 (131) 5.3.3 Storage and destruction of pharmacokinetic samples 
Pharmacokinetic (PK) samples will be disposed of after the study report finalization or six 
months after issuance of the draft study report (whichever is earlier), unless requested for future analyses.   
Pharmacokinetic samples may be disposed of or destroyed and anonymised by pooling. 
5.4 Immunogenicity 
Instructions for immunogenicity (antidrug antibody [ADA] and neutralising antibodies [nAb]) 
sample collection, processing, storage, and shipment can be found in the separate laboratory manual provided to the study centers. 
5.4.1 Anti-drug antibodies 
The pre-dose and follow-up serum samples to measure presence of ADA will be collected 
according to the Study Plan (Table 3, Table 4).  The presence or absence of ADA will be determined in the serum samples using validated bioanalytical methods. 
5.4.2 Neutralising antibodies  
Neutralising antibodies testing will only occu r on samples that are ADA positive.  Samples 
that are ADA negative will not be tested for nAb.  The presence or absence of neutralizing 
ADA will be determined using a validated bioanalytical method.
 
5.5 Pharmacodynamics 
5.5.1 21-gene type I IFN PD signature in whole blood (PD marker) 
Type I IFN inducible signature in whole blood will be assessed by a 21-gene assay to be used 
as a PD marker to follow the biologic effect of anifrolumab on its target throughout the study. 
Whole blood will be collected for RNA isolatio n at the visits indicated in the Study Plan 
(Table 3 and Table 4) in order to evaluate the mRNA expression levels of 21 type I IFN-
inducible genes.  The remaining mRNA from the PD sample may be utilised for additional 
biomarker work to further characterise the effects of anifrolumab on its target. 
Instructions for sample collection, processing, storage, and shipment can be found in the 
separate laboratory manual provided to the study centers. Pharmacodynamic samples are exhausted in the isolation process.  Any remaining back up 
whole blood samples will be stored for a maximum of 15 years from the date of the Last Subject’s Last Visit, after which they will be destroyed. 
5.5.2 4-gene type I IFN test  
At screening the IFN test will be used for assessment of 4 type I IFN inducible transcripts in 
whole blood.  The primary intent is to prospe ctively identify subjects as IFN “test-high” or 
“test-low” for the purpose of randomization of subj ects into the study.  Only subjects with a 
“test-high” result will be eligible for participation  in the study.  The kit uses the expression of 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
66 (131) the transcripts IFI27, IFI44, IFI44L and RSAD2 compared with 3 reference transcripts; 18S, 
ACTB and GAPDH.  The result is expressed as a score that is compared with a pre-
established cut-off that classifies subjects into 2 groups with low or high levels of IFN 
inducible transcript expression.  The results of the test will not be shared with the investigative 
site (i.e., all site personnel will remain blinded to IFN test results).  The IFN test will be 
conducted at a designated central laboratory and a detailed description of the test procedure will be included in the laboratory manual.  The data will be evaluated for development of a companion diagnostic. 
The IFN test utilizes the analysis of mRNA and does not include the assessment of any DNA 
sequences.  There are no pharmacogenetic analyses planned in this study.  
5.5.3 Exploratory Transcriptome Analysis (optional) 
Whole transcriptome and specific inflammatory pathway RNA transcript analyses using RNA 
isolated from whole blood and skin tape strip samples will be performed as an optional part of 
study.  The purpose of these analyses will be to retrospectively evaluate whole blood transcript biomarkers predictive of subject re sponse at baseline, prior to investigational 
product administration, as well as to potentia lly identify additional PD biomarkers in whole 
blood and skin.
Whole bloodRNA isolated from whole blood samples collected for 21-gene type I IFN analysis according 
to Study Plan in Table 3 and Table 4 as described in Section 5.5.1 will be used for 
transcriptome analyses. 
Skin tape strips 
Skin tape strips will be collected at Week 0 and Week 12 from subjects consenting to this 
optional part of study.  The skin tape stri ps will be collected using non-invasive adhesive 
patches applied to lesiona l and non-lesional skin.  
Instructions for sample collection, processing, storage, and shipment of skin tape strips can be found in the separate laboratory manual provided to the study centers. 
5.6 Pharmacogenetics (Not Applicable) 
5.7 Biomarker analysis (Not Applicable) 
5.8 Storage, re-use and destruction of biological samples 
Samples will be stored for a maximum of 15 y ears from the date of the Last Subject’s Last 
Visit, after which they will be destroyed.   
5.9 Labelling and shipment of biological samples 
The Principal Investigator ensures that samples are labelled and shipped in accordance with 
the Laboratory Manual and the Biological Substance, Category B Regulations (materials 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
67 (131) containing or suspected to contain infectious substances that do not meet Category A criteria), 
see Appendix B ‘IATA 6.2 Guidance Document’. 
Any samples identified as Infectious Category A materials are not shipped and no further 
samples will be taken from the subject unless  agreed with AstraZ eneca and appropriate 
labelling, shipment and contai nment provisions are approved. 
5.10 Chain of custody of biological samples  
A full chain of custody is maintained fo r all samples throughout their lifecycle. 
The Principal Investigator at each centre keeps full traceability of collected biological samples 
from the subjects while in storage at the centre  until shipment or dis posal (where appropriate) 
and keeps documentation of receipt of arrival. 
The sample receiver keeps full traceability of th e samples while in storage and during use until 
used or disposed of or until further shipment and keeps documentation of receipt of arrival. 
AstraZeneca keeps oversight of the entire life cycle through internal procedures, monitoring of 
study sites and auditing of external laboratory providers. 
5.11 Withdrawal of Informed Consent for donated biological samples  
If a subject withdraws consent to the use of donated biological samples, the samples will be 
disposed of/destroyed, and the action documented.  If samples are already analysed , 
AstraZeneca is not obliged to dest roy the results of this research. 
The Principal Investigator: 
x Ensures subjects’ withdrawal of informed consent to the use of donated 
samples is notified immediately to AstraZeneca 
x Ensures that biological samples from that subject, if stored at the study site, are immediately identified, disp osed of /destroyed, and the action 
documented 
x Ensures the laboratory(ies) holding the samples is/are informed about the withdrawn consent immediately and that samples are disposed of/destroyed, the action documented and the signed document returned to 
the study site 
x Ensures that the subject and AstraZeneca are informed about the sample 
disposal. 
AstraZeneca ensures the central laboratory(ies) holding the samples is/are informed about the withdrawn consent immediately and that sample s are disposed of/destroyed and the action 
documented and returned to the study site. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
68 (131) 6. SAFETY REPORTING AND MEDICAL MANAGEMENT 
The Principal Investigator is res ponsible for ensuring that all s taff involved in the study are 
familiar with the content of this section. 
6.1 Definition of adverse events 
An adverse event is the development of an u ndesirable medical condition or the deterioration 
of a pre-existing medical condition following or during exposure to a pharmaceutical product, 
whether or not considered caus ally related to the product.  An undesirable medical condition 
can be symptoms (e.g., nausea , chest pain), signs (e.g., tachycardia, enlarged liver) or the 
abnormal results of an investigation (e.g., laboratory findings, electrocardiogram).  In clinical 
studies, an AE can include an undesirable medical condition occurring at any time, including 
run-in or washout periods, even if no study treatment has been administered. 
The term AE is used to include both serious and non-serious AEs. 
6.2 Definitions of serious adverse event 
A serious adverse event is an AE occurring during any study phase (i.e., run-in, treatment, 
washout, follow-up), that fulfils one or more of the following criteria: 
x Results in death 
x Is immediately life-threatening 
x Requires in-patient hospitalisati on or prolongation of existing 
hospitalisation  
x Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions 
x Is a congenital abnormality or birth defect 
x Is an important medical event that may jeopardize the subject or may 
require medical intervention to prevent one of the outcomes listed above. 
For further guidance on the definition of a SAE , see Appendix A to the Clinical Study 
Protocol. 
6.3 Recording of adverse events 
6.3.1 Time period for collection of adverse events 
Adverse Events and SAEs will be collected from time of signature of informed consent 
throughout the treatment period and including the follow-up peri od (10 weeks post final dose). 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
69 (131) 6.3.2 Follow-up of unresolved adverse events 
Any AEs that are unresolved at the subject’s last visit in the study are followed up 
by the Investigator for as long as medically indicated, but without further recording in the CRF.  AstraZeneca retains the right to request additional information for any subject with ongoing AE (s)/SAE(s) at the end of the study, if 
judged necessary. 
6.3.3 Variables  
The following variables will be collect for each AE; 
x AE (verbatim) 
x The date and time when the AE started and stopped 
x Maximum intensity  
x Whether the AE is serious or not 
x Investigator causality rating against the Investigational Product (yes or 
no) 
x Action taken with regard to investigational product 
x Outcome. 
In addition, the following variables will be collected for SAEs: 
x Date AE met criteria for serious AE 
x Date Investigator became aware of serious AE 
x AE is serious due to 
- Date of hospitalisation 
- Date of discharge 
- Probable cause of death - Date of death 
- Autopsy performed 
x Causality assessment in relation to Study procedure(s) 
x Description of AE. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
70 (131) It is important to distinguish between serious and severe AEs.  Severity is a measure of 
intensity whereas seriousness is defined by the criteria in Section 6.2.  An AE of severe 
intensity need not necessarily be considered se rious.  For example, nausea that persists for 
several hours may be considered severe naus ea, but not a SAE unless it meets the criteria 
shown in Section 6.2.  On the other hand, a stroke that results in only a limited degree of 
disability may be considered a mild stroke but would be a SAE when it satisfies the criteria shown in Section 6.2. 
6.3.4 Causality collection 
The Investigator will assess causal relations hip between Investigational Product and each 
Adverse Event, and answer ‘yes’ or ‘no’ to th e question ‘Do you consider that there is a 
reasonable possibility that the event may have been caused by the investigational product?’ 
For SAEs causal relationship will also be assessed for other medication and study procedures 
and additional study drug (e.g., OCS, azathioprine, antimalarials, mycophenolate 
mofetil/mycophenolic acid, methotre xate, and mizoribine). Note that for SAEs that could be 
associated with any study procedure the causal relationship is implied as ‘yes’. 
A guide to the interpretation of the causality question is found in Appendix A to the Clinical 
Study Protocol. 
6.3.5 Adverse events based on signs and symptoms 
All AEs spontaneously reported by the subject or care provider or reported in response to the 
open question from the study personnel: ‘Have you/the child had any health problems since 
the previous visit/you were last asked?’ , or revealed by observation will be collected and 
recorded in the CRF.  When collecting AEs, the recording of diagnoses is preferred (when possible) to recording a list of signs and symptoms.  However, if a diagnosis is known and 
there are other signs or symptoms that are not ge nerally part of the diagnosis, the diagnosis 
and each sign or symptom will be recorded separately. 
6.3.6 Adverse events based on examinations and tests 
The results from protocol mandated laboratory tests and vital signs will be summarised in the 
clinical study report.  Deterioration as compared to baseline in prot ocol-mandated laboratory 
values, vital signs, and other safety assessments should therefore only be reported as AEs if 
they fulfil any of the SAE criteria or are the reason for discontinuation of treatment with the 
investigational product. 
If deterioration in a laboratory value/vital sign  is associated with clinical signs and symptoms, 
the sign or symptom will be reported as an AE and the associated laboratory result/vital sign 
will be considered as additional information.  Wherever possible the reporting Investigator 
uses the clinical, rather than the laboratory term (e.g., anaemia versus low haemoglobin 
value). In the absence of clinical signs or sy mptoms, clinically relevant  deteriorations in non-
mandated parameters should be reported as AE(s). 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
71 (131) Deterioration of a labor atory value, which is unequivocally  due to disease progression, should 
not be reported as an AE/SAE. 
Any new or aggravated clinically relevant abnormal medical finding at a physical examination 
as compared with the baseline assessment will be reported as an AE. 
6.3.7 Hy’s Law 
Cases where a subject shows elevations in liv er biochemistry may require further evaluation 
and occurrences of AST or ALT  3xULN together with total bilirubin  2xULN may need to 
be reported as SAEs.  Please refer to Appendix C for further instruction on cases of increases 
in liver biochemistry and evaluation of Hy’s Law. 
6.3.8 Disease progression/worsening of SLE 
Disease progression can be considered as a worsening of a subject’s condition attributable to 
SLE.  It may be an increase in the severity of the existing of manifestations of SLE or the 
appearance of new manifestations.  Worsening of  SLE should not be reported as an AE, unless 
the signs and symptoms meet criteria for an SAE.   
New manifestation or worsening of existing manifestations of SLE should be captured per 
PI’s judgement.  
6.4 Reporting of serious adverse events 
All SAEs have to be reported, whether or not considered causally related to the investigational 
product, or to the study procedure(s).  All SAEs will be recorded in the CRF. 
If any SAE occurs in the course of the study, then Investigators or other site personnel inform 
the appropriate AstraZeneca representatives within one day i.e., immediately but no later 
than 24 hours  of when he or she becomes aware of it. 
The designated AstraZeneca representative works with the Investigator to ensure that all the 
necessary information is provided to the Ast raZeneca Patient Safe ty data entry site within 1  
calendar day  of initial receipt for fatal and life threatening events and within 5 calendar  
days of initial receipt for all other SAEs. 
For fatal or life-threatening adverse events where important or relevant information is missing, 
active follow-up is undertaken immediately.  Investigators or other site personnel inform 
AstraZeneca representatives of any follow-u p information on a previously reported SAE 
within one calendar day i.e., immediately but no later than 24 hours of when he or she 
becomes aware of it. 
Once the Investigators or other site personnel indica te an AE is serious in the WBDC system, 
an automated email alert is sent to the designated AstraZeneca representative. 
If the WBDC system is not available, then the Investigator or other study site personnel 
reports a SAE to the appropriate Ast raZeneca representative by telephone. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
72 (131) The AstraZeneca representative will advise the Investigator/study site personnel how to 
proceed.  
The reference document for definition of expectedness/listedness is the IB for the AstraZeneca 
drug Anifrolumab.  
6.5 Overdose 
An overdose in this study is defined as a su bject receiving a dose of investigational product 
that is greater than the dose that was intended to be given  
x An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the relevant AE modules in the CRF and on the Overdose CRF module. 
x An overdose without associated symptoms is only reported on the Overdose CRF module. 
If an overdose on an AstraZeneca study drug occu rs in the course of the study, then the 
Investigator or other site personnel inform appropriate AstraZeneca representatives 
immediately, or no later than 24 hours  of when he or she becomes aware of it. 
The designated Astr aZeneca representative work s with the Investigator to ensure that all 
relevant information is provid ed to the AstraZeneca Patient Safety data entry site. 
For overdoses associated with a SAE, the standard reporting timelines apply, see Section 6.4.  
For other overdoses, reporting must occur within 30 days. 
6.6 Pregnancy
All pregnancies and pregnancy outcomes should be reported to AstraZeneca. 
6.6.1 Maternal exposure 
The required methods of contraception are desc ribed in Section 3.1.  If a subject becomes 
pregnant during the course of the study IP sh ould be discontinued immediately.  Pregnancy is 
not regarded as an AE unless the IP under study is suspected to have interfered with 
effectiveness of the contraceptive medication used.  Congenital abnormalities/birth defects 
and spontaneous miscarriages should be report ed and handled as SAEs.  Elective abortions 
without complications should not be handled as AEs.   The outcome of all pregnancies should 
be followed up and documented even if the subject was discontinued from the study. 
If a pregnancy occurs during the study, the Inve stigator or other site personnel must inform 
the appropriate AstraZeneca representatives immediately but no later than 24 hours of when 
he or she becomes aware of it. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
73 (131) The designated AstraZeneca representative works with the Investigator to ensure that all 
relevant information is provided to the AstraZenec a Patient Safety data entry site within 1 or 5 
calendar days for SAEs (see Section 6.4) and within 30 days for all other pregnancies. 
The same timelines apply when outcome information is available. 
The PREGREP module in the CRF is used to re port the pregnancy and the PREGOUT is used 
to report the outcome of the pregnancy. 
6.6.2 Paternal exposure  
Male subjects should refrain from fathering a ch ild or donating sperm as described in Section 
3.1.  Pregnancy of the subject’s partner is not considered as an AE, but the outcome of all 
pregnancies (or any conception) should if possible be followed up and documented. 
Information on the pregnancy of a subject’s pa rtner must be obtained directly from the 
subject’s partner. Therefore, prior to obta ining information about the pregnancy, the 
Investigator must obtain the consent of the subject’s partner. 
6.7 Adverse Events of Special Interest  
An AESI is an AE of scientific and medical c oncern specific to understanding biologics and 
requires close monitoring and rapid comm unication by the Investigator to the 
Sponsor/Sponsor’s delegate. An AESI may be serious or non-serious. 
Adverse Events of Special Interest in this prot ocol will be assessed at each visit in the CRF. 
The events of interest are serious infections, including non-opportunistic serious infections, 
opportunistic infections, anaphylaxis, malignanc y, herpes zoster, TB (including latent TB), 
influenza, vasculitis (non-SLE), and MACE (incl uding non-fatal myocardial infarction, non-
fatal stroke, and CV death). 
An AESI that meets 1 of the seriousness outcomes listed in Section 6.2 will be categorised as 
an SAE for the purposes of follow-up responsibility and safety reporting.  A non-serious AESI 
will be categorised as an AE.  For reporting of AESIs, see Section 6.8. 
6.7.1 Non-opportunistic serious infection 
A serious non-opportunistic infection is any non-opportunistic infection that meets the SAE 
criteria in Section 6.2.  Serious non-opportunistic infection adverse events are reported as 
SAEs and AESIs.  It is expected that culture re sults and all diagnostic or therapeutic procedure 
results performed on a subject experiencing a serious non-opportunistic infection will be provided as an SAE update.  Non-serious non-oppo rtunistic infections will not be captured as 
AESIs. 
6.7.2 Opportunistic serious infection  
An opportunistic infection is an invasive infection caused by microorganisms that are 
normally non-pathogenic or rarely pathogenic in individuals with normal immune function or 
cause an infection of a type or severity not seen in the normal host. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
74 (131) Examples of opportunistic infections that may oc cur in SLE subjects include: herpes zoster 
meningoencephalitis, Salmonella bacteremia, Pneumocystis jiroveci  pneumonia or progressive 
multifocal leukoencephalopathy.  It is expecte d that culture results and all diagnostic or 
therapeutic procedure results performed on a subject expe riencing a serious opportunistic 
infection will be provided as an SAE update.  Since anifrolumab is an immunomodulatory 
agent and the sponsor needs to understand the safety profile of this investigational product, 
including assessment of how anifrolumab may affect resistance to different types of 
infections, investigators are asked to undertak e appropriate microbiologic identification 
including culture and report culture results fo r all patients who develop serious infections. 
6.7.3 Anaphylaxis 
Anaphylaxis is a severe, potentially fatal, system ic allergic reaction that occurs suddenly after 
contact with an allergy-causing substance, such as investigational product.  For the purposes 
of this study, the definition detailed in Appendix K is provided as a simp le and rapid means to 
make the diagnosis of anaphylaxis during injection with investigational product.  This 
definition was a product of a symposium convened by the National Institute of Allergy and 
Infectious Diseases and Food Allergy and An aphylaxis Network (Sampson et al, 2006). 
6.7.4 Malignancy  
Malignancy is a neoplasm characterised by cell s with abnormal features, uncontrolled rapid 
growth with invasive and/or metastatic tendencies  diagnosed based on pa thologic and clinical 
standards.  Understanding risk of developing different malignancies is critical to establishing 
the benefit: risk profile for anifrolumab.  Investigators are therefore requested to obtain biopsy results and pertinent biomarker and/or genetic testing results performed and to report these for 
any malignancies reported during the study. 
6.7.5 Herpes zoster  
Herpes zoster  is a viral infection characterized by a cutaneous vesicular eruption on an 
erythematous base presenting along dermatom e(s) and usually associated with prodromal 
pain. Herpes zoster results from the reactivation of varicella-zoster  virus; multiple 
dermatomes may be involved (>3 indicates disseminated disease) and organ or systemic 
infection may occur (invasive; therefore an opportunistic infection).  Polymerase chain 
reaction testing of samples from vesicles , biopsy, or other specimens (for example, 
cerebrospinal fluid) may confirm the presence of varicella-zoster  virus. 
For additional information regarding Herpes zoster , refer to the Investigator Brochure.  As this 
is an event of special intere st, the Sponsor will collect information including whether or not 
subjects have received vaccination for Herpes zoster.  The Herpes zoster  vaccine will be 
captured in the appropriate sections of the CRF. 
6.7.6 Tuberculosis 
Tuberculosis is a mycobacterial infectious disease generally presenting as cough with 
systemic symptoms of infection diagnosed by skin  test (purified protein derivative), blood test 
(IFN-gamma release assay), radiographic imaging, body fluid and tissue sampling; 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
75 (131) presentation may include disseminated or latent disease.  An infection may be new (at least 
conversion of a TB test to positive) or reactivation of dormant disease (new active disease in a previously TB test positive subject without prior evidence of active disease). 
x A bacteriologically confirmed TB  case is case where a biological 
specimen is positively by smear microscopy, culture or rapid diagnostic 
such as PCR or nucleic acid amplification test (Xpert MTB/RIF) 
x A clinically diagnosed TB  case is a case where the subject dose not fulfil 
the criteria for bacteriological confir mation, but has been diagnosed with 
active TB by a clinician or other medical practitioner who has decided to 
give the subject a full course of TB treatment.  This definition includes cases diagnosed on the basis of x-ray abnormalities or suggestive histology and extra-pulmonary cases without laboratory confirmation. Clinically diagnosed cases subseque ntly found to be bacteriologically 
positive (before or after starting treatment) should be reclassified as bacteriologically confirmed.   
Bacteriologically confirmed or cl inically diagnosed cases of TB are also classified according 
to: anatomical site of disease; history of previous treatment; drug resistance; HIV status 
(World Health Organization, 2014). 
Latent TB  is a mycobacterial infection without clinical , bacteriological findings, or radiologic 
findings consistent with active TB and a TB  blood test such as an IGRA (QuantiFERON 
Gold) or purified protein deriva tive skin test that is positive both at the time of provisional 
diagnosis and on repeat assessment. 
Subjects identified with latent TB will be as sessed by a local TB sp ecialist to confirm the 
diagnosis and local SOC that will be used in treatment.  Once latent TB is confirmed, 
treatment must be instituted immediately and no  investigational product may be administered 
until treatment of latent TB has begun.  Additionally, subjects with newly diagnosed latent TB 
must agree to complete a locally recommended c ourse of treatment for latent TB in order to 
continue receiving IP. 
6.7.7 Influenza 
Influenza is a severe viral infection that includes the following symptoms: temperature greater 
than 100.8 eF (38.2e C), and malaise, headache, or myalgia.  It is often accompanied by 
nausea, vomiting, and diarrhea, and at least 1 of the following respiratory symptoms: cough, 
sore throat, or shortness of breath. 
Laboratory criteria for influenza include at least 1 of the following: isolation of influenza virus 
from a clinical specimen, detection of influenz a virus nucleic acid in a clinical specimen, 
identification of influenza virus antigen by direct fluorescent antibody test in a clinical 
specimen, OR influenza-sp ecific antibody response. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
76 (131) A confirmed case of influenza meets the clinical and laboratory criteria for the viral illness. 
Laboratory confirmation should be done using locally available, rapid, commercial tests approved by Regulatory Agencies and sampling respiratory specimens. 
Not all upper respiratory viral infections or gastrointestinal viral infections are influenza.  In 
the case where a subject reports a viral infection severe enough to be considered, in the 
opinion of the Investigator, influenza, a viral te st should be performed (if possible) to confirm 
the diagnosis.  If, in the opinion of the Invest igator, the subject has had influenza (the specific 
viral infection), this should be reported as an  AESI, whether or not a test to confirm the 
diagnosis has been performed.  Less severe viral infection should be reported as an AE only. 
6.7.8 Vasculitis (non-Systemic Lupus Erythematosus)  
Vasculitis (non-SLE) is defined as an inflammatory disorder of blood vessels involving 
arteries and/or veins and characterized by characteristic clinical signs/symptoms and 
diagnosed by biopsy, imaging such as angiography or blood tests such as findings of 
antineutrophil cytoplasmic antibodies consistent with the diagnosis.  Underlying causes should 
be identified, such as medications including study drug, infections or systemic inflammatory 
syndromes, wherever possible.  See Appendix N for a list of vasculitic syndromes excluded 
from the study. 
6.7.9 Major acute cardiovascular events 
As a measure of enhanced Pharmacovigilance,  an independent Cardiovascular Event 
Adjudication Committee (CV-EAC) will review deaths (due to any cause) and all SAEs in 
both the Cardiac and Vascular  MedDRA System Organ Classe s and all SAEs in the Central 
Nervous System Vascular Disorders Standard Medical Query for evaluation.  The CV-EAC 
chair may adjudicate some events that do not fall into the above categories. 
The CV-EAC will review cases of interest to determine if they meet accepted diagnostic 
criteria.  Causality assessments will not be made by the CV-EAC, nor will the committee possess governance authority.  The CV-EAC will be blinded regarding any information relating to the randomization group. Please refer to the adjudication charter for details. 
6.8 Reporting of adverse events of special interest 
Adverse Events of Special Interest will be assessed by the Investigator for severity, 
relationship to the investigational product, possible aetiologies, and whether the event also 
meets criteria of an SAE.  All AESIs (serious or  non-serious) will be re corded on the AE CRF 
(using a recognized medical term or diagnosis that accurately reflects the event). 
The reporting period for AESIs is the period immediately following the time that written 
informed consent is obtained through the end of subject participation in the study.  Following 
detection of an AESI (non-serious), reporting is required within 72 hours of knowledge of the event, and for serious AESIs the standard 24-hour timeline for reporting to the appropriate 
AstraZeneca representative or designee applies. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
77 (131) 6.9 Management of IP related toxicities  
6.9.1 Anaphylaxis, hypersensitivity, and injection-related reactions 
Hypersensitivity reactions including anaphylaxis have been reported with the subcutaneous 
administration of monoclonal antibodies. As w ith any antibody, aller gic reactions to dose 
administration are possible. Therefore, appropriate drugs and medical equipment to treat acute 
anaphylactic reactions must be immediately available, and study personnel must be trained to 
recognize and treat anaphylaxis.  
Subjects should not be premedicated unless they have had a prior hypersensitivity reaction to 
anifrolumab.  However, if a prior hypersensitivity reaction has been documented, the 
Investigator may elect to administer an appropriate medication prophylactically potentially including an antihistamine and/or acetaminophe n/paracetamol for the comfort and safety of 
the subject prior to subsequent investigational product administration.  Prophylactic use of glucocorticosteroids prior to subsequent injection is not permitted. 
6.9.2 Infections 
When an infection is reported as an SAE or AESI, cultures should be obtained and culture 
results should be reported with the event.  Other specific laboratory or other investigations 
(e.g., chest x-ray for pneumonia) that confirm or aid in the diagnosis or treatment should be 
obtained when indicated and results should be reported with the SAE or AESI.  
Subjects who develop a new infection whil e undergoing treatment with investigational 
product should receive appropriate medical thera py, as determined by local standards, and be 
monitored closely until the condition resolves.  Investigational product should not be 
administered to a subject with a clinically significant, active infection as determined by the 
Investigator.  For any active infection (e.g., varicella zoster infection/chickenpox) or 
significant exposure to any infection (e.g., varicella zoster  infection in a naive subject, 
bacterial pneumonia), the Investigator should consider whether to interrupt investigational 
product administration and should notify the medical monitor. 
Similarly, if a subject presents with signs or  symptoms where opportunistic infections are 
considered (e.g., CNS symptoms consistent with progressive multifocal leukoencephalopathy 
or herpes encephalitis  or atypical pneumonia suggesting pneumocystis jiroveci  pneumonia), 
investigational product should be interrupted until the Investigator confirms the symptoms and 
signs of infection have resolved or that no active infection has developed. 
If dosing is resumed after resolution of a safety  concern (i.e., infection or other AE) the 
investigational product must be administered within 14 days of the scheduled time of the 
missed dose.  If this is not possible, dosing should be resumed at the time of the next 
scheduled dose. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
78 (131) 6.10 Study governance and oversight 
The safety of all AstraZeneca clinical studies is closely monitored on an on-going basis by 
AstraZeneca representatives.  Issues identified will be addressed; for instance this could 
involve amendments to the study protocol and letters to Investigators. 
7. INVESTIGATIONAL PRODUCT AND OTHER TREATMENTS 
7.1 Identity of investigational product(s) 
Investigational product Dosage form and strength Manufacturer 
Anifrolumab (MEDI-546) 150 mg/mL solution of anifrolumab 
intended for SC administration  MedImmune, LLC 
Placebo Solution intended for SC 
administration  MedImmune, LLC 
Each vial of investigational product or placebo contains 1.3mL fill volume. Investigational 
product and placebo will be supplied to the site as follows: 
For the 150 mg anifrolumab and matched placebo groups = one kit will be dispensed per visit 
from the IXRS  
x Sixteen subjects will be randomized at  a 3:1 ratio to receive anifrolumab 
at a fixed dose of 150 mg (12 subjects) as added to SOC or placebo (4 
subjects) plus SOC, given Q2W as one SC injection (= 1 mL) 
For the 300 mg anifrolumab and matched placebo groups = two kits will be dispensed per visit from the IXRS 
x Sixteen subjects will be randomized at  a 3:1 ratio to receive anifrolumab 
at a fixed dose of 300 mg (12 subjects) as added to SOC or placebo (4 
subjects) plus SOC, given Q2W as two SC injections (=2 x 1 mL). 
Each kit will have a unique number that will be printed on all labels within the kit (i.e., the 
outer carton label and the label on the vial within the carton). 
Preparation of investigational product and plac ebo must be performed by a trained unblinded 
team member (e.g., pharmacist, study nurse) at the site.   
AstraZeneca will provide detailed preparation, storage and handling instructions for each 
product and treatment. 
7.2 Dose and treatment regimens 
Anifrolumab or placebo, will be administered as SC injections Q2W.  Anifrolumab 150 mg 
and corresponding placebo will be given as one  injection in a total volume of 1 mL and 
anifrolumab 300 mg and corresponding placebo will be given as two injections of a volume of 
1 mL each. IP dosing must be at least 10 days apart. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
79 (131) All investigational products will be labelled in a double-blind fashion.  AstraZeneca will 
provide anifrolumab (MEDI-546) 150 mg and Placebo kits containing 1 vial/kit.  1 vial of 150 
mg anifrolumab or 1 vial of placebo.  The vial will be labelled with a blinded booklet label.  
7.2.1 Investigational product administration procedures 
An unblinded qualified study site personel, who wi ll not be involved in the management of the 
subjects, will inject the IP into the SC tissue of the anterior thigh or abdomen.  Two injections 
(150 mg per injection) are required in order to administer anifrolumab at the 300 mg dose and 
for the corresponding placebo.  Therefore at each administration of anifrolumab 300 mg, and 
corresponding placebo, two separate injection sites on the anterior thigh or abdomen at least 3 
cm apart and on the same side for both injections should be used.  Injection sites should be 
rotated at each visit.  The time of the first SC injection will be recorded for each subject. 
The IP will be administered via a 27-gauge 1/2-inch needle.  The person administering the 
dose will wipe the skin surface of the anterior thigh or abdomen with alcohol and allow to air 
dry. The skin will be pinched to isolate the SC tissue from the muscle.  The needle will be inserted at a 90-degree angle approximately halfway into the SC tissue.  The IP will be slowly 
injected (at least 5-second duration is recommende d) into the SC tissue using gentle pressure.  
The area should not be massaged after injection. 
7.2.2 Monitoring of investigational product administration 
Vital signs (blood pressure, temperature, pulse rate, and respiration rate) will be obtained 
before IP administration on all treatment visits .  After IP administration, subjects will be 
monitored for immediate drug reactions; vital signs will be taken immediately after 
administration of IP and at least every 30 minutes (± 5 minutes) thereafter.  In addition, injection sites will be visually inspected..  For the first 3 doses of IP (Weeks 0, 2, and 4), 
subjects will remain at site for a minimum of 2 hours or until stable, whichever is later.  If no 
safety concerns subjects will remain at site for a minimum of 1 hour or until stable, whichever 
is later, for the subsequent IP doses, i.e., from dose 4 (Week 6) and onwards.  Discharge from 
site will be determined by the investigator.  
7.3 Labelling
Labels will be prepared in accordance with Good Manufacturing Practice (GMP) and local 
regulatory guidelines.  The labels will fulfill GMP Annex 13 requirements and medical device directive for labelling.  Label text will be translated into local language. 
Before the kit is dispensed to the subject, the investigator must fill in the required information 
on the empty lines on the front cover page, locate the page with local label text, and 
demonstrate to the subject.  Booklet labels must be opened to find full label text in local 
language. 
7.4 Storage 
All study drugs should be kept in a secure place under appropriate storage conditions.  The 
investigational product should be stored at 2 to 8°C (36 to 46°F) and must not be frozen. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
80 (131) 7.5 Compliance 
The administration of all study drugs (including investigational products) should be recorded 
in the appropriate sections of the Case Report Form.  The investigator product will be 
administered by study personnel, who will monitor compliance.  
7.6 Accountability 
The study drug provided for this study will be used only as directed in the study protocol. 
The study personnel will account for all st udy drugs administered to the subjects. 
The Investigator’s or site’s designated investigat ional product manager is required to maintain 
accurate investigational product accountability records.  Upon completion of the study, copies 
of investigational product accountability records will be returned to AstraZeneca or designee. 
The investigator will either return any unused IP to AstraZeneca or its designate, or destroy IP at the site depending on local regulations.  If the IP is destroyed at site, the site personnel will 
count for all unused IP or appropriated destruction.  If the IP is returned to AstraZeneca or its 
designate, the study site personnel or the AstraZeneca monitor will account  for all received IP 
received at the site, unused IP and for appropriated destruction. 
7.7 Concomitant treatment 
As anifrolumab is an investigational immunomodulatory agent, non-protocol permitted changes to immune modifiers or immunosuppressants during the study are not allowed.  If a 
subject receives any of the prohibited medications the administration of IP must be 
immediately discontinued and AstraZeneca study physician notified immediately.  If a subject 
is given any of the allowed, but restricted, medications in unpermitted doses or time periods 
the Investigator must notify AstraZeneca Study Physician immediately.  The subject will be 
considered as a non-responder for exploratory efficacy assessments and AstraZeneca Study 
Physician will determine if the subject may continue to receive IP or not. 
From Day 1 through the end of the study subj ects must be instructed not to take any 
medications, including over-the-counter products, without first consulting the Investigator. 
7.7.1 Standard of Care treatment for SLE 
Permitted medications for  SOC treatment for SLE  are listed below and must be kept at 
stable  doses within the dose ranges described below  from indicated time points and 
throughout the treatment period. 
Concomitant medications should only be administer ed after all visit assessments, including IP 
administration and, if applicable, post-injection PK blood tests. 
Antimalarials, oral corticosteroids and other imm unosuppressants (azathioprine, methotrexate, 
and mycophenolate mofetil/mycophenolic acid, a nd mizoribine) are permitted, and at least 1 is 
required, as part of SLE therapy on Day 1.  Dose  regimens must remain stable from Day 1 to 
the completion of Week 52 but may be decrease d for toxicity or to optimise management of 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
81 (131) an AE, such as infection.  The toxicity/event must be confirmed as a documented AE.  The 
dose can be returned to the Day 1 level if the t oxicity/event resolves and if clinically indicated. 
Antimalarials/immunosuppressants should not be changed if a subject has increased SLE 
disease activity during the OCS tapering period. 
Permitted SLE SOC treatment Maximal dose allowed Stable dose prior 
to randomization
Methotrexate (oral, sc, or im) 25 mg per weeka 8 weeks 
Hydroxychloroquine,  400 mg per day 8 weeks 
Chloroquine, quinacrine 200 mg per day 8 weeks 
Azathioprine 200 mg per day 8 weeks 
Mycophenolate mofetil 2000 mg per day 8 weeks 
Mycophenolic acid  1440 mg per day 8 weeks 
OCS <40 mg per day prednisone or equivalent 2 weeks 
Topical treatment for skin 
symptoms According to recommended maximal dosing 2 weeks 
aRoute of administration must remain stable.  
 
All permitted SOC SLE therapies received from initiation of screening through the end of the 
study will be recorded on the source document and CRF, and will include the specific 
indication for use (e.g., general SLE activity, skin involvement, nephritis, pleurisy) as well as 
the dose, start and stop dates, frequency, and rout e of administration.  In addition, any change 
in permitted SOC SLE therapy and the reas on for change must be documented.  
7.7.2 Corticosteroid treatment  
7.7.2.1 Protocol-specified corticosteroid tapering 
Oral corticosteroid doses should remain stable  through week 12 unless there is a clinical, 
safety, or ethical reason to taper earlier, in wh ich case OCS dose reductions may be permitted 
from Week 4.  Corticosteroid tapering must  be attempted in all subjects with an OCS dose 
10.0 mg per day of prednisone or equivalent  at randomization and aim for a target OCS dose 
of 7.5 mg/day at Week 40.  Tapering will start at Week 12 and may continue until end of 
study unless at least 1 of the following criteria is met: 
x SLEDAI-2K activity which is worsened  compared to baseline in major 
organ systems (renal, CNS, cardiopulmonary, vasculitis, fever, 
thrombocytopenia, or haemolytic anaemia, or gastrointestinal activity) 
x Newly-affected organ system(s) based on the SLEDAI-2K, excluding serological abnormalities (dsDNA antibodies, hypocomplementemia) 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
82 (131) x Persistent moderately to severely active skin manifestations as reflected 
by a CLASI activity score of 10. 
x Moderate to severe arthritis disease as reflected by an active joint count 
of 8 tender and/or swollen joints 
Tapering can be started on the scheduled study visit day (e.g., Week 12 Visit) based on 
clinical manifestations and the laboratory values from the previous visit.  If laboratory values 
or clinical evaluation of the current visit show increased or persistent SLE activity the tapering can be reversed.  Steroid tapering must be star ted within 14 days of the visit.  If steroid 
tapering is not attempted in an eligible s ubject, the AstraZeneca study physician must be 
contacted immediately.  The recommended steroi d-tapering regimen is provided in Appendix 
H but Investigators will have flexibility in how the OCS dose is reduced at each visit. 
Investigators will not be required, but may continue, to taper OCS dose beyond the target of 7.5 mg/day up to end of study based on diseas e activity.  If a subject experience increased 
disease activity secondary to OCS tapering, the dose may be increased up to a maximum of 
the baseline OCS dose for up to 2 weeks followed by a new tapering attempt. 
7.7.2.2 Corticosteroid bursts 
Week 0 to Week 12 
In order to allow adequate time for the investigational product to achieve significant clinical 
benefit, Investigators may administer 1 burst and taper of corticosteroids between Week 0 
(Day 1) and Week 12 for increased SLE disease activity/non-SLE activity.  After Week 12 
additional steroid bursts may be given as per investigators judgem ent of clinical need. 
A steroid burst as described below is defined as 1 of the following: 
x OCS increase up to a maximum daily dose of 40 mg/day prednisone (or 
equivalent) for up to a total of 14 days and that must be fully administered and tapered to less than or equal to the Day 1 dose by the end of the 14th day.; or 
x Intramuscular methylprednisone ( 80 mg) or equivalent administered as 
a single dose between Day 1 and Week 12; or 
x A maximum of 2 intra-articular/tendon sheath/bursal injections (for a 
total methylprednisolone 80 mg or equivalent) can be given. 
Subjects who receive any intra-articular/tend on sheath/bursal injections should not receive 
OCS or intramuscular burst between Day 1 and Week 12.  Subjects who receive more than 1 
steroid burst and taper from Week 0 (Day 1) to Week 12, or who violate any of the criteria above, may continue in the study, but AZ study physician should be contacted. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
83 (131) From Week 12 until end of study 
After Week 12 and up until end of study, addition al steroid bursts, defined as above, may be 
given for SLE increased disease activity. 
Adjustments of OCS doses above Day 1 dose fo r increased SLE activity may be allowed after 
Week 12 with the AZ study physician approval. 
Intra-articular/tendon sheath/bursal injections are allowed for non-SLE related disorders from 
Week 12 and onwards. The injection should be administered after the completion of all 
assessments, including IP administration and post-injection PK blood test (if applicable). 
7.7.2.3 Increase in oral corticosteroids for intercurrent disease or to prevent adrenal 
insufficiency 
Steroid bursts for non-SLE causes (e.g., asthma or COPD exacerbation) are allowed 
throughout the study but the AstraZeneca study physician should be informed.  A burst may include OCS up to 20 mg/day of prednisone (or equivalent) for up to a total of 14 days and 
must be tapered to less than or equal to the Da y 1 dose within 14 days.  The non-SLE reason 
for the burst must be clearly indicated in the source documents.  If a subject receives >40 mg prednisone or equivalent) or a dose above baseline level for more than 14 days, it must be 
reported to the AstraZeneca st udy physician, whom will determine if the subject may continue 
to receive IP. 
In addition to the burst and tapers described above, subjects who are taking 7.5 mg/day 
prednisone or equivalent will be allowed to receive up to an additional 7.5 mg/day to a total of 
15 mg/day prednisone or equivalent for a tota l of up to 14 days or a single dose of IV 
hydrocortisone ( 100 mg hydrocortisone followed by half that dose for 2 days before 
returning to their usual dose) for severe illness, surgery, or symptoms of adrenal insufficiency 
or corticosteroid withdrawal if clinically warranted from Day 1 to Week 52. 
7.7.2.4 Topical therapy 
Concurrent use of topical therapy for cuta neous lupus erythematosus (e.g., topical 
corticosteroids, topical immunosuppressants) is  permitted.  During the study, topical therapy 
may be reduced or discontinued based on clin ical manifestations and Investigator discretion. 
Should cutaneous skin manifestations reoccur,  the same topical therapy may be resumed at 
same dose as was being used at the time of randomization.  It is encouraged that no new 
dermatologic preparations be initiated for the duration of the study.  Subjects should use 
sunscreen (list as concomitant medication for SL E) and avoid sun exposure for the duration of 
the study. 
7.7.3 Anti-hypertensive agents and statins 
Anti-hypertensive agents including; Angiotensin-Converting-Enzyme Inhibitor (ACEI),  
Angiotensin II Receptor Blockers (ARB), calcium channel blockers, beta blockers, Į receptor 
blockers, are allowed and doses may be adjusted as clinically indicated. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
84 (131) Statins must be kept at stable doses after Day 1.  Decreases in the dose are allowed only to 
reduce statin-related side effects. 
Cholestyramine must be discontinued prior to the day of randomization. 
7.7.4 NSAIDs 
Prescription NSAIDs may be used within label-approved dose ranges.  Prescription NSAIDs 
cannot be administered with other NSAIDs (inc luding over-the-counter non-steroidals) except 
for low-dose aspirin ( 325 mg/day).  On a given visit day, prescription NSAIDs should not be 
taken until after all assessments have been completed.  
7.7.5 Acetaminophen or equivalent 
Pain medications should not be used within a minimum of 6 to 12 hours (based on known 
duration of effect) of a scheduled visit.  Normal release (not extended release) acetaminophen 
or equivalent (e.g., paracetamol) may be used for pain as required. 
7.7.6 Low-dose aspirin 
Low-dose aspirin (maximum of 325 mg/day) for cardiovascular disease is permitted. 
7.7.7 Narcotic analgesics 
These can be used during the study as clinically indicated. 
7.7.8 Other concomitant treatment Other medication other than that described above, which is considered necessary for the 
subject’s safety and wellbeing, may be given at the discretion of the Investigator and recorded in the appropriate sections of the CRF. 
7.8 Prohibited medications 
The prohibited medications listed below are not allowed at any time point after enrolment  
and must be discontinued prior to signing ICF  in accordance with the time periods below.  
Prohibited Medication Discontinuation 
prior to signing ICF
Abatacept (CTLA 4 Ig) 24 weeks 
Acthar gel 6 weeks 
Adalimumab 12 weeks 
Anakinra 12 weeks 
Alefacept 12 weeks 
Apremilast 4 weeks 
Atacicept (TACI-Ig) 40 weeks 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
85 (131) Prohibited Medication Discontinuation 
prior to signing ICF
Baricitinib 4 weeks 
Belimumab 12 weeks 
Blisibimod (AMG 623) 12 weeks 
Certolizumab pegol 24 weeks 
Chlorambucil 24 weeks 
Corticosteroid pulse treatment (oral or IV) with doses >500 mg 
methylprednisolone or equivalent 24 weeks 
Cyclophosphamide (or any other alkylating agent) 24 weeks 
Cyclosporine (oral) 8 weeks 
Cytokines (eg IFN) Wash out time 
Dapsone 4 weeks 
Danazol 4 weeks 
Eculizumab 12 weeks 
Efalizumab 12 weeks 
Epratuzumab 12 weeks 
Etanercept 4 weeks 
Golimumab 12 weeks 
Infliximab 12 weeks 
Intravenous immunoglobulins 4 weeks 
Lenalidomide 8 weeks 
Lupuzor (IPP-201101) 12 weeks 
Memantine 4 weeks 
Natalizumab 24 weeks 
Obinutuzumab 26 weeks 
Ocrelizumab 26 weeks 
Ofatumumab 26 weeks 
Pimecrolimus 4 weeks 
Plasmapheresis or plasma exchange 24 weeks 
Retinoids 4 weeks 
Rituximab 26 weeks 
Sirolimus 4 weeks 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
86 (131) Prohibited Medication Discontinuation 
prior to signing ICF
Tabalumab 12 weeks 
Tacrolimus 4 weeks 
Thalidomide 8 weeks 
Tocilizumab 12 weeks 
Tofacitinib 4 weeks 
MEDI-545 (sifalimumab) 26 weeks 
Sirolimus 4 weeks 
NOTE: If any of the medications listed above is started at any time after ICF is signed, it will 
lead to immediate discontinuation of the IP as per Section 3.9. 
7.9 Post Study Access to Study Treatment 
At the end of the study, the sponsor will not continue to supply study drug to 
subjects/investigators unless the sponsor chooses to  extend the study.  The investigator should 
ensure that the subject receives appropriate  SOC treatment for the condition under study. 
8. STATISTICAL ANALYS ES BY ASTRAZENECA 
8.1 Statistical considerations 
Summary data will be presented in tabular format.  Continuous variables will be summarised 
by descriptive statistics, including number, mean, standard deviation, median, minimum, 
maximum and coefficient of variance [%CV].  Co nfidence intervals (CIs) will be two-sided, 
unless otherwise stated.  Categorical data will be summarized by the number and percentage of subjects in each category. 
The study will be double-blind until the databa se lock, performed after all subjects complete 
Week 12.  Thereafter, the sponsor will be unblinded, whilst the investigators and subjects will 
remain blinded throughout the remainder of study, including the treatment period up to Week 52 and the follow-up period up to Week 60.  Analyses will be performed by AstraZeneca or its representatives. 
A comprehensive Statistical Analysis Plan (SAP) will be prepared prior to first subject 
enrolled and any subsequent amendments will be documented, with final amendments 
completed prior to unblinding of the data at W eek 12.  Details of endpoint analyses will be 
described in the SAP. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
88 (131) 8.4.1 Primary outcome measures 
8.4.1.1 Pharmacodynamics (PD) 
The 21-gene type 1 IFN signature score and neutralization ratio (relative to baseline) will be 
used to characterize PD over time, with the primary time point at Week 12. 
8.4.1.2 Pharmacokinetics (PK) 
Due to the limited sampling schedule, the PK assessment will be primarily based on the 
observed steady-state serum trough (predose) concentrations, C trough. Maximum concentration 
after the first dose will also be evaluated.  Additional PK parameters may be determined where appropriate. 
8.4.2 Secondary outcome measures 
8.4.2.1 Immunogenicity 
ADA assessments will be conducted utilising a tiered approach (screen, confirm, titre).  The 
presence of nAb will be tested in all ADA-positive samples using appropriate summary 
statistics. 
8.4.2.2 Safety 
The following safe ty data will be  collected: vital signs, physical examination, 12-lead ECG, 
chest x-ray, haematology, serum chemistry, urinalysis, reported AEs and SAEs (including 
AEs of special interest, see Section 6.7) and C-SSRS.  Marked abnormal ECG values or 
changes from baseline will be identified base d on pre-determined criteria. Occurrence of 
suicidal behaviour and ideation, based on the C-SSRS, from baseline up to Week 52 will be 
explored. Other safety assessments: Coagulation Tests, Hemoglobin A1c (only diabetics), Serum ȕ-hCG pregnancy test, Follicle-stimulating hormone, Pap smear, B cell count (only if 
prior B cell-depleting treatment), HIV, Hepatitis B and C, QuantiFERON-TB Gold test, TB questionnaire. 
Change from baseline to each post-treatment time point where scheduled assessments were 
made will be calculated for relevant measurements.  Adverse events will be summarised by 
means of descriptive statistics and qualitative summaries. 
Other significant adverse events: During the ev aluation of the AE data, a medically qualified 
expert from Sponsor/Designee team will review: 
x AESI: The AESI are listed in Section 6.7. These will be reported in the 
CSR. 
x A list of AEs that were not repo rted as SAEs, or AEs leading to 
discontinuations: significant AEs of particular clinical importance may, 
after consultation with the Astra Zene ca Global Patient Safety Physician, 
be considered as other significant AE s (OAEs) and reported as such in 
the CSR.  Examples of these are marked haematological and other 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
89 (131) laboratory abnormalities, and certain events that lead to intervention 
(other than those already classified as serious), dose reduction, or 
significant additional treatment.  
8.4.3 Exploratory outcome measures 
8.4.3.1 Efficacy 
The efficacy outcomes for anifrolumab groups and placebo will be explored using the 
following outcome measures. 
CLASI activity score 
The effect of anifrolumab on skin will primarily be characterized by a  50% improvement in 
CLASI activity score from baseline. 
Additionally, the absolute levels, as well as the change from baseline in CLASI activity scores 
will be characterized over time. 
SLEDAI-2K score and Physician global assessment of disease activity (PGA) 
The SLE disease activity will be characterized by SLEDAI and PGA. 
SLEDAI will be characterized longitudinally  over time by the absolute levels and changes 
from baseline in SLEDAI-2K. 
Physician global assessment (PGA) will be characterized longitudinally over time using the 
change from baseline in PGA (VAS scale 0-100 mm). 
Autoantibodies and inflammatory markers 
The outcome variables for disease-related auto antibodies including; anti-nuclear antibody 
(ANA), parameters of the biological domain  (complements C3, C4 and CH50), and the 
inflammatory marker ESR, will be measured by change from baseline, longitudinally over 
time. 
8.4.3.2 Oral corticosteroid management 
OCS management will be characterized over time. 
8.4.3.3 Skin tape test (optional) 
The skin tape test will be char acterized by the 21-gene type 1 IFN signature scores.  Further 
details will be presented in the SAP.  
8.5 Methods for statistical analyses 
No formal comparisons will be made between treatment groups, and all results will be 
presented by treatment.  The two placebo arms will be pooled for the analyses.  In addition, if 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
90 (131) deemed appropriate, data from the two anifrolu mab arms may be pooled for the exploratory 
analyses of efficacy, and details for when to do this will be presented in the SAP. 
Missing data 
Subjects who discontinue IP will be encouraged to come to visits 4, 6, 8, 10, 12, 14, 16, 18, 
20, 22, 24, 26, and 28 (as applicable) (or for a minimum of 10 weeks after last dose of 
investigational product for subjects for whom investigational product was discontinued within 
10 weeks prior to Week 52). After subjects discontinue IP, visits that they  are not required to 
attend, and do not attend, will be classified as missing. 
 Presentation of results 
Data will be presented by treatment groups.  De scriptive statistics (number, mean, standard 
deviation [SD], median, minimum, maximum and coefficient of variance [%CV]) will be 
provided for continuous variables, and count s and percentages will be presented for 
categorical variables.  
8.5.1 Analysis of the primary variable (s) 
The primary characterization of the effect of anifrolumab on the 21-gene type I IFN PD 
signature will be carried out through the individual and median 21-gene type 1 IFN signature scores and neutralization ratios at Week 12.  Th e PD gene signature will also be explored over 
time.  A subset of the full analysis set will be used, defined as subjects who are randomized, 
received at least 1 dose of investigational product (modified Intention-To-Treat) and did not 
discontinue IP, will be used.  
The primary characterization of anifrolumab PK will be done by descriptive statistics of the 
derived PK parameters.  Individual and mean an ifrolumab concentrations will also be plotted 
over time. 
8.5.2 Analysis of the secondary variables 
8.5.2.1 Safety 
Adverse events (including AESIs) will be summarised by means of counts summaries by 
Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class and Preferred 
Term (PT).  All AEs will be listed. 
Laboratory data for haematology and clinical chemistry will be summarised.  The frequency 
of changes with respect to normal ranges betw een baseline and each po st-treatment time point 
will be tabulated.  Frequencies of clinically note worthy values (d efined in the SAP) occurring 
during the clinical study will also be given.  Sh ifts from normal to abnormal between baseline 
and each post-baseline time point will be characterized for urinalysis. 
The incidence of markedly abnormal values and changes from baseline in the ECG parameters 
will be summarised by treatmen t group, with placebo pooled. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
91 (131) The proportion of subjects with suicidal behaviour and suicidal ideation throughout the study 
based on the C-SSRS will be presented for each treatment group.  The proportion of subjects 
within each of the 4 suicidal behaviour categori es and within each of the 5 suicidal ideation 
sub-categories will also be presented for each treatment group.  Descriptive statistics on the 
total number of attempts, total number of interrupted attempts, and total number of aborted attempts will be summarised for each treatmen t group, with placebo pooled.  Other safety 
variables may be summarised as appropriate.  Further details will be provided in the SAP. 
8.5.2.2 Immunogenicity 
Antibodies to anifrolumab will be summarised using descriptive stat istics at each visit by 
treatment group.  ADA titres-time profiles of anifrolumab by treatment group will be 
generated.  The impact of ADA on PK and PD endpoints will be assessed.  The potential 
association of ADA with safety and efficacy will be explored. 
8.5.3 Interim analysis 
The treatment period will be double-blind up until the data base lock performed after all 
randomized subjects complete Week 12 or discon tinue the study prior to Week 12 (the main 
analysis).  At this time poin t Sponsor personnel will be unblinded whereas investigators and 
subjects will remain blinded throughout the entire study.  An additional data base lock will 
take place once all subjects ha ve completed Week 60 or discontinued the study prior to Week 
60.  Further details will be presented in the SAP (end of extension analysis). 
8.5.4 Sensitivity analysis 
Various missing data assumptions may be explored for the primary PD outcome and 
exploratory outcomes.  Further details will be provided in the SAP. 
8.5.5 Analysis methods for exploratory outcome measures 
8.5.5.1 Efficacy 
The efficacy outcomes for anifrolumab groups and placebo will be explored using the analysis 
methods stated below.  These analyses will be performed on individual and pooled 
anifrolumab treatment groups, where appropriate.  Placebo groups will be pooled for all analyses. 
CLASI activity score 
CLASI activity will be characterized at Week 12 by the proportion of subjects achieving a  
50% improvement in CLASI activity score from baseline.  The proportion of patients 
achieving a  50% improvement in CLASI activity score from baseline will also be 
characterized longitudinally fro m Week 2 up until Week 52. 
Change from baseline and overall CLASI activity scores will be characterized up to Week 12 for subjects using line charts.  This will also be characterized longitudinally up to study end. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
92 (131) Shift plots in overall CLASI activity score fro m baseline to Week 12 and baseline to Week 52 
will be created. 
Further details will be presented in the SAP. 
SLEDAI-2K score 
SLEDAI-2K will be characterized by summary statistics for change from baseline and overall 
score at Week 12.  Summary statistics for chan ge from baseline and overall score will also be 
characterized longitudinally from up until Week 52. 
Change from baseline and overall SLEDAI-2K scores will be characterized up to Week 12 for 
subjects using line charts.  This will also be characterized longitudinally up to Week 52. 
Physician global assessment of disease activity (PGA) 
Physician global assessment (PGA) will be characterized by summary statistics for change 
from baseline and overall score at Week 12.  Summary statistics for change from baseline and 
overall score will also be characterize d longitudinally up until Week 52. 
Autoantibodies and inflammatory markers 
The outcome variables for disease-related auto antibodies including; anti-nuclear antibody 
(ANA), parameters of the biological domain  (complements C3, C4 and CH50), and the 
inflammatory marker ESR, will be characterized by summary statistics for change from 
baseline, longitudinally over time. 
Further details will be provided in the SAP. 8.5.5.2 Oral corticosteroid management 
Shift tables and plots of the OCS dose at baseline and; Week 12, Week 24, and Week 52, will 
be produced.  The potential association between change in OCS dose and CLASI will also be explored graphically.  Further details will be presented in the SAP. 
8.5.5.3 Skin tape test 
Skin tape test outcome measures will be summarised as appropriate.  Further details will be 
provided in the SAP. 
9. STUDY AND DATA MANAGEMENT BY ASTRAZENECA 
9.1 Training of study site personnel 
Before the first subject is entered into the stu dy, an AstraZeneca representative will review 
and discuss the requirements of the Clinical St udy Protocol and related documents with the 
investigational staff and also train them in any study specific procedures and the WBDC 
system(s) utilised. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
93 (131) The Principal Investigator will ensure that appropriate training relevant to the study is given to 
all of these staff, and that any new information relevant to the performance of this study is 
forwarded to the staff involved. 
The Principal Investigator will maintain a re cord of all individuals involved in the study 
(medical, nursing and other staff). 
9.2 Monitoring of the study 
During the study, an AstraZeneca representative will have regular contacts with the study site, 
including visits to: 
x Provide information and support to the Investigator(s) 
x Confirm that facilities remain acceptable 
x Confirm that the investigational team is  adhering to the protocol, that data 
are being accurately and timely recorded in the CRFs, that biological samples are handled in accordance with the Laboratory Manual and that study drug accountability checks are being performed 
x Perform source data verification (a comparison of the data in the CRFs with the subject’s medical records at the hospital or practice, and other records relevant to the study) including verification of informed consent of participating subjects. This will require direct access to all original 
records for each subject (e.g., clinic charts) 
x Ensure withdrawal of informed consent to the use of the subject’s 
biological samples is reported and bi ological samples are identified and 
disposed of/destroyed accordingly, and the action is documented, and 
reported to the subject. 
The AstraZeneca representative will be available between visits if the Investigator(s) or other 
staff at the centre needs information and advice about the study conduct. 
9.2.1 Source data 
Refer to the Clinical Study Agreement for location of source data. 
9.2.2 Study agreements 
The Principal Investigator at each centre should comply with all the terms, conditions, and 
obligations of the Clinical Study Agreement, or equivalent, for this study.  In the event of any 
inconsistency between this Clinical Study Prot ocol and the Clinical Study Agreement, the 
terms of Clinical Study Protocol shall prevail with respect to the conduct of the study and the 
treatment of subjects and in all other respects, no t relating to study conduct or treatment of 
subjects, the terms of the Clinical Study Agreement shall prevail. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
94 (131) Agreements between AstraZeneca and the Principal Investigator should be in place before any 
study-related procedures can take place, or subjects are enrolled. 
9.2.3 Archiving of study documents 
The Investigator follows the principles outlined in the Clinical Study Agreement (CSA). 
9.3 Study timetable and end of study 
The end of the study is defined as ‘the last vi sit of the last subject undergoing the study’. 
The study is expected to start in Q4 2016 and to end by Q4 2018. 
The study may be terminated at individual ce ntres if the study procedures are not being 
performed according to GCP, or if recruitment is slow.  AstraZeneca may also terminate the 
entire study prematurely if concerns for safety arise within this study or in any other study 
with anifrolumab.  
9.4 Data management by AstraZeneca or delegate 
Data management will be performed by Ast raZeneca Data Management Centre staff 
according to the Data Management Plan. 
The data collected through third party sources will be obtained and reconciled against study 
data. 
Adverse events and medical/surgical history will be classified according to the terminology of 
the latest version the Medical Dictionary for Regulatory Activities (MedDRA).  Medications will be classified according to the AstraZeneca Drug Dictionary.  All coding will be 
performed by the Medical Coding Team at the AstraZeneca Data Management Centre.  
Data queries will be raised for inconsistent, impossible or missing data.  All entries to the 
study database will be available in an audit trail. 
The data will be validated as defined in the Data Management Plan. Quality control 
procedures will be applied to each stage of data handling to ensure that all data are reliable 
and have been processed correctly.  The Data Management Plan will also clarify the roles and 
responsibilities of the various functions and personnel involved in the data management process 
When all data have been coded, validated, signed  and locked, clean file will be declared.  Any 
treatment revealing data may thereafter be ad ded and the final database will be locked. 
Serious Adverse Event (SAE) Reconciliation 
SAE reconciliation reports are produced and reconciled with the Patient Safety database 
and/or the investigational site  
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
95 (131) Data associated with human biological samples 
Data associated wi th biological samples will be transferred from laboratory(ies) internal or 
external to AstraZeneca. 
Management of external data 
The data collected through third party sources will be obtained and re conciled against study 
data. 
10. ETHICAL AND REGULATORY REQUIREMENTS 
10.1 Ethical conduct of the study 
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, applicable 
regulatory requirements and the AstraZenec a policy on Bioethics and Human Biological 
Samples. 
10.2 Subject data  protection 
The Informed Consent Form will incorporate (or, in some cases, be accompanied by a 
separate document incorporating) wording that complies with relevant data protection and 
privacy legislation. 
10.3 Ethics and regulatory review 
An Ethics Committee (EC)/Institutional Review Board (IRB) should approve the final study 
protocol, including the final version of the Informed Consent Form and any other written 
information and/or materials to be provided to th e subjects.  The Investig ator will ensure the 
distribution of these documents to the applicable EC/IRB, and to the study site staff. 
The opinion of the EC/IRB should be given in writing. The Investigator should submit the written approval to AstraZeneca before enrolment of any subject into the study.  
The EC/IRB should approve all advertising used to recruit subjects for the study. 
AstraZeneca should approve any modifications to  the Informed Consent Form that are needed 
to meet local requirements. 
If required by local regulations, the protocol should be re-approved by the EC/IRB annually. 
Before enrolment of any subject into the study, the final study protocol, including the final 
version of the Informed Consent Form, is approve d by the national regulatory authority or a 
notification to the national regulatory author ity is done, according to local regulations. 
AstraZeneca will handle the distribution of any of these documents to the national regulatory 
authorities. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
96 (131) AstraZeneca will provide Regulatory Authorities, EC/IRB and Principal Investigators with 
safety updates/reports accord ing to local requirements. 
Each Principal Investigator is responsible for providing the EC/IRB with reports of any 
serious and unexpected adverse drug reactions  from any other study conducted with the 
investigational product.  AstraZeneca will provide this information to the Principal 
Investigator so that he/she can meet these reporting requirements. 
10.4 Informed consent 
The Principal Investigator(s) at each centre will: 
x Ensure each subject is given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study 
x Ensure each subject is notified that they are free to discontinue from the 
study at any time 
x Ensure that each subject is given the opportunity to ask questions and allowed time to consider the information provided 
x Ensure each subject provides signed  and dated informed consent before 
conducting any procedure specifically for the study 
x Ensure the original , signed Informed Consent Form(s) is/are stored in the 
Investigator’s Study File 
x Ensure a copy of the signed Informed Consent Form is given to the subject 
x Ensure that any incentives for subjects who participate in the study as well as any provisions for subjects harmed as a consequence of study participation are described in the informed consent form that is approved by an EC/IRB. 
10.5 Changes to the protocol and informed consent form 
Study procedures will not be changed without the mutual agreement of the International co-
ordinating Investigator and AstraZeneca. 
If there are any substantial changes to the study protocol, then a new version of the study 
protocol will be generated. 
The amendment is to be approved by the relevant EC/IRB and if applicable, also the national 
regulatory authority approval, before implementation.  Local requirements are to be followed for revised protocols. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
97 (131) AstraZeneca will distribute any subsequent amendments and new versions of the protocol to 
each Principal Investigator(s). For di stribution to EC/IRB see Section 10.3. 
If a protocol amendment requires a change to a centre’s Informed Consent Form, AstraZeneca 
and the centre’s EC/IRB are to approve the revised Informed Consent Form before the revised form is used.  
If local regulations require, any administrative change will be communicated to or approved 
by each EC/IRB. 
10.6 Audits and inspections 
Authorised representatives of AstraZeneca, a regulatory authority, or an Ethics Committee 
may perform audits or inspections at the centre, including source data verification.  The purpose of an audit or inspection is to system atically and independently examine all study-
related activities and documents, to determine whether these activities were conducted, and data were recorded, anal ysed, and accurately repo rted according to the protocol, Good Clinical 
Practice (GCP), guidelines of the International Conference on Harmonisation (ICH), and any applicable regulatory requirements.  The Investigator will contact AstraZeneca immediately if 
contacted by a regulatory agency about an inspection at the centre. 
11. LIST OF REFERENCES 
ACR ad hoc committee, September 1999 ACR ad hoc committee. Guidelines for Referral and Management of systemic Lupus Erythematosus in Adults. Arthritis & Rheumatism Vol. 42, No. 9, September 1999, pp 1785–
1796). 
American Psychiatric Association, 1994 
American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. American Psychiatric Association, Washington, DC. 
Bengtsson et al, 2000 
Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of 
type I interferon system in systemic lupus erythematosus correlates with disease activity but 
not with antiretroviral anti bodies. Lupus. 2000;9:664-71. 
Bertsias et al, 2008 Bertsias G, Ioannidis JPA, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR 
recommendations for the management of systemic lupus erythematosus. Report of a Task 
Force of the EULAR Standing Committee for International Clinical Studies Including 
Therapeutics, Ann Rheum Dis 2008; 67:195–205). 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
98 (131) Blomberg S et al, 2001 
Blomberg S, Eloranta ML, Ce derblad B, Nordlin K, Alm GV,  Rönnblom L. Presence of 
cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. 
Lupus. 2001;10(7):484-90. 
Cellestis, 2005 
Clinicians Guide to QuantiFERON®-TB Gold. 
CHMP, February 2015 
CHMP Guideline on clinical investigation of medi cinal products for the treatment of 
systemiclupus erythematosus and lupus nephritis (26 February 2015; 
EMA/CHMP/51230/2013). 
Cooper et al, 1998 
Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Parks CG, Gilkeson GS. Hormonal, 
environmental, and infectious risk factors for developing systemic lupus erythematosus. 
Arthritis Rheum. 1998;41(10):1714-24. 
Dall’era et al, 2005 
Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis Jr, JC. Type I Interferon correlates 
with clinical and serologic manifestations of systemic lupus erythematosus. Ann Rheum Dis. 
2005; 64:1692-7. 
Doria and Briani, 2008 
Doria A, Briani C. Lupus: improving lo ng-term prognosis. Lupu s. 2008;17(3):166-70. 
Farkas et al, 2001 Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneou s lupus erythematosus 
lesions. Am J Pathol. 2001;159(1):237-43. 
Grönhagen CM et al, 2010  
Grönhagen, C. M., Gunnarsson, I., Svenungsson, E., & Nyberg, F. Cutaneous manifestations 
and serological findings in 260 patients wi th systemic lupus erythematosus. Lupus, 2010 
19(10), 1187-1194. 
Kapadia N et al, 1996 
Kapadia, N., & Haroon, T. S. Cutaneous manifestations of systemic lupus erythematosus: study from Lahore, Pakistan. International jo urnal of dermatology, 1996. 35(6), 408-409. 
Lahita, 1999 Lahita RG. The role of sex hormones in system ic lupus erythematosus.  Curr Opin Rheumatol. 
1999;11(5):352-6. 
Clinical Study Protocol 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
99 (131) Merrill, 2014 
Merrill, J.M. Guidelines for use of the SLEDAI-2K to assess disease activity (modified 
forassessment over one month). Lupus Foundation of America. Accessed 08 December 2014 at:http://www.lupus.org/ 
Petri, 2001 
Petri M. Long-term outcomes in lupus. Am J Managed Care. 2001;7(16) Suppl: S480-5. 
Posner et al, 2007 
Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm 
of Suicide Assessment (C-CASA): Classification of Suicidal Events in the FDA’s 
PediatricSuicidal Risk Analys is of Antidepressants Am J Psychiatry 2007; 164(7):1035-1043 
Ramsey-Goldman and Manzi, 2000 
Ramsey-Goldman R, Manzi S. Systemic lupus erythematosus. Women and health. Academic 
Press 2000:704. 
Rothfield N et al, 2006 
Rothfield, N., Sontheimer, R. D., & Bernstein, M. Lupus erythematosus: systemic and 
cutaneous manifestations. Clinics in dermatology. 2006; 24(5), 348-362. 
Sampson et al, 2006 
Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report-second 
National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network 
symposium. J Allergy Clin Immunol. 2006;117(2):391-7. 
World Health Organization, 2014 
World Health Organization. Definitions and reporting framework for tuberculosis - 2013 
revision (updated December 2014) 
http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345 eng.pdf 
Wysenbeek AJ et al, 1992 
Wysenbeek, A. J., Guedj, D., Amit, M., & Weinberger, A. Rash in systemic lupus 
erythematosus: prevalence and relation to cutaneous and non-cutaneous disease 
manifestations. Annals of the rheumat ic diseases, 1992  51(6), 717-719. 
Yao et al, 2009 
Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, et al. 
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I 
trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. 
Arthritis Rheum. 2009 Jun;60(6):1785-96. 
Zonana-Nanach et al, 2000 
Zonana-Nanach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus 
and its association with corticosteroids. Arthritis Rheum. 2000;43(8):1801-8. 
Clinical Study Protocol Appendix A 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
100 (131) Appendix A Additional Safety Information 
Further Guidance on the Definition of a Serious Adverse Event (SAE) 
Life threatening 
‘Life-threatening’ means that the subject was at immediate risk of death from the AE as it 
occurred or it is suspected that use or continued use of the product would result in the 
subject’s death.  ‘Life-threatening ’ does not mean that had an AE  occurred in a more severe 
form it might have caused death (e.g., hepati tis that resolved without hepatic failure). 
Hospitalisation 
Outpatient treatment in an emergency room is not in itself a serious AE, although the reasons 
for it may be (e.g., bronchospasm, laryngeal oe dema).  Hospital admissions and/or surgical 
operations planned before or during a study are not considered AEs if the illness or disease 
existed before the subject was enrolled in the st udy, provided that it did not deteriorate in an 
unexpected way during the study. 
Important medical event or medical intervention 
Medical and scientific judgement should be exerci sed in deciding whether a case is serious in 
situations where important medical events may not be immediately life threatening or result in 
death, hospitalisation, disability or incapacity but may jeopardize the subject or may require medical intervention to prevent one or more outcomes listed in the definition of serious.  These should usually be considered as serious. 
Simply stopping the suspect drug does not mean that it is an important medical event; medical 
judgement must be used. 
x Angioedema not severe enough to require intubation but requiring iv 
hydrocortisone treatment 
x Hepatotoxicity caused by paracetamol (acetaminophen) overdose 
requiring treatment with N-acetylcysteine 
x Intensive treatment in an emergency room or at home for allergic 
bronchospasm 
x Blood dyscrasias (eg, neutropenia or anaemia requiring blood transfusion, 
etc) or convulsions that do not result in hospitalisation 
Development of drug dependency or drug abuse 
A Guide to Interpreting the Causality Question 
When making an assessment of causality consider the following factors when deciding if there 
is a ‘reasonable possibility’ that an AE may have been caused by the drug. 
Clinical Study Protocol Appendix A 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
101 (131) x Time Course.  Expos ure to suspect drug.  Has the subject actually 
received the suspect drug?  Did the AE occur in a reasonable temporal 
relationship to the administration of the suspect drug? 
x Consistency with known drug profile.  Was the AE consistent with the 
previous knowledge of the suspect drug (pharmacology and toxicology) 
or drugs of the same pharmacological class? Or could the AE be anticipated from its pharmacological properties? 
x De-challenge experience.  Did the AE  resolve or improve on stopping or 
reducing the dose of the suspect drug? 
x No alternative cause.  The AE cannot be reasonably explained by another aetiology such as the underlying disease, other drugs, other host or environmental factors. 
x Re-challenge experience.  Did the AE  reoccur if the suspected drug was 
reintroduced after having been stopped? AstraZeneca would not normally recommend or support a re-challenge. 
x Laboratory tests.  A specific laboratory investigation (if performed) has confirmed the relationship. 
In difficult cases, other factors  could be considered such as: 
x Is this a recognized featur e of overdose of the drug? 
x Is there a known mechanism? 
Causality of ‘related’ is made if following a review of the relevant data, there is evidence for a ‘reasonable possibility’ of a causal relationship for the individual case.  The expression ‘reasonable possibility’ of a causal relationship is meant to convey, in general, that there are 
facts (evidence) or arguments to suggest a causal relationship. 
The causality assessment is performed based on the available data including enough 
information to make an informed judgment.  With limited or insufficient information in the case, it is likely that the event(s) will be assessed as ‘not related’. 
Causal relationship in cases where the disease under study has deteriorated due to lack of 
effect should be classified as no reasonable possibility. 
Clinical Study Protocol Appendix B 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
102 (131) Appendix B International Airline Transportation Association (IATA) 6.2 
Guidance Document 
Labelling and shipment of biohazard samples 
International Airline Transporta tion Association (IATA) classifies biohazardous agents into 3 
categories.  For transport purposes the classification  of infectious substanc es according to risk 
groups was removed from the Dangerous Good s Regulations (DGR) in the 46th edition 
(2005).  Infectious substances are now classified either as Category A, Category B or Exempt.  
There is no direct relationship betwee n Risk Groups and categories A and B. 
Category A  Infectious Substances  are infectious substances in a form that, when exposure to 
it occurs, is capable of causing permanent disability, life-threatening or fatal disease in 
otherwise healthy humans or animals.  Category A pathogens are eg, Ebola, Lassa fever virus: 
x are to be packed and shipped in accordance with IATA Instruction 602. 
Category B Infectious Substances  are infectious Substances that do not meet the criteria for 
inclusion in Category A.  Category B pathogen s are eg, Hepatitis A, B, C, D, and E viruses, 
Human immunodeficiency virus (HIV) types 1 and 2.  They are assigned the following UN 
number and proper shipping name: 
x UN 3373 – Biological Substance, Category B 
x are to be packed in accordan ce with UN3373 and IATA 650 
Exempt - all other materials with minimal risk of containing pathogens 
x Clinical trial samples will fall into Category B or exempt under IATA 
regulations 
x Clinical trial samples will routinely be packed and transported at ambient temperature in IATA 650 compliant packaging  
x Biological samples transported in dry ice require additional dangerous 
goods specification for the dry-ice content 
x IATA compliant courier and packaging materials should be used for 
packing and transportation and packing should be done by an IATA 
certified person, as applicable 
x Samples routinely transported by road or rail are subject to local 
regulations which require that they ar e also packed and transported in a 
safe and appropriate way to contain any risk of infection or 
contamination by using approved couriers and packaging / containment materials at all times.  The IATA 650 biological sample containment 
Clinical Study Protocol Appendix B 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
103 (131) standards are encouraged wherever poss ible when road or rail transport is 
used. 
Clinical Study Protocol Appendix C 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
104 (131) Appendix C Actions Required in Cases of Increases in Liver 
Biochemistry and Evaluation of Hy’s Law 
Introduction
This Appendix describes the process to be followed in order to identify and appropriately 
report cases of Hy’s Law.  It is not intended to be a comprehensive guide to the management 
of elevated liver biochemistries.  
During the course of the study the Investigator  will remain vigilant for increases in liver 
biochemistry.  The investigator is responsible for determining whether a patient meets 
potential Hy’s Law (PHL) criteria at any point during the study. 
The Investigator participates, together with AstraZeneca clinic al project representatives, in 
review and assessment of cases meeting PHL crite ria to agree whether H y’s Law (HL) criteria 
are met.  HL criteria are met if there is no alternative explanation for the elevations in liver 
biochemistry other than Drug  Induced Liver Injury (DILI) caused by the Investigational 
Medicinal Product (IMP).  
The Investigator is responsible for record ing data pertaining to PHL/HL cases and for 
reporting Adverse Events (AE) and Serious Adverse Events (SAE) according to the outcome 
of the review and assessment in line with standard safety reporting processes. 
Definitions 
Potential Hy’s Law (PHL) 
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT)  3x Upper Limit of 
Normal (ULN) together with  Total Bilirubin (TBL)  2xULN at any point during the study 
following the start of study medication  irrespective of an increase in Alkaline Phosphatase 
(ALP).  
Hy’s Law (HL) AST or ALT  3x ULN  together with TBL  2xULN, where no other reason, other than the 
IMP, can be found to explain the combination of increases, eg, elevated ALP indicating 
cholestasis, viral hepatitis, another drug.   
For PHL and HL the elevation in transaminases mu st precede or be coincident with (i.e. on the 
same day) the elevation in TBL, but there is no specified timeframe within which the 
elevations in transaminases and TBL must occur. 
Identification of Potential Hy’s Law Cases 
In order to identify cases of PHL it is importa nt to perform a comprehensive review of 
laboratory data for any patient who meets any of the following identification criteria in 
isolation or in combination: 
x ALT  3xULN 
Clinical Study Protocol Appendix C 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
105 (131) x AST  3xULN 
x TBL   2xULN 
When a patient meets any of the identification criteria, in isolation or in combination, the 
central laboratory will immediately send an alert to the Investigator (also sent to AstraZeneca 
representative).  
The Investigator will also remain vigilant for any local laboratory reports where the 
identification criteria are met, where this is the case the Investigator will: 
x Notify the AstraZeneca representative 
x Request a repeat of the test (new blood draw) by the central laboratory 
x Complete the appropriate unscheduled laboratory CRF module(s) with 
the original local laboratory test result 
When the identification criteria are met from cent ral or local laboratory results the Investigator 
will without delay: 
x Determine whether the patient meets PHL criteria (see Definitions within this Appendix for definition) by reviewing laboratory reports from all 
previous visits (including both central and local laboratory results) 
The Investigator will without delay review each new laboratory report and if the identification 
criteria are met will: 
x Notify the AstraZeneca representative 
x Determine whether the patient meets PHL  criteria (see Definitions within 
this Appendix for definition) by reviewing laboratory reports from all 
previous visits 
x Promptly enter the laboratory data into the laboratory CRF 
Follow-up
Potential Hy’s Law Criteria not met 
If the patient does not meet PHL criteria the Investigator will: 
x Inform the AstraZeneca representative that the patient has not met PHL 
criteria. 
x Perform follow-up on subsequent laboratory results according to the guidance provided in the Clinical Study Protocol. 
Clinical Study Protocol Appendix C 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
106 (131) Potential Hy’s Law Criteria met 
If the patient does meet PHL criteria the Investigator will: 
x Notify the AstraZeneca representative who will then inform the central 
Study Team   
The Study Physician contacts the Investigator, to provide guidance, discuss and agree an 
approach for the study patients’ follow-up and th e continuous review of data.  Subsequent to 
this contact the Investigator will: 
x Monitor the patient until liver biochemistry parameters and appropriate clinical symptoms and signs return to normal or baseline levels, or as 
long as medically indicated  
x Investigate the etiology of the event and perform diagnostic 
investigations as discussed with the Study Physician.   
x Complete the three Liver CRF Modules as information becomes available  
x If at any time (in consultation with the Study Physician) the PHL case meets serious criteria, report it as an SAE using standard reporting 
procedures 
Review and Assessment of Potential Hy’s Law Cases 
The instructions in this Section should be followed for all cases where PHL criteria are met. 
No later than 3 weeks after the biochemistry abnormality was initially detected, the Study 
Physician contacts the Investigator in order to  review available data and agree on whether 
there is an alternative explanation for meeting PHL criteria other than DILI caused by the 
IMP.  The AstraZeneca Medical Science Direct or and Global Safety Physician will also be 
involved in this review together with othe r subject matter experts as appropriate.   
According to the outcome of the review and assessment, the Investigator will follow the 
instructions below. 
If there is an agreed alternative explanation for the ALT or AST and TBL elevations, a 
determination of whether the alternative explanation is an AE will be made and subsequently 
whether the AE meets the criteria for a SAE: 
x If the alternative explanation is not an AE, record the alternative 
explanation on the appropriate CRF 
x If the alternative explanation is an AE/SAE, record the AE /SAE in the 
CRF accordingly and follow the AZ standard processes 
Clinical Study Protocol Appendix C 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
107 (131) If it is agreed that there is no explanation that would explain the ALT or AST and TBL 
elevations other than the IMP: 
x Report an SAE (report term ‘Hy’s Law’) according to AstraZeneca 
standard processes.  
- The ‘Medically Important’ serious criterion should be used if no other 
serious criteria apply 
- As there is no alternative explanation for the HL case, a causality 
assessment of ‘related’ should be assigned. 
If, there is an unavoidable delay, of over 3 weeks, in obtaining the information necessary to 
assess whether or not the case meets the criteria for HL, then it is assumed that there is no 
alternative explanation until such time as an informed decision can be made: 
x Report an SAE (report term ‘Potential Hy’s Law’) applying serious 
criteria and causality assessment as per above 
x Continue follow-up and review acco rding to agreed plan.  Once the 
necessary supplementary information is obtained, repeat the review and 
assessment to determine whether HL criteria are met.  Update the SAE 
report according to the outcome of the review 
References 
FDA Guidance for Industry (issued July 2009) ‘Drug-induced liver injury: Premarketing 
clinical evaluation’: 
http://www fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf 
 
Clinical Study Protocol Appendix D 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
108 (131) Appendix D American College of Rheumat ology Criteria for Systemic 
Lupus Erythematosus Classification 
ACR Criteria for SLE Classification 
Item Definition 
Malar rash  
  Fixed erythema, flat or raised, over the malar eminences, sparing the nasolabial folds 
Discoid rash  Erythematous, raised patches with adherent keratotic scaling and follicular 
plugging: atrophic scarring may occur in older lesions 
Photosensitivity   Skin rash as a result of unusual reaction to sunlight, by patient history or physician 
observation 
Oral ulcers   
  Oral or nasopharyngeal ulceration, usually painless, observed by a physician 
Nonerosive arthritis  
  Involving 2 or more peripheral joints, characterized by tenderness, swelling, or effusion 
Pleuritis or pericarditis    
 a. Pleuritis--convincing history of pleuritic pain or rub heard by a physician or 
evidence of pleural effusion 
OR
b. Pericarditis – documented by electrocardiogram or rub or evidence of 
pericardial effusion 
Renal disorder  
  a. Persistent proteinuria > 0.5 gm per day or > 3+ if quantitation not performed 
OR b. Cellular casts--may be red cell, hemoglobin, granular, tubular, or mixed 
Neurologic disorder  a. Seizures--in the absence of offending drugs or known metabolic derangement, 
eg, uremia, ketoacidosis, or electrolyte imbalance 
 OR 
b. Psychosis--in the absence of offending drugs or known metabolic derangement, 
eg, uremia, ketoacidosis, or electrolyte imbalance 
Hematologic disorder 
  a. Hemolytic anemia with reticulocytosis 
 OR 
b. Leukopenia--< 4,000/mm3 on  2 occasions  
 OR 
c. Lymphopenia--< 1,500/mm3 on  2 occasions 
 OR 
d. Thrombocytopenia--< 100,000/mm3 in the absence of offending drugs 
Clinical Study Protocol Appendix D 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
109 (131) ACR Criteria for SLE Classification 
Item Definition 
Immunologic disorder 
  
 a. Anti-DNA: antibody to native DNA in abnormal titer 
 OR 
b. Anti-Sm: presence of antibody to Sm nuclear antigen 
 OR 
c. Positive finding of antiphospholipid antibodies based on: 1) an abnormal serum 
level of IgG or IgM anticardiolipin antibodies; 2) a positive test result for lupus 
anticoagulant using a standard method; or 3) a false-positive test result for at 
least 6 months and confirmed by Treponema pallidum immobilization or 
fluorescent treponemal antibody absorption test. 
Positive antinuclear 
antibody    An abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at any point in time in the absence of drug. 
 
  
Clinical Study Protocol Appendix E 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
110 (131) Appendix E Systemic Lupus Erythema tosus Disease Activity Index 2000 
SLEDAI 2K  
(Modified for assessment over one month) 
Study No.:     Patient Name:      Visit Date:    
(Enter weight in SLEDAI Score column if descriptor is present at the time of the visit or in the preceding 14 days.)

Clinical Study Protocol Appendix E 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
111 (131)  

Clinical Study Protocol Appendix F 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 Date 20 Sep 2016 
112 (131) Appendix F Cutaneous Lupus Erythematosus Disease Area and Severity 
Index 
 
 

Clinical Study Protocol Appendix G 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 Date 20 Sep 2016 
113 (131)  
Appendix G Physician global assessment  
 

Clinical Study Protocol Appendix H 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
114 (131) Appendix H Oral Corticosteroid Guidance    
Examples of Equivalent Doses of Oral Prednisone 
Oral Prednisone and Equivalents Equivalent Dose 
Oral Prednisone  7.5 mg 10 mg 20 mg 30 mg 40 mg 
Cortisone 37.5 mg 50 mg 100 mg 150 mg 200 mg 
Hydrocortisone 30 mg 40 mg 80 mg 120 mg 160 mg 
Methylprednisolone 6 mg 8 mg 16 mg 24 mg 32 mg 
Prednisolone 7.5 mg 10 mg 20 mg 30 mg 40 mg 
Triamcinolone 8 mg 8 mg 16 mg 24 mg 32 mg 
 
Example of OCS Tapering Schedule 
Time point Initial Dose of Oral Prednisone or Equivalent (mg/day) 
40 35 30 25 20 15 10 
Week 12 35 30 25 20 15 12.5 10 
Week 16 30 25 20 15 12.5 12.5 10 
Week 20 25 20 15 12.5 12.5 12.5 7.5 
Week 24 20 15 12.5 12.5 10 10 7.5 
Week 28 15 12.5 12.5 10 10 10 7.5 
Week 32 12.5 10 10 10 7.5 7.5 7.5 
Week 36 10 10 7.5 7.5 7.5 7.5 7.5 
Week 40 7.5 7.5 7.5 7.5 7.5 7.5 7.5 
* Note: patients on OCS doses equivalent to 10 mg prednisone/day may tolerate tapering by 1 mg/day per 
visit rather than an abrupt drop from 10 mg/day to 7.5 mg/day. The stepwise tapering of OCS dose should 
be performed at the discretion of the Investigator. 
Clinical Study Protocol Appendix I 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
115 (131) Appendix I General guidance for Determination of Major Surgery 
The goal of this guidance is to maximize the be nefit/risk for each patient entering this study. 
An important aspect to this goal is taking into  account all relevant hi story, including recent 
surgeries and/or injuries that could influence the safety of the patient potentially being 
exposed to an additional immunomodulatory medica tion or could bias the efficacy endpoints 
of the trial. 
Given the advancement and availability of surg ical techniques, major surgery is in the 
judgment of the Investigator and his/her evaluation of the following criteria, regardless of the 
specific surgical procedure: 
1. Has the patient completely recovered (m entally, emotionally, and physically) from 
the surgery and is not receiving additional  medications related to the prior surgery 
(ie, antibiotics)? 
2. Has the patient completed all follow-up visits related to the surgery, including 
ancillary services such as physical and/or occupational therapy? 
3. Has the patient resumed all of their prior activities? 4. Has the patient returned to his/her ba seline medications for SLE and non-SLE 
indications? 
Clinical Study Protocol Appendix J 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
116 (131) Appendix J Guidance for abnormal Pap-smear results 
Pap Smear Result Abbreviatio
nAlso Known As Suggested Action 
Atypical squamous cells–
undetermined significance ASC–US — Permitted to enter study 
Atypical squamous cells–cannot exclude HSIL ASC–H — Permitted to enter study 
Atypical glandular cells AGC — Permitted to enter study 
Low-grade squamous intraepithelial lesion LSIL  
Mild dysplasia Cervical intraepithelial 
neoplasia–1 (CIN–1) Permitted to enter study 
High-grade squamous 
intraepithelial lesion HSIL  
Moderate dysplasia 
CIN-2 / CIN II Permitted to enter study 
High-grade squamous 
intraepithelial lesion HSIL  
CIN–3 / CIN III 
Carcinoma in situ (CIS) Exclude/discontinue subject 
Endocervical 
adenocarcinoma in situ AIS — Exclude/discontinue subject 
 
 
Clinical Study Protocol Appendix K 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
117 (131) Appendix K Anaphylaxis 
In adults, anaphylaxis is highly likely when any 1 of the following 3 criteria is fulfilled: 
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (eg, generalised hives, pruritus or flushing, swollen lips, 
tongue and/or uvula)  
AND AT LEAST ONE OF THE FOLLOWING: 
x Respiratory compromise (eg, dysp noea, wheeze-bronchospasm, stridor, 
reduced peak expiratory flow, hypoxaemia) 
x Reduced BP (see number 3 below for de finition) or associated symptoms 
of end-organ dysfunction (eg, hypotonia [collapse], syncope, 
incontinence) 
2. Two or more of the following that occur rapidly after exposure to a likely allergen 
for that patient (minutes  to several hours):  
x Involvement of the skin-mucosal tissue (eg, generalised hives, itch, flush, 
swollen lips, tongue and/or uvula) 
x Respiratory compromise (eg, dysp noea, wheeze-bronchospasm, stridor, 
reduced peak expiratory flow, hypoxaemia) 
x Reduced BP (see number 3 below for de finition) or associated symptoms 
(eg, hypotonia [collapse], syncope, incontinence) 
x Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting) 
3. Reduced BP after exposure to known al lergen for that patient (minutes to several 
hours); for adults a systolic BP of less than 90 mm Hg or greater than 30% decrease 
from that person’s baseline BP (taken at or immediately prior to the injection), 
whichever BP is lower (Sampson et al, 2006). 
The following definitions are provided for the purposes of this study: 
Hypersensitivity reaction: an acute onset of an illness with involvement of the skin, mucosal 
tissue, or both during or after the injection of investigational product (but does not meet the 
definition of anaphylaxis described above). 
 
To assist with the mitigation of these AEs,  see Table 6, which categorizes reactions by 
severity of symptoms, proposes severity-specific treatment and offers guidance on management of investigational product. Final treatment is at the discretion of the Investigator and should reflect local SOC. 
Clinical Study Protocol Appendix K 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
118 (131) Table 6 An approach to management of anaphylactic and hypersensitivity 
Severity of symptoms Treatment Investigational product 
Mild reactions (hypersensitivity) 
Mild reactions such as 
headache, nausea, non-
pruritic rash, or mild 
hypersensitivity reactions including localised cutaneous 
reactions such as mild 
pruritus, flushing, rash, 
dizziness, headache, 20 mmHg change in 
systolic BP from 
pre-injection 
measurement Evaluate patient, including close 
monitoring of vital signs  
At the discretion of the Investigator, 
treat patient, for example, with: 
- Normal saline (~500 to 
1000 mL/hour IV) and/or 
- Diphenhydramine 50 mg IV or 
equivalent and/or 
- Acetaminophen 500 to 650 mg 
or equivalent dose of 
paracetamol and/or 
- Topical antihistamines and/or 
low-potency topical corticosteroid preparations and/or 
- Anti-nausea medication, as 
needed Stop investigational product 
injection immediately 
Option 1: do not resume 
investigational product injection; 
Option 2: discontinue any 
further administration of 
investigational product; OR at the discretion of the Investigator, continue future investigational 
product administrations and 
pretreating patient 1.5 to 0.5 
hours prior to investigational product administration, for example with: 
- Diphenhydramine 50 mg IV 
or equivalent 
- Acetaminophen 500 to 
650 mg or equivalent dose of paracetamol 
Moderate reactions ( 
hypersensitivity)
IP related reaction such 
as those listed above under mild reactions but excluding moderate hypersensitivity reactions (see below) Evaluate patient, including close 
monitoring of vital signs  
Treat patient, for example, with: 
- Normal saline (~500 to 
1000 mL/hour IV) and/or 
- Diphenhydramine 50 mg IV or 
equivalent and/or 
- Acetaminophen 500 to 650 mg 
or equivalent dose of 
paracetamol and/or 
- Anti-nausea and/or antiemetic 
intramuscular, as needed Stop investigational product 
injection immediately 
Option 1: do not resume 
investigational product injection; OR based on risk/benefit 
evaluation, at the discretion of 
the Investigator, resume current 
investigational product injection 
under observation after treatment of current signs and symptoms 
as suggested (eg, normal saline 
and/or Tylenol and/or topical 
antihistamines) 
Clinical Study Protocol Appendix K 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
119 (131) Severity of symptoms Treatment Investigational product 
  Additional Options for Future Administration of investigational product 
Discontinue any further 
administrations of 
investigational product; OR 
Further investigational product 
injections, at the discretion of 
the Investigator, continue 
investigational product 
administration and pretreating 
patient 0.5 to 1.5 hours prior to 
investigational product 
administration, for example with: 
- Diphenhydramine 50 mg IV 
or equivalent 
- Acetaminophen 500 to 
650 mg or equivalent dose of paracetamol 
- Anti-nausea and/or 
antiemetic by mouth 
If moderate event recurs in the same patient, discontinue further investigational product 
administration 
Moderate 
hypersensitivity
reactions 
IP- related reactions 
which may include 
generalised rash or 
urticaria, palpitations, 
chest discomfort, shortness of breath, 
hypo- or hypertension 
with >20 mmHg change 
in systolic BP from 
pre-injection measurement Evaluate patient, including close 
monitoring of vital signs  
Treat patient, for example, with: 
- Normal saline (~500 to 
1000 mL/hour IV) and/or 
- Diphenhydramine 50 mg IV or 
equivalent and/or 
- Acetaminophen 500 to 650 mg 
or equivalent dose of 
paracetamol and/or 
- IV corticosteroids, such as 
hydrocortisone 100 mg or 
methylprednisolone 20 to 40 mg Stop investigational product 
injection immediately 
DO NOT resume current 
injection 
Discontinue any further 
administrations of investigational product 
Consider need for additional oral 
antihistamine administration or 
oral corticosteroid administration to prevent 
reoccurrence of symptoms over 
subsequent 2 to 3 days 
 
Clinical Study Protocol Appendix K 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
120 (131) Severity of symptoms Treatment Investigational product 
Severe 
Above plus fever with 
rigors, hypo- or hypertension with 40 
mmHg change in 
systolic BP, signs of end 
organ dysfunction (eg, 
symptomatic hypotension such as hypotonia, syncope, 
incontinence, seizure) 
from pre-injection 
measurement, or wheezing, angioedema, or stridor 
OR  
Life-threatening 
Defined as a reaction 
that is life-threatening and requires pressor and/or ventilator support or shock associated with acidemia and impairing vital organ function due to tissue hypoperfusion Evaluate patient, including close monitoring of vital signs 
Maintain airway, oxygen if available Treat patient immediately, for 
example with: 
- Normal saline (~500 to 
1000 mL/hour IV) 
- Epinephrine for bronchospasm, 
hypotension unresponsive to IV fluids, or angioedema. Dose and 
route as per local SOC, 
example, epinephrine 1:1000, 
0.5 to 1.0 mL administered SC for mild cases and intramuscular for more severe cases 
- IV corticosteroids, such as 
hydrocortisone 100 mg or 
methylprednisolone 20 to 40 mg 
- Diphenhydramine 50 mg IV or 
equivalent 
- Acetaminophen 500 to 650 mg 
or equivalent dose of 
paracetamol 
Call emergency medical transport for transport to emergency hospital based on judgment of the 
Investigator 
Grade 3 wheezing, hypotension or 
angioedema is unresponsive to single 
dose of epinephrine 
Grade 4 event At the discretion of the Investigator Stop investigational product 
injection immediately 
Permanently discontinue 
investigational product administration 
Consider need for additional oral 
antihistamine administration or oral corticosteroid 
administration to prevent 
reoccurrence of symptoms over 
subsequent 2 to 3 days 
 
Clinical Study Protocol Appendix L 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008 
Version 1.0 
Date 20 Sep 2016 
121 (131) Appendix L Classification criteria for catastrophic anti-phospholipid 
syndrome 
 
Classification Criteria for Catastrophic Antiphospholipid Syndrome 
Criteria 
1. Evidence of involvement of three or more organs, systems and/or tissues 
2. Development of manifestations simultaneously or in less than a week 
3. Confirmation by histopathology of small vessel occlusion in at least one organ or 
tissue 
4. Laboratory confirmation of the presen ce of anti-phospholipid antibodies (lupus 
anticoagulants and/or anticardiolipin antibodies) 
Classification 
 Definite catastrophic antiphospholipid syndrome 
Requires all four criteria 
 Probable catastrophic antiphospholipid syndrome 
 All four criteria, except for only two organs, systems, and/or sites of tissue involvement 
or 
 All four criteria, except for the laboratory confirmation at least 6 weeks apart due to early 
death of a patient never tested for antiphospholipid before catastrophic antiphospholipid syndrome or 
 Criteria 1, 2, and 4 above, or 
 Criteria 1, 3, and 4, and the development of a third event in more than a week, but less than a month, despite anticoagulation 
Adapted from Asherson R, Cervera R, de Groot P, Erkan D, Boffa MC, Piette JC, et al. Catastrophic 
antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. 
Lupus. 2003;12(7): 530–534. 
Clinical Study Protocol Appendix M 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008  
Version 1.0 Date 20 Sep 2016 
123 (131) 

Clinical Study Protocol Appendix M 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008  
Version 1.0 Date 20 Sep 2016 
124 (131) 

Clinical Study Protocol Appendix M 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008  
Version 1.0 Date 20 Sep 2016 
126 (131) 

Clinical Study Protocol Appendix M 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008  
Version 1.0 Date 20 Sep 2016 
127 (131) 

Clinical Study Protocol Appendix N 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008  
Version 1.0 
Date 20 Sep 2016 
128 (131) Appendix N Vasculitic syndromes excluded from the study 
Subjects with a history or current diagnosis of the following vasculitis syndromes are 
excluded from participating in the study. Vasculitis due to SLE is allowed in the study. 
x Behçet’s Disease 
x Buerger’s Disease 
x Central Nervous System Vasculitis 
x Churg Strauss Syndrome 
x Cryoglobulinemia 
x Giant Cell Arteritis 
x Henoch-Schönlein Purpura 
x Kawasaki Disease 
x Microscopic Polyangiitis 
x Polyarteritis Nodosa 
x Polymyalgia Rheumatica 
x Takayasu’s Arteritis 
x Wegener’s Granulomatosis 
Clinical Study Protocol Appendix O 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008  
Version 1.0 
Date 20 Sep 2016 
129 (131) Appendix O Patient Survey at Week 12 
Participant Questionnaire on Study Experience  
Thank you for your participation in D3461C00008  study. In this questionnaire, we would like 
to ask you a few questions about your experien ce of the study with specific focus on study 
design, the study medication injections, and proc edures during the study visits. Your response 
is very valuable and will allow us to make futu re trials better tailored to patient´s need. For 
each question below, please mark the box that  best matches your experience and feelings 
about the study. 
1 Did you think the information you received before joining the study was consistent with your 
experience during the study? 
[   ] Yes, it was consistent 
[   ] No there was some inconsistency, please specify:  
________________________________________________________________________
________________________________________________________________________
2 Do you believe you received enough information before and during the study? 
[   ] Yes 
[   ] No 
What additional information should we have shared with you before and during the study? 
________________________________________________________________________
________________________________________________________________________
3 You had 25% chance of receiving placebo, rather than the active study medication. Was this a 
concern and did this affect your willingness to participate in the study? 
[   ] No, I had no concern 
[   ] Yes, I had some concern but still wanted to participate in the trial 
4 You might have had to stop taking medications after joining this study. If you had to do so, 
how did you feel about that? [   ] I did not have to stop taking any medication. 
[   ] Reasonable 
[   ] Unreasonable but acceptable 
[   ] Unacceptable, please specify the name of medications. 
______________________________________________________________________
5 How did you feel about the frequency of visits (every 2 week on-site visit) in this study? 
[   ] Comfortable 
Clinical Study Protocol Appendix O 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008  
Version 1.0 
Date 20 Sep 2016 
130 (131) [   ] Inconvenient but acceptable 
[   ] Uncomfortable 
6 How did you feel about having the injections once every second week? 
[   ] Comfortable [   ] Inconvenient but acceptable 
[   ] Very inconvenient, please give us some advice: 
________________________________________________________________________
7 How did you feel about having to come to the clinic for the injections? 
[   ] Comfortable [   ] Inconvenient but acceptable 
[   ] Very inconvenient 
8 Would you prefer to perform the subcutaneous injections yourself at home? 
[   ] Yes, I would prefer to inject myself 
[   ] No, I prefer injections administered by my doctor or nurse 
9 If training were to be provided, would you prefer to give yourself study drug injections? 
[   ] Yes 
[   ] No 
10 Were you comfortable with blood samples being taken during the study? 
[   ] Yes [   ] No 
 If no, please select reasons below. 
[   ] Frequency of blood samples taken 
[   ] Volume of blood samples taken 
[   ] Pain associated with venous puncture 
11 What did you find most challenging in this study? 
________________________________________________________________________ 
 
______
__________________________________________________________________ 
 
________________________________________________________________________ 
 
_______________________________________________________________________ 
Clinical Study Protocol Appendix O 
Drug Substance Anifrolumab (MEDI-546)  
Study Code D3461C00008  
Version 1.0 
Date 20 Sep 2016 
131 (131) 12 Is there anything we could do to improve your experience during this study? (For example, 
study design, study procedure and site service, etc.) 
________________________________________________________________________ 
 
________________________________________________________________________ 
 
________________________________________________________________________ 
________________________________________________________________________ 
13 Do you see any other advantages or disadvantages as a result of participating in the study? 
________________________________________________________________________ 
 
________________________________________________________________________ 
14 If we run another study with similar design, would you want to participate? 
[   ] Yes 
[   ] No, please specify the reason:  
 
________________________________________________________________________  
 